

Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population..... 2

Listing of Subjects and SARS-CoV-2 Variants With Multiple COVID-19 Occurrence After Dose 1 – Dose 1 All-Available Efficacy Population 260

Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period – Dose 1 All-Available Efficacy Population 263

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1003 10031122 (USA/NEW YORK/48/M)	Placebo	Dose 2/77	05NOV2020	24NOV2020	Neg/Neg/Neg	Fever	Pos/Neg, 06NOV2020, B.1.280
C4591001 1003 10031167 (USA/NEW YORK/57/F)	Placebo	Dose 2/67	02NOV2020	11DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased cough New or increased shortness of breath Sore throat	Neg/, 06NOV2020, NS
		Dose 2/112	17DEC2020	16JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath	Pos/Pos, 19DEC2020, B.1.404

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1003 10031204 (USA/NEW YORK/39/F)	Placebo	Dose 2/95	07DEC2020	12JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat New or increased cough New or increased shortness of breath	Pos/Pos, 11DEC2020, B.1.349
C4591001 1005 10051358 (USA/NEW YORK/52/F)	Placebo	Dose 2/59	10JAN2021	20JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Fever Pos/, 12JAN2021, B.1.243

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1005 10051360 (USA/NEW YORK/77/M)	Placebo	Dose 2/29	10DEC2020	26DEC2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/, 12DEC2020, B.1.243
C4591001 1006 10061012 (USA/UTAH/53/M)	Placebo	Dose 2/68	06NOV2020	16NOV2020	Neg/Neg/Neg	New or increased cough Sore throat New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/, 06NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1006 10061025 (USA/UTAH/65/F)	Placebo	Dose 2/82	21NOV2020	02DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 24NOV2020, B.1.2
C4591001 1006 10061066 (USA/UTAH/39/F)	Placebo	Dose 2/59	11NOV2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 11NOV2020, B.1.2
C4591001 1006 10061075 (USA/UTAH/42/F)	Placebo	Dose 2/69	16NOV2020	04JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 16NOV2020, B.1.2
C4591001 1006 10061076 (USA/UTAH/61/F)	Placebo	Dose 2/123	11JAN2021	16JAN2021	Neg/Neg/Neg	New or increased	Pos/, 12JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1006 10061084 (USA/UTAH/27/F)	Placebo	Dose 2/48	27OCT2020	10NOV2020	Neg/Neg/Neg	shortness of breath Sore throat Fever	Pos/, 28OCT2020, B.1.2
C4591001 1006 10061091 (USA/UTAH/20/F)	Placebo	Dose 2/50	30OCT2020	10NOV2020	Neg/Neg/Neg	New or increased cough New or increased cough Sore throat	Pos/, 01NOV2020, B.1.2
C4591001 1006 10061114 (USA/UTAH/21/M)	Placebo	Dose 2/35	20OCT2020	03NOV2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/, 23OCT2020, B.1.443

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1006 10061206 (USA/UTAH/12/M)	Placebo	Dose 2/10	01JAN2021	03JAN2021	Neg/Neg/Neg	Sore throat Fever	Pos/, 01JAN2021, B.1.400
C4591001 1006 10061260 (USA/UTAH/12/F)	Placebo	Dose 2/17	21JAN2021	27JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 21JAN2021, B.1.1.29
C4591001 1006 10061284 (USA/UTAH/14/M)	Placebo	Dose 2/8	15JAN2021	16JAN2021	Neg/Neg/Pos	Diarrhea	Pos/, 18JAN2021, B.1.142
C4591001 1007 10071163 (USA/OHIO/80/F)	Placebo	Dose 2/76	14NOV2020	28NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 27NOV2020, B.1.2
C4591001 1007 10071246 (USA/OHIO/30/F)	Placebo	Dose 2/129	16JAN2021	19JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 19JAN2021, B.1.2
C4591001 1007 10071306 (USA/OHIO/58/F)	Placebo	Dose 2/60	31DEC2020	16JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills Sore throat Diarrhea	Pos/, 01JAN2021, B.1.2
C4591001 1007 10071425 (USA/OHIO/50/F)	Placebo	Dose 2/25	06DEC2020	11DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 11DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1007 10071448 (USA/OHIO/16/M)	Placebo	Dose 2/46	16JAN2021	24JAN2021	Neg/Neg/Neg	Fever	Pos/, 19JAN2021, B.1.234
C4591001 1007 10071456 (USA/OHIO/17/F)	Placebo	Dose 2/35	10JAN2021	14JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 13JAN2021, B.1.240
C4591001 1007 10071527 (USA/OHIO/12/M)	Placebo	Dose 2/10	07JAN2021	10JAN2021	Neg/Neg/Pos	Sore throat	Pos/Pos, 10JAN2021, B.1.2
C4591001 1007 10071559 (USA/OHIO/14/F)	Placebo	Dose 2/11	14JAN2021	26JAN2021	Neg/Neg/Neg	Fever	Pos/, 15JAN2021, B.1.2
C4591001 1007 10071603 (USA/OHIO/13/M)	Placebo	Dose 2/35	22FEB2021	28FEB2021	Neg/Neg/Neg	Sore throat Fever	Pos/, 23FEB2021, B.1.2
C4591001 1008 10081011 (USA/MISSOURI/55/F)	Placebo	Dose 2/52	22OCT2020	31OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 26OCT2020, B.1.2
C4591001 1008 10081015 (USA/MISSOURI/33/M)	Placebo	Dose 2/97	07DEC2020	12DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 14DEC2020, B.1.2
C4591001 1008 10081044 (USA/MISSOURI/58/F)	Placebo	Dose 2/66	12NOV2020	17NOV2020	Neg/Neg/Neg	Fever	Pos/, 13NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081048 (USA/MISSOURI/38/F)	Placebo	Dose 2/60	07NOV2020	27NOV2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain Sore throat Diarrhea New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 11NOV2020, B.1.1.222

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081060 (USA/MISSOURI/71/F)	Placebo	Dose 2/78	25NOV2020	04DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 01DEC2020, B.1.2
C4591001 1008 10081069 (USA/MISSOURI/57/F)	Placebo	Dose 2/97	15DEC2020	22DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 16DEC2020, B.1.2
C4591001 1008 10081092 (USA/MISSOURI/62/F)	Placebo	Dose 2/76	29NOV2020	12DEC2020	Neg/Neg/Neg	Fever New or increased cough Sore throat Diarrhea	Pos/, 30NOV2020, B.1.2
C4591001 1008 10081103 (USA/MISSOURI/35/F)	Placebo	Dose 2/86	10DEC2020	17DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 17DEC2020, B.1.1.304

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081123 (USA/MISSOURI/57/F)	Placebo	Dose 2/103	28DEC2020	22JAN2021	Neg/Neg/Neg	New or increased muscle pain New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 30DEC2020, B.1.2
C4591001 1008 10081130 (USA/MISSOURI/52/F)	Placebo	Dose 2/32	17OCT2020	29OCT2020	Neg/Neg/Neg	New or increased shortness of breath	Pos/, 23OCT2020, INDETERMINATE
C4591001 1008 10081145 (USA/MISSOURI/78/M)	Placebo	Dose 2/97	26DEC2020	31DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 30DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081153 (USA/MISSOURI/31/F)	Placebo	Dose 2/71	01DEC2020	04DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 02DEC2020, B.1.2
C4591001 1008 10081210 (USA/MISSOURI/57/F)	Placebo	Dose 2/58	25NOV2020	13DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 30NOV2020, B.1.311
C4591001 1008 10081214 (USA/MISSOURI/62/M)	Placebo	Dose 2/42	09NOV2020	13NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/, 09NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081232 (USA/MISSOURI/53/F)	Placebo	Dose 2/79	16DEC2020	27DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 18DEC2020, B.1.311
C4591001 1008 10081281 (USA/MISSOURI/20/F)	Placebo	Dose 2/99	06JAN2021	19JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 08JAN2021, B.1.2
C4591001 1008 10081285 (USA/MISSOURI/60/F)	Placebo	Dose 2/57	27NOV2020	06DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath	Pos/, 27NOV2020, B.1.2
C4591001 1008 10081319 (USA/MISSOURI/79/F)	Placebo	Dose 2/31	04NOV2020	08NOV2020	Neg/Neg/Neg	Chills	Pos/, 06NOV2020, B.1.509
C4591001 1008 10081356 (USA/MISSOURI/63/M)	Placebo	Dose 2/25	31OCT2020	10NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 04NOV2020, B.1.311

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081415 (USA/MISSOURI/56/M)	Placebo	Dose 2/53	04DEC2020	14DEC2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 07DEC2020, B.1.2
C4591001 1008 10081493 (USA/MISSOURI/19/M)	Placebo	Dose 2/47	29NOV2020	04DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 01DEC2020, B.1.428
C4591001 1008 10081563 (USA/MISSOURI/72/M)	Placebo	Dose 2/14	08NOV2020	20NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 17NOV2020, B.1.2
C4591001 1008 10081596 (USA/MISSOURI/38/F)	Placebo	Dose 2/61	02JAN2021	09JAN2021	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 04JAN2021, B.1.1.222
C4591001 1008 10081612 (USA/MISSOURI/38/F)	Placebo	Dose 2/24	27NOV2020	05DEC2020	Neg/Neg/Neg	Fever	Pos/, 30NOV2020, B.1.1.7

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1008 10081664 (USA/MISSOURI/49/F)	Placebo	Dose 2/22	02DEC2020	14DEC2020	Neg/Neg/Neg	New or increased cough Chills	Pos/, 04DEC2020, B.1.243
C4591001 1009 10091005 (USA/UTAH/31/M)	Placebo	Dose 2/66	06NOV2020	11NOV2020	Neg/Neg/Neg	Sore throat	Pos/, 03NOV2020, B.1.2
C4591001 1009 10091018 (USA/UTAH/70/M)	Placebo	Dose 2/89	01DEC2020		Neg/Neg/Neg	New or increased cough	Pos/, 04DEC2020, B.1.2
C4591001 1009 10091102 (USA/UTAH/22/F)	Placebo	Dose 2/115	08JAN2021	20JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 13JAN2021, B.1.429
C4591001 1009 10091110 (USA/UTAH/46/F)	Placebo	Dose 2/69	21NOV2020	09DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 20NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1009 10091114 (USA/UTAH/77/F)	Placebo	Dose 2/105	27DEC2020	15JAN2021	Neg/Neg/Neg	New or increased cough Diarrhea	Pos/, 31DEC2020, B.1.2
C4591001 1009 10091115 (USA/UTAH/78/M)	Placebo	Dose 2/108	30DEC2020	17JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 04JAN2021, B.1.2
C4591001 1009 10091128 (USA/UTAH/51/M)	Placebo	Dose 2/30	15OCT2020	24FEB2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 20OCT2020, B.1.2
C4591001 1009 10091129 (USA/UTAH/38/M)	BNT162b2 (30 µg)	Dose 2/135	28JAN2021		Neg/Neg/Neg	Fever	Pos/, 08FEB2021, B.1.427

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1009 10091153 (USA/UTAH/68/M)	Placebo	Dose 2/66	29NOV2020	06DEC2020	Unk/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 01DEC2020, B.1.1.161
C4591001 1009 10091208 (USA/UTAH/15/M)	Placebo	Dose 2/66	10JAN2021	14JAN2021	Neg/Neg/Neg	Sore throat New or increased cough New or increased shortness of breath	Pos/, 10JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1009 10091214 (USA/UTAH/47/F)	Placebo	Dose 2/24	27NOV2020	09DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 30NOV2020, B.1.210
C4591001 1009 10091235 (USA/UTAH/16/M)	Placebo	Dose 2/17	27NOV2020	01DEC2020	Neg/Neg/Neg	New or increased cough Sore throat Diarrhea	Pos/, 30NOV2020, B.1.2
C4591001 1009 10091236 (USA/UTAH/45/F)	Placebo	Dose 2/16	26NOV2020	03DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 30NOV2020, B.1
C4591001 1009 10091282 (USA/UTAH/14/M)	Placebo	Dose 2/42	01FEB2021	02FEB2021	Neg/Neg/Neg	Chills	Pos/, 02FEB2021, B.1.427
C4591001 1009 10091412 (USA/UTAH/15/M)	Placebo	Dose 2/29	01MAR2021		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat New or increased cough	Pos/, 01MAR2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1012 10121006 (USA/ARIZONA/52/M)	Placebo	Dose 2/71	06NOV2020	23NOV2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/, 15NOV2020, B.1.2
C4591001 1012 10121042 (USA/ARIZONA/63/M)	Placebo	Dose 2/71	18NOV2020		Neg/Neg/Neg	Fever New or increased cough New loss of taste or smell Diarrhea	Pos/, 23NOV2020, B.1.2
C4591001 1012 10121059 (USA/ARIZONA/28/F)	Placebo	Dose 2/95	13DEC2020	10FEB2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat	Pos/, 15DEC2020, B.1.2
C4591001 1012 10121164 (USA/ARIZONA/37/M)	Placebo	Dose 2/84	23DEC2020	02JAN2021	Neg/Neg/Neg	Fever	Pos/, 24DEC2020, B.1.189

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131014 (USA/FLORIDA/29/M)	Placebo	Dose 2/131	29DEC2020	05JAN2021	Neg/Neg/Neg	New or increased cough Diarrhea Fever	Pos/, 05JAN2021, B.1.234
C4591001 1013 10131064 (USA/FLORIDA/28/F)	Placebo	Dose 2/155	25JAN2021	03FEB2021	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Diarrhea Fever	Pos/, 28JAN2021, B.1 New or increased cough Chills

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131166 (USA/FLORIDA/50/M)	Placebo	Dose 2/117	28DEC2020	13JAN2021	Neg/Neg/Unk	New or increased muscle pain Sore throat New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 05JAN2021, B.1.2
C4591001 1013 10131167 (USA/FLORIDA/50/F)	Placebo	Dose 2/119	30DEC2020	13JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 05JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131257 (USA/FLORIDA/61/F)	Placebo	Dose 2/89	11DEC2020	30DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Diarrhea Vomiting	Pos/, 13DEC2020, B.1.2
C4591001 1013 10131288 (USA/FLORIDA/53/M)	Placebo	Dose 2/11	25SEP2020	06OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell	Pos/, 28SEP2020, B.1.396

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131296 (USA/FLORIDA/44/M)	Placebo	Dose 2/72	25NOV2020	11DEC2020	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 30NOV2020, B.1.1.122
C4591001 1013 10131396 (USA/FLORIDA/41/M)	Placebo	Dose 2/75	05DEC2020	09DEC2020	Neg/Neg/Neg	New loss of	Pos/, 08DEC2020, B.1.2
C4591001 1013 10131398 (USA/FLORIDA/36/M)	Placebo	Dose 2/86	16DEC2020	21DEC2020	Pos/Neg/Neg	New or increased cough Chills Sore throat	Pos/, 17DEC2020, B.1.234
C4591001 1013 10131409 (USA/FLORIDA/35/M)	Placebo	Dose 2/90	21DEC2020	03JAN2021	Neg/Neg/Neg	Fever	Pos/, 30DEC2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131460 (USA/FLORIDA/56/F)	BNT162b2 (30 µg)	Dose 2/93	30DEC2020	27JAN2021	Neg/Neg/Neg	New or increased cough Chills Sore throat Chills	Pos/, 04JAN2021, B.1.1.222
C4591001 1013 10131471 (USA/FLORIDA/20/M)	Placebo	Dose 2/46	13NOV2020	16NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Fever	Pos/, 17NOV2020, B.1.280
C4591001 1013 10131475 (USA/FLORIDA/49/F)	Placebo	Dose 2/23	22OCT2020	25OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain New or increased cough	Pos/, 26OCT2020, B.1.369

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131539 (USA/FLORIDA/70/F)	Placebo	Dose 2/94	07JAN2021	17JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat New or increased cough Sore throat	Pos/, 08JAN2021, B.1.2
C4591001 1013 10131540 (USA/FLORIDA/71/M)	Placebo	Dose 2/91	04JAN2021	06JAN2021	Neg/Neg/Neg	Fever Sore throat	Pos/, 06JAN2021, B.1.2
C4591001 1013 10131720 (USA/FLORIDA/55/M)	BNT162b2 (30 µg)	Dose 2/93	05FEB2021	03MAR2021	Neg/Neg/Neg	Chills New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 09FEB2021, A.2.4

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1013 10131758 (USA/FLORIDA/60/M)	Placebo	Dose 2/48	28DEC2020		Neg/Neg/Neg	Vomiting New or increased shortness of breath Chills New or increased muscle pain	Pos/, 30DEC2020, B.1.1.222
C4591001 1015 10151094 (USA/MASSACHUSETTS/50/F)	Placebo	Dose 2/123	14JAN2021		Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 19JAN2021, B.1.2
C4591001 1016 10161003 (USA/KENTUCKY/23/F)	Placebo	Dose 2/57	14OCT2020	26OCT2020	Neg/Neg/Neg	Fever	Pos/, 16OCT2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1016 10161004 (USA/KENTUCKY/51/F)	BNT162b2 (30 µg)	Dose 2/58	15OCT2020	22OCT2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell	Pos/, 17OCT2020, B.1.2
C4591001 1016 10161017 (USA/KENTUCKY/18/F)	Placebo	Dose 2/19	07SEP2020	29OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/, 09SEP2020, B.1.1.4
C4591001 1016 10161035 (USA/KENTUCKY/70/F)	Placebo	Dose 2/67	29OCT2020	29OCT2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell	Pos/, 30OCT2020, B.1.2
C4591001 1016 10161048 (USA/KENTUCKY/52/F)	Placebo	Dose 2/75	06NOV2020	31JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 06NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1016 10161114 (USA/KENTUCKY/22/F)	BNT162b2 (30 µg)	Dose 2/122	02JAN2021	08JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Chills	Pos/, 04JAN2021, B.1.2
C4591001 1016 10161123 (USA/KENTUCKY/48/F)	Placebo	Dose 2/98	09DEC2020	25DEC2020	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 11DEC2020, B.1.2
C4591001 1016 10161146 (USA/KENTUCKY/59/F)	Placebo	Dose 2/89	07DEC2020	20DEC2020	Neg/Neg/Neg	Chills Fever	Pos/, 10DEC2020, B.1.2
						New or increased cough New or increased muscle pain New loss of taste or smell	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1016 10161183 (USA/KENTUCKY/31/F)	Placebo	Dose 2/32	16OCT2020	01NOV2020	Neg/Neg/Neg	Sore throat Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Vomiting	Pos/ (R1 Pos), 16OCT2020 (23OCT2020), B.1.2 (B.1.2)
C4591001 1016 10161207 (USA/KENTUCKY/62/F)	Placebo	Dose 2/27	14OCT2020	01NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 16OCT2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1016 10161209 (USA/KENTUCKY/33/F)	Placebo	Dose 2/98	28DEC2020	05JAN2021	Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/, 04JAN2021, B.1.2
C4591001 1016 10161305 (USA/KENTUCKY/16/M)	Placebo	Dose 2/8	09NOV2020	13NOV2020	Neg/Neg/Pos	New or increased cough	Pos/, 11NOV2020, QNS
C4591001 1016 10161317 (USA/KENTUCKY/17/M)	Placebo	Dose 2/51	26DEC2020	03JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 29DEC2020, B.1.2
C4591001 1018 10181083 (USA/TEXAS/45/M)	Placebo	Dose 2/72	06NOV2020	16NOV2020	Neg/Neg/Neg	New or increased muscle pain Fever New or increased cough Chills New or increased muscle pain	Pos/, 15NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1018 10181107 (USA/TEXAS/26/F)	BNT162b2 (30 µg)	Dose 2/125	02JAN2021		Neg/Neg/Neg	Diarrhea Vomiting New or increased cough New loss of taste or smell	Pos/, 05JAN2021, B.1.2
C4591001 1018 10181198 (USA/TEXAS/50/F)	Placebo	Dose 2/55	04NOV2020	05NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 05NOV2020, B.1.234
C4591001 1018 10181289 (USA/TEXAS/49/M)	Placebo	Dose 2/88	31DEC2020	13JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 03JAN2021, B.1.2
C4591001 1019 10191038 (USA/TEXAS/47/F)	Placebo	Dose 2/61	03NOV2020	18NOV2020	Neg/Neg/Neg	Fever	Pos/, 09NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1019 10191184 (USA/TEXAS/52/M)	Placebo	Dose 2/36	05NOV2020	08DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell Diarrhea	Pos/, 05NOV2020, B.1.2
C4591001 1019 10191200 (USA/TEXAS/67/M)	Placebo	Dose 2/77	22DEC2020	19JAN2021	Neg/Neg/Neg	New or increased muscle pain Vomiting	Pos/, 28DEC2020, B.1.2
C4591001 1019 10191242 (USA/TEXAS/28/F)	Placebo	Dose 2/70	29DEC2020	05JAN2021	Neg/Neg/Neg	Fever New or increased cough New loss of taste or smell	Pos/, 31DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1019 10191251 (USA/TEXAS/19/M)	Placebo	Dose 2/45	06DEC2020	16DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 10DEC2020, B.1
C4591001 1019 10191256 (USA/TEXAS/49/M)	Placebo	Dose 2/41	08DEC2020	15DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills Sore throat	Pos/, 11DEC2020, B.1.403
C4591001 1021 10211093 (USA/NORTH CAROLINA/72/M)	Placebo	Dose 2/99	21DEC2020		Neg/Neg/Neg	New or increased cough	Pos/, 10JAN2021, B.1.1.244
C4591001 1021 10211122 (USA/NORTH CAROLINA/57/F)	Placebo	Dose 2/114	12JAN2021	12FEB2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 14JAN2021, B.1.2
C4591001 1022 10221053 (USA/WASHINGTON/64/F)	Placebo	Dose 2/112	03JAN2021	10JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain	Pos/, 04JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1024 10241080 (USA/NEW JERSEY/54/M)	Placebo	Dose 2/142	03FEB2021	21FEB2021	Neg/Neg/Neg	Vomiting Chills	Pos/, 04FEB2021, A.2.4
C4591001 1024 10241092 (USA/NEW JERSEY/53/F)	Placebo	Dose 2/86	10DEC2020	13DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 11DEC2020, B.1.509
C4591001 1027 10271086 (USA/NORTH CAROLINA/46/F)	Placebo	Dose 2/77	03DEC2020	18DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 07DEC2020, B.1
C4591001 1027 10271202 (USA/NORTH CAROLINA/57/F)	Placebo	Dose 2/68	19DEC2020	01JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/Pos, 21DEC2020, B.1.1.139
C4591001 1028 10281038 (USA/NORTH DAKOTA/53/F)	Placebo	Dose 2/31	10OCT2020	22OCT2020	Neg/Neg/Neg	Fever	Pos/, 13OCT2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1028 10281054 (USA/NORTH DAKOTA/51/M)	Placebo	Dose 2/63	16NOV2020	18DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 20NOV2020, B.1.2
C4591001 1028 10281057 (USA/NORTH DAKOTA/63/M)	Placebo	Dose 2/93	29DEC2020	08JAN2021	Neg/Neg/Neg	New or increased cough Chills	Pos/, 30DEC2020, B.1.2
C4591001 1028 10281100 (USA/NORTH DAKOTA/47/F)	Placebo	Dose 2/19	11OCT2020	21OCT2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 13OCT2020, B.1.240
C4591001 1028 10281122 (USA/NORTH DAKOTA/44/F)	Placebo	Dose 2/53	15NOV2020	27NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 18NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1028 10281132 (USA/NORTH DAKOTA/61/M)	Placebo	Dose 2/14	11OCT2020	21OCT2020	Neg/Neg/Neg	New or increased muscle pain Vomiting Fever	Pos/, 13OCT2020, B.1.2
C4591001 1028 10281138 (USA/NORTH DAKOTA/38/F)	Placebo	Dose 2/25	23OCT2020	03NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/, 27OCT2020, B.1.400
C4591001 1028 10281152 (USA/NORTH DAKOTA/51/M)	Placebo	Dose 2/94	30DEC2020	06JAN2021	Neg/Neg/Neg	Chills Sore throat Diarrhea Fever	Pos/, 02JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1028 10281187 (USA/NORTH DAKOTA/82/M)	Placebo	Dose 2/59	09DEC2020	30DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 09DEC2020, B.1
C4591001 1028 10281269 (USA/NORTH DAKOTA/29/F)	Placebo	Dose 2/9	19NOV2020	24NOV2020	Neg/Neg/Neg	Fever	Pos/, 19NOV2020, B.1
C4591001 1030 10301025 (USA/OHIO/66/F)	Placebo	Dose 2/85	15DEC2020	24DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 16DEC2020, B.1.2
C4591001 1030 10301048 (USA/OHIO/33/M)	Placebo	Dose 2/74	05DEC2020	11DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 06DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1030 10301069 (USA/OHIO/29/F)	Placebo	Dose 2/64	04DEC2020	10DEC2020	Neg/Neg/Neg	Sore throat New or increased cough New loss of taste or smell	Pos/, 05DEC2020, B.1.2
C4591001 1030 10301088 (USA/OHIO/39/F)	Placebo	Dose 2/87	30DEC2020	12JAN2021	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/, 02JAN2021, B.1.2
C4591001 1030 10301113 (USA/OHIO/30/F)	Placebo	Dose 2/35	12NOV2020	17NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell Diarrhea	Pos/, 19NOV2020, B.1.2
C4591001 1030 10301123 (USA/OHIO/45/F)	Placebo	Dose 2/64	15DEC2020	30DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 21DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1036 10361035 (USA/TENNESSEE/63/M)	BNT162b2 (30 µg)	Dose 2/71	24NOV2020	29NOV2020	Neg/Neg/Neg	Sore throat New or increased cough New loss of taste or smell Diarrhea	Pos/, 01DEC2020, B.1.265
C4591001 1037 10371004 (USA/TENNESSEE/57/F)	Placebo	Dose 2/69	16NOV2020	03FEB2021	Neg/Neg/Neg	Chills	Pos/, 19NOV2020, B.1.2
C4591001 1037 10371016 (USA/TENNESSEE/84/M)	Placebo	Dose 2/88	05DEC2020	11DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 10DEC2020, B.1.2
C4591001 1037 10371036 (USA/TENNESSEE/62/M)	Placebo	Dose 2/52	31OCT2020	11DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 05NOV2020, B.1.361
C4591001 1037 10371113 (USA/TENNESSEE/71/F)	Placebo	Dose 2/70	29NOV2020	09DEC2020	Neg/Neg/Neg	Fever	Pos/, 02DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1037 10371146 (USA/TENNESSEE/78/M)	Placebo	Dose 2/96	27DEC2020		Neg/Neg/Neg	New or increased cough Chills New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat Diarrhea	Pos/, 30DEC2020, B.1.2
C4591001 1037 10371155 (USA/TENNESSEE/55/M)	Placebo	Dose 2/75	12DEC2020		Unk/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 14DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1037 10371187 (USA/TENNESSEE/78/M)	Placebo	Dose 2/69	06DEC2020	14DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/, 14DEC2020, B.1.2
C4591001 1037 10371193 (USA/TENNESSEE/76/F)	Placebo	Dose 2/36	05NOV2020	15NOV2020	Neg/Neg/Neg	Chills Fever	Pos/, 17NOV2020, B.1.234
C4591001 1037 10371200 (USA/TENNESSEE/29/F)	Placebo	Dose 2/70	15DEC2020	27DEC2020	Neg/Neg/Neg	New or increased shortness of breath Chills Diarrhea New or increased cough New or increased shortness of breath Sore throat	Pos/, 16DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1037 10371280 (USA/TENNESSEE/58/M)	Placebo	Dose 2/28	10NOV2020	04DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 11NOV2020, B.1.2
C4591001 1037 10371307 (USA/TENNESSEE/43/F)	Placebo	Dose 2/59	16DEC2020	25DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 18DEC2020, B.1.2
C4591001 1037 10371323 (USA/TENNESSEE/48/F)	Placebo	Dose 2/36	02DEC2020	06DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 02DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1037 10371353 (USA/TENNESSEE/37/M)	Placebo	Dose 2/18	28NOV2020	21DEC2020	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New loss of taste or smell Diarrhea	Pos/, 03DEC2020, B.1.1.231
C4591001 1038 10381044 (USA/TENNESSEE/32/F)	Placebo	Dose 2/79	02DEC2020	13DEC2020	Pos/Neg/Neg	New or increased shortness of breath Chills	Pos/, 07DEC2020, INDETERMINATE
C4591001 1038 10381051 (USA/TENNESSEE/69/M)	Placebo	Dose 2/51	07NOV2020	25NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 09NOV2020, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1039 10391025 (USA/TEXAS/55/F)	Placebo	Dose 2/40	25OCT2020	15NOV2020	Neg/Neg/Neg	New or increased shortness of breath Sore throat Sore throat	Pos/, 28OCT2020, B.1.2
C4591001 1039 10391268 (USA/TEXAS/13/F)	Placebo	Dose 2/33	29JAN2021	03MAR2021	Neg/Neg/Neg	Fever	Pos/, 29JAN2021, B.1
C4591001 1042 10421133 (USA/TEXAS/61/F)	Placebo	Dose 2/142	28JAN2021	11FEB2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Fever	Pos/, 01FEB2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1042 10421168 (USA/TEXAS/59/F)	Placebo	Dose 2/76	30NOV2020	21DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 02DEC2020, B.1.2
C4591001 1042 10421223 (USA/TEXAS/71/F)	Placebo	Dose 2/90	27DEC2020	16JAN2021	Neg/Neg/Neg	New loss of taste or smell Fever New or increased cough New or increased muscle pain Sore throat	Pos/, 28DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1044 10441138 (USA/VIRGINIA/63/M)	Placebo	Dose 2/102	22JAN2021	23JAN2021	Neg/Neg/Neg	Fever	Pos/, 25JAN2021, B.1.351
C4591001 1044 10441167 (USA/VIRGINIA/42/F)	Placebo	Dose 2/103	05FEB2021	25FEB2021	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell	Pos/, 09FEB2021, B.1.2
C4591001 1044 10441242 (USA/VIRGINIA/17/M)	Placebo	Dose 2/49	01FEB2021	07FEB2021	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/, 04FEB2021, B.1.2
C4591001 1044 10441374 (USA/VIRGINIA/15/M)	Placebo	Dose 2/13	14FEB2021	17FEB2021	Neg/Neg/Neg	Chills New loss of taste or smell Vomiting	Pos/, 16FEB2021, B.1.243
C4591001 1046 10461037 (USA/ALABAMA/60/M)	BNT162b2 (30 µg)	Dose 2/109	21DEC2020	28DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 22DEC2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1046 10461058 (USA/ALABAMA/44/F)	Placebo	Dose 2/62	09NOV2020	16NOV2020	Neg/Neg/Neg	New or increased muscle pain New or increased muscle pain	Pos/, 09NOV2020, B.1.240
C4591001 1046 10461101 (USA/ALABAMA/31/F)	Placebo	Dose 2/98	21DEC2020	24DEC2020	Neg/Neg/Neg	Fever	Pos/, 21DEC2020, B.1.2
C4591001 1046 10461124 (USA/ALABAMA/36/F)	Placebo	Dose 2/105	29DEC2020	04JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Fever	Pos/, 29DEC2020, B.1.2
						New or increased cough New or increased muscle pain	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1046 10461203 (USA/ALABAMA/55/F)	Placebo	Dose 2/53	23NOV2020	30NOV2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 24NOV2020, B.1.2
C4591001 1046 10461204 (USA/ALABAMA/54/M)	Placebo	Dose 2/55	23NOV2020	27NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 24NOV2020, B.1.2
C4591001 1046 10461235 (USA/ALABAMA/59/M)	BNT162b2 (30 µg)	Dose 2/86	23DEC2020	29DEC2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 23DEC2020, B.1.2
C4591001 1046 10461334 (USA/ALABAMA/53/F)	Placebo	Dose 2/28	16DEC2020	17DEC2020	Neg/Neg/Neg	Fever	Pos/, 16DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1047 10471024 (USA/ALABAMA/63/F)	BNT162b2 (30 µg)	Dose 2/37	16OCT2020	18OCT2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 17OCT2020, B.1.139
C4591001 1047 10471079 (USA/ALABAMA/21/F)	Placebo	Dose 2/87	13DEC2020	25DEC2020	Neg/Neg/Neg	Diarrhea Vomiting Fever	Pos/, 15DEC2020, B.1.2
C4591001 1047 10471080 (USA/ALABAMA/43/F)	Placebo	Dose 2/56	12NOV2020	20NOV2020	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/Pos, 13NOV2020, B.1.2
C4591001 1047 10471170 (USA/ALABAMA/63/M)	BNT162b2 (30 µg)	Dose 2/62	01DEC2020	15JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 03DEC2020, QNS
C4591001 1047 10471217 (USA/ALABAMA/49/F)	Placebo	Dose 2/72	19DEC2020	22DEC2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 22DEC2020, B.1.240
C4591001 1047 10471327 (USA/ALABAMA/35/M)	Placebo	Dose 2/59	09JAN2021	13JAN2021	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 15JAN2021, B.1.366

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1048 10481027 (USA/ARIZONA/46/M)	Placebo	Dose 2/112	05JAN2021	19JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 11JAN2021, B.1.2
C4591001 1048 10481064 (USA/ARIZONA/52/F)	Placebo	Dose 2/107	06JAN2021	10JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 08JAN2021, B.1.2
C4591001 1048 10481104 (USA/ARIZONA/57/F)	Placebo	Dose 2/43	11NOV2020	16DEC2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/, 13NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1048 10481118 (USA/ARIZONA/67/F)	Placebo	Dose 2/32	02NOV2020	11NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 13NOV2020, B.1.2
C4591001 1052 10521082 (USA/CALIFORNIA/38/F)	Placebo	Dose 2/110	09JAN2021	10JAN2021	Neg/Neg/Neg	Fever	Pos/, 12JAN2021, B.1.429
C4591001 1052 10521110 (USA/CALIFORNIA/53/F)	Placebo	Dose 2/112	13JAN2021	13JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 13JAN2021, B.1.2
C4591001 1054 10541001 (USA/CALIFORNIA/50/F)	Placebo	Dose 2/134	19JAN2021	09FEB2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/, 24JAN2021, B.1.409

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1054 10541002 (USA/CALIFORNIA/51/M)	BNT162b2 (30 µg)	Dose 2/134	19JAN2021	25JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Vomiting Fever	Pos/, 26JAN2021, B.1.409
C4591001 1054 10541035 (USA/CALIFORNIA/29/M)	BNT162b2 (30 µg)	Dose 2/81	29NOV2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat New or increased cough New or increased	Pos/, 04DEC2020, B.1.1.29

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1054 10541038 (USA/CALIFORNIA/27/F)	Placebo	Dose 2/88	10DEC2020	04FEB2021	Neg/Neg/Neg	shortness of breath Chills New or increased muscle pain New loss of taste or smell Fever	Pos/, 12DEC2020, B.1.2
C4591001 1054 10541137 (USA/CALIFORNIA/42/M)	Placebo	Dose 2/100	07JAN2021	13JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 08JAN2021, B.1.2
C4591001 1054 10541146 (USA/CALIFORNIA/65/F)	BNT162b2 (30 µg)	Dose 2/62	09DEC2020	12DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 11DEC2020, B.1.399

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1054 10541194 (USA/CALIFORNIA/58/F)	Placebo	Dose 2/29	03DEC2020	17DEC2020	Neg/Neg/Neg	Sore throat	Pos/ (R1 Pos), 05DEC2020 (04JAN2021), B.1.2 (B.1.525)
C4591001 1054 10541202 (USA/CALIFORNIA/57/M)	Placebo	Dose 2/60	11JAN2021		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/, 12JAN2021, INDETERMINATE
C4591001 1055 10551016 (USA/CALIFORNIA/38/F)	BNT162b2 (30 µg)	Dose 2/104	12DEC2020	18DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 16DEC2020, B.1.241
C4591001 1055 10551099 (USA/CALIFORNIA/30/M)	Placebo	Dose 2/100	22DEC2020	28DEC2020	Neg/Neg/Neg	Fever New loss of taste or smell	Pos/, 27DEC2020, B.1.429
C4591001 1055 10551123 (USA/CALIFORNIA/67/M)	Placebo	Dose 2/64	19NOV2020	29NOV2020	Neg/Neg/Neg	Fever	Pos/, 20NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1055 10551203 (USA/CALIFORNIA/49/M)	Placebo	Dose 2/48	17NOV2020	27NOV2020	Neg/Neg/Neg	New or increased cough New or increased cough Chills	Pos/Pos, 18NOV2020, B.1.2
C4591001 1055 10551228 (USA/CALIFORNIA/39/F)	Placebo	Dose 2/48	21NOV2020	14DEC2020	Neg/Neg/Neg	New or increased muscle pain Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 22NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1055 10551243 (USA/CALIFORNIA/18/M)	Placebo	Dose 2/67	20DEC2020	29DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 22DEC2020, B.1.2
C4591001 1056 10561041 (USA/FLORIDA/49/F)	BNT162b2 (30 µg)	Dose 2/116	10JAN2021	01FEB2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 15JAN2021, B.1.1.143
C4591001 1056 10561349 (USA/FLORIDA/59/F)	Placebo	Dose 2/72	05JAN2021	13JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New loss of taste or smell	Pos/, 11JAN2021, B.1.375

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1056 10561502 (USA/FLORIDA/64/F)	Placebo	Dose 2/65	05JAN2021	17JAN2021	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain	Pos/, 07JAN2021, B.1.2
C4591001 1056 10561514 (USA/FLORIDA/30/F)	Placebo	Dose 2/9	13NOV2020	18NOV2020	Neg/Neg/Neg	Sore throat Diarrhea	Pos/, 17NOV2020, B.1.2
C4591001 1057 10571238 (USA/FLORIDA/49/F)	Placebo	Dose 2/60	13DEC2020	21DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 15DEC2020, B.1.2
C4591001 1057 10571363 (USA/FLORIDA/17/F)	Placebo	Dose 2/48	24JAN2021	01FEB2021	Neg/Neg/Neg	Sore throat Fever New or increased cough Chills	Pos/, 26JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1066 10661050 (USA/IDAHO/59/M)	Placebo	Dose 2/116	03JAN2021	18JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/, 04JAN2021, B.1
C4591001 1066 10661129 (USA/IDAHO/44/F)	Placebo	Dose 2/73	28NOV2020	21DEC2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat	Pos/, 30NOV2020, B.1.2
C4591001 1066 10661163 (USA/IDAHO/24/M)	Placebo	Dose 2/56	16NOV2020	28NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 18NOV2020, B.1.2
C4591001 1066 10661167 (USA/IDAHO/50/F)	Placebo	Dose 2/81	12DEC2020	05JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 17DEC2020, B.1.2
C4591001 1066 10661176 (USA/IDAHO/61/M)	Placebo	Dose 2/99	31DEC2020	03JAN2021	Neg/Neg/Neg	Fever	Pos/, 05JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1066 10661242 (USA/IDAHO/54/M)	Placebo	Dose 2/90	30DEC2020	08JAN2021	Neg/Neg/Neg	New or increased muscle pain Chills	Pos/, 04JAN2021, B.1.2
C4591001 1066 10661313 (USA/IDAHO/66/F)	Placebo	Dose 2/34	17NOV2020	28NOV2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough Chills	Pos/, 19NOV2020, B.1.2
C4591001 1068 10681003 (USA/MONTANA/42/F)	Placebo	Dose 2/108	25DEC2020	11JAN2021	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 31DEC2020, B.1.2
C4591001 1068 10681037 (USA/MONTANA/22/F)	Placebo	Dose 2/116	07JAN2021	09JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/Pos, 12JAN2021, B.1.2
C4591001 1068 10681082 (USA/MONTANA/58/M)	Placebo	Dose 2/42	01NOV2020	25NOV2020	Neg/Neg/Neg	Fever	Pos/, 02NOV2020, B.1.395

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1068 10681083 (USA/MONTANA/26/F)	Placebo	Dose 2/105	03JAN2021	08JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Sore throat	Pos/Pos, 06JAN2021, B.1.2
C4591001 1068 10681110 (USA/MONTANA/30/F)	Placebo	Dose 2/22	16OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 21OCT2020, B.1.2
C4591001 1068 10681115 (USA/MONTANA/28/M)	Placebo	Dose 2/93	31DEC2020	08JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/Pos, 04JAN2021, B.1.2
C4591001 1071 10711022 (USA/NEBRASKA/47/M)	Placebo	Dose 2/72	10NOV2020	16NOV2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/, 11NOV2020, B.1.139

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1071 10711028 (USA/NEBRASKA/54/F)	Placebo	Dose 2/93	03DEC2020	09DEC2020	Neg/Neg/Neg	Sore throat Fever	Pos/, 11DEC2020, B.1.311
C4591001 1071 10711034 (USA/NEBRASKA/49/F)	Placebo	Dose 2/111	20DEC2020	27DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 24DEC2020, B.1.234
C4591001 1071 10711058 (USA/NEBRASKA/72/F)	Placebo	Dose 2/60	06NOV2020	25NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 07NOV2020, B.1.2
C4591001 1071 10711147 (USA/NEBRASKA/70/M)	Placebo	Dose 2/86	22DEC2020	24DEC2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain	Pos/, 27DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1071 10711197 (USA/NEBRASKA/61/M)	Placebo	Dose 2/31	13NOV2020	15NOV2020	Neg/Neg/Neg	Fever Chills	Pos/, 16NOV2020, B.1.2
C4591001 1071 10711198 (USA/NEBRASKA/54/F)	Placebo	Dose 2/31	13NOV2020	15NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 16NOV2020, B.1.2
C4591001 1071 10711249 (USA/NEBRASKA/44/M)	Placebo	Dose 2/59	15JAN2021		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell	Pos/, 19JAN2021, B.1.2
C4591001 1072 10721004 (USA/ALABAMA/59/M)	Placebo	Dose 2/129	15JAN2021	12FEB2021	Neg/Neg/Neg	New or increased cough	Pos/, 20JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1072 10721024 (USA/ALABAMA/51/F)	BNT162b2 (30 µg)	Dose 2/137	25JAN2021		Neg/Neg/Neg	New or increased cough	Pos/Pos, 26JAN2021, B.1.2
C4591001 1072 10721057 (USA/ALABAMA/70/M)	Placebo	Dose 2/41	26OCT2020	16NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 05NOV2020, B.1.2
C4591001 1072 10721064 (USA/ALABAMA/77/M)	Placebo	Dose 2/85	09DEC2020	26DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/Pos, 15DEC2020, B.1.2
C4591001 1072 10721089 (USA/ALABAMA/19/F)	Placebo	Dose 2/157	26FEB2021		Neg/Neg/Neg	New or increased cough	Pos/, 01MAR2021, B.1.1.7
C4591001 1072 10721096 (USA/ALABAMA/70/M)	Placebo	Dose 2/93	31DEC2020	05FEB2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 01JAN2021, B.1
C4591001 1073 10731029 (USA/ARIZONA/43/F)	Placebo	Dose 2/104	07DEC2020	11DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 09DEC2020, B.1.2
C4591001 1073 10731036 (USA/ARIZONA/50/F)	Placebo	Dose 2/82	17NOV2020	02DEC2020	Neg/Neg/Neg	Fever	Pos/, 19NOV2020, B.1.234

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1073 10731060 (USA/ARIZONA/78/F)	Placebo	Dose 2/127	04JAN2021	10JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/, 07JAN2021, B.1.243
C4591001 1073 10731067 (USA/ARIZONA/24/F)	Placebo	Dose 2/127	06JAN2021	09JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New or increased cough	Pos/, 08JAN2021, B.1
C4591001 1073 10731068 (USA/ARIZONA/39/M)	Placebo	Dose 2/126	05JAN2021	08JAN2021	Neg/Neg/Neg	New or increased muscle pain New or increased shortness of breath Sore throat	Pos/, 06JAN2021, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1073 10731085 (USA/ARIZONA/51/F)	Placebo	Dose 2/105	14DEC2020	16DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 16DEC2020, B.1.2
C4591001 1073 10731093 (USA/ARIZONA/48/F)	BNT162b2 (30 µg)	Dose 2/77	24NOV2020	05DEC2020	Neg/Neg/Neg	Chills New or increased muscle pain	Pos/, 27NOV2020, B.1.2
C4591001 1073 10731098 (USA/ARIZONA/70/M)	Placebo	Dose 2/100	16DEC2020	20DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 17DEC2020, B.1.2
C4591001 1073 10731103 (USA/ARIZONA/49/M)	Placebo	Dose 2/133	18JAN2021	22JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 20JAN2021, B.1.2
C4591001 1073 10731123 (USA/ARIZONA/73/F)	Placebo	Dose 2/69	22NOV2020	25NOV2020	Neg/Neg/Neg	Fever Sore throat	Pos/, 25NOV2020, B.1.2
C4591001 1073 10731124 (USA/ARIZONA/76/M)	Placebo	Dose 2/67	20NOV2020	25NOV2020	Neg/Neg/Neg	Fever	Pos/, 25NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1077 10771175 (USA/NEW YORK/61/M)	Placebo	Dose 2/85	15DEC2020	05JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/, 21DEC2020, B.1.240
C4591001 1077 10771176 (USA/NEW YORK/61/F)	BNT162b2 (30 µg)	Dose 2/90	20DEC2020	03JAN2021	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell Fever	Pos/, 21DEC2020, B.1.240
C4591001 1077 10771189 (USA/NEW YORK/51/M)	Placebo	Dose 2/51	11NOV2020	01DEC2020	Neg/Neg/Neg	New or increased cough Diarrhea	Pos/, 15NOV2020, B.1.110.3
C4591001 1077 10771195 (USA/NEW YORK/73/F)	Placebo	Dose 2/40	01NOV2020	29NOV2020	Neg/Neg/Neg	Fever	Pos/, 07NOV2020, B.1.110.3

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1077 10771239 (USA/NEW YORK/59/M)	Placebo	Dose 2/58	04DEC2020	07DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Fever	Pos/, 07DEC2020, B.1.404
C4591001 1079 10791046 (USA/NORTH CAROLINA/55/F)	Placebo	Dose 2/62	26OCT2020	17DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 30OCT2020, B.1
C4591001 1079 10791054 (USA/NORTH CAROLINA/28/F)	Placebo	Dose 2/63	29OCT2020	14NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 30OCT2020, B.1.1.29
C4591001 1079 10791098 (USA/NORTH CAROLINA/53/M)	Placebo	Dose 2/111	22DEC2020	04JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 07JAN2021, B.47

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1079 10791123 (USA/NORTH CAROLINA/61/F)	Placebo	Dose 2/135	13JAN2021	18JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 22JAN2021, B.1.2
C4591001 1079 10791230 (USA/NORTH CAROLINA/19/M)	Placebo	Dose 2/83	13DEC2020	20DEC2020	Neg/Pos/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 18DEC2020, B.1.1.244
C4591001 1079 10791255 (USA/NORTH CAROLINA/58/M)	Placebo	Dose 2/96	01JAN2021	03JAN2021	Neg/Neg/Neg	Fever Chills	Pos/, 04JAN2021, B.1.2
C4591001 1079 10791257 (USA/NORTH CAROLINA/45/M)	Placebo	Dose 2/98	05JAN2021	08FEB2021	Neg/Neg/Neg	Fever New or increased cough New or increased	Pos/, 06JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1079 10791296 (USA/NORTH CAROLINA/40/F)	Placebo	Dose 2/29	26NOV2020	10DEC2020	Neg/Neg/Neg	shortness of breath Chills New or increased muscle pain Diarrhea New or increased cough New loss of taste or smell Sore throat Diarrhea	Pos/Pos, 01DEC2020, B.1.2
C4591001 1080 10801135 (USA/FLORIDA/28/M)	Placebo	Dose 2/126	28JAN2021	17FEB2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills	Pos/, 11FEB2021, QNS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1081 10811014 (USA/OHIO/63/M)	Placebo	Dose 2/103	12DEC2020	20FEB2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 15DEC2020, B.1.2
C4591001 1081 10811043 (USA/OHIO/58/F)	Placebo	Dose 2/90	06DEC2020	21DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 08DEC2020, B.1.2
C4591001 1081 10811077 (USA/OHIO/50/F)	Placebo	Dose 2/132	19JAN2021	02FEB2021	Neg/Neg/Neg	Fever	Pos/, 23JAN2021, B.1.1.222
C4591001 1081 10811086 (USA/OHIO/45/F)	Placebo	Dose 2/117	09JAN2021	05FEB2021	Neg/Neg/Neg	New or increased cough Chills Fever	Pos/, 14JAN2021, B.1.438
						New or increased cough Chills	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1081 10811151 (USA/OHIO/79/F)	Placebo	Dose 2/10	30SEP2020	14OCT2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 14OCT2020, QNS
C4591001 1081 10811173 (USA/OHIO/66/M)	Placebo	Dose 2/99	31DEC2020		Neg/Neg/Neg	New or increased cough Diarrhea	Pos/, 04JAN2021, B.1.2
C4591001 1081 10811196 (USA/OHIO/48/F)	Placebo	Dose 2/90	29DEC2020	26JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 31DEC2020, B.1.2
C4591001 1081 10811210 (USA/OHIO/51/M)	BNT162b2 (30 µg)	Dose 2/85	31DEC2020	21JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/ (R1 Pos), 02JAN2021 (03JAN2021), B.1.2 (B.1.2)
C4591001 1082 10821016 (USA/TENNESSEE/46/F)	Placebo	Dose 2/44	06OCT2020	27OCT2020	Neg/Neg/Neg	Fever	Pos/, 07OCT2020, B.1.400

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1082 10821026 (USA/TENNESSEE/48/M)	Placebo	Dose 2/81	13NOV2020	24DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 18NOV2020, B.1.2
C4591001 1082 10821143 (USA/TENNESSEE/41/M)	Placebo	Dose 2/48	11NOV2020	05DEC2020	Neg/Neg/Neg	Fever	Pos/, 13NOV2020, B.1
C4591001 1082 10821162 (USA/TENNESSEE/72/M)	Placebo	Dose 2/50	27NOV2020	23DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Fever	Pos/, 03DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1083 10831181 (USA/TEXAS/35/F)	Placebo	Dose 2/99	28DEC2020	03JAN2021	Neg/Neg/Neg	Chills New or increased cough New or increased shortness of breath New loss of taste or smell	Pos/, 30DEC2020, B.1.2
C4591001 1084 10841016 (USA/TEXAS/43/M)	Placebo	Dose 2/130	31DEC2020	05JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 07JAN2021, B.1.2
C4591001 1084 10841089 (USA/TEXAS/28/M)	Placebo	Dose 2/85	20NOV2020	02DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 24NOV2020, B.1.2
C4591001 1084 10841188 (USA/TEXAS/48/F)	Placebo	Dose 2/83	25NOV2020	07DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 30NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1084 10841302 (USA/TEXAS/65/F)	Placebo	Dose 2/56	12NOV2020	30NOV2020	Neg/Neg/Neg	New or increased shortness of breath Vomiting	Pos/, 16NOV2020, B.1.2
C4591001 1084 10841392 (USA/TEXAS/72/F)	Placebo	Dose 2/80	25DEC2020	27DEC2020	Neg/Neg/Neg	New or increased shortness of breath Fever	Pos/, 29DEC2020, B.1.2
C4591001 1085 10851004 (USA/TEXAS/49/F)	Placebo	Dose 2/120	17DEC2020	18DEC2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell	Pos/, 18DEC2020, B.1.509
C4591001 1085 10851027 (USA/TEXAS/50/F)	Placebo	Dose 2/101	02DEC2020	25FEB2021	Neg/Neg/Neg	New or increased	Pos/, 04DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1085 10851177 (USA/TEXAS/70/M)	Placebo	Dose 2/107	01JAN2021	05JAN2021	Neg/Neg/Neg	shortness of breath New or increased muscle pain New or increased cough	Pos/, 05JAN2021, B.1.2
C4591001 1085 10851258 (USA/TEXAS/58/M)	Placebo	Dose 2/100	30DEC2020	03JAN2021	Neg/Neg/Neg	Chills	Pos/, 04JAN2021, B.1.2
C4591001 1085 10851293 (USA/TEXAS/63/F)	Placebo	Dose 2/37	07NOV2020	27NOV2020	Neg/Neg/Neg	Fever	Pos/, 10NOV2020, INDETERMINATE
C4591001 1085 10851347 (USA/TEXAS/77/F)	Placebo	Dose 2/75	22DEC2020	29DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased cough	Pos/, 29DEC2020, B.1.2
C4591001 1085 10851374 (USA/TEXAS/17/F)	Placebo	Dose 2/48	03JAN2021	07JAN2021	Neg/Neg/Neg	Chills Sore throat	Pos/, 04JAN2021, NS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1087 10871572 (USA/NORTH CAROLINA/54/M)	Placebo	Dose 2/88	31JAN2021	15FEB2021	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 01FEB2021, B.1.243
C4591001 1088 10881011 (USA/NORTH CAROLINA/48/F)	Placebo	Dose 2/89	27NOV2020	19DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 03DEC2020, B.1.2
C4591001 1088 10881016 (USA/NORTH CAROLINA/50/F)	Placebo	Dose 2/119	28DEC2020	02JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 29DEC2020, B.1.2
C4591001 1088 10881024 (USA/NORTH CAROLINA/32/F)	Placebo	Dose 2/96	06DEC2020	20DEC2020	Neg/Neg/Neg	Fever	Pos/, 09DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1088 10881075 (USA/NORTH CAROLINA/68/F)	Placebo	Dose 2/83	02DEC2020	13DEC2020	Neg/Neg/Neg	Chills Sore throat New or increased cough	Pos/, 07DEC2020, B.1.2
C4591001 1088 10881086 (USA/NORTH CAROLINA/69/F)	Placebo	Dose 2/106	28DEC2020	04JAN2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 29DEC2020, B.1.2
C4591001 1088 10881091 (USA/NORTH CAROLINA/66/F)	Placebo	Dose 2/132	25JAN2021	03MAR2021	Neg/Neg/Unk	New or increased muscle pain Sore throat Fever	Pos/, 28JAN2021, B.1.243
C4591001 1088 10881097 (USA/NORTH CAROLINA/57/M)	Placebo	Dose 2/83	07DEC2020	17DEC2020	Neg/Neg/Neg	Chills Fever New or increased cough Chills	Pos/, 08DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1088 10881126 (USA/NORTH CAROLINA/65/M)	Placebo	Dose 2/68	29NOV2020	01DEC2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 30NOV2020, B.1.2
C4591001 1088 10881142 (USA/NORTH CAROLINA/61/F)	Placebo	Dose 2/94	25DEC2020	29DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 29DEC2020, B.1.2
C4591001 1088 10881148 (USA/NORTH CAROLINA/28/F)	Placebo	Dose 2/73	04DEC2020	10DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 09DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1088 10881164 (USA/NORTH CAROLINA/58/F)	Placebo	Dose 2/46	13NOV2020	03DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 18NOV2020, B.1.2
C4591001 1088 10881188 (USA/NORTH CAROLINA/67/F)	Placebo	Dose 2/84	21DEC2020	15JAN2021	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 23DEC2020, B.1.2
C4591001 1088 10881219 (USA/NORTH CAROLINA/63/M)	Placebo	Dose 2/17	25OCT2020	16NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 26OCT2020, B.1.2
C4591001 1088 10881233 (USA/NORTH CAROLINA/47/M)	Placebo	Dose 2/15	02NOV2020	12NOV2020	Neg/Neg/Neg	Fever	Pos/, 04NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1089 10891100 (USA/NORTH CAROLINA/33/F)	Placebo	Dose 2/115	24DEC2020	05FEB2021	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/, 28DEC2020, B.1.361
C4591001 1089 10891110 (USA/NORTH CAROLINA/59/F)	Placebo	Dose 2/158	04FEB2021	20FEB2021	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Fever	Pos/, 11FEB2021, B.1.2
C4591001 1089 10891115 (USA/NORTH CAROLINA/55/M)	BNT162b2 (30 µg)	Dose 2/140	21JAN2021	25FEB2021	Neg/Neg/Neg	New or increased cough Diarrhea Vomiting New loss of taste or smell	Pos/, 26JAN2021, B.1.210

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1089 10891235 (USA/NORTH CAROLINA/29/F)	Placebo	Dose 2/47	08NOV2020	18NOV2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 12NOV2020, B.1.2
C4591001 1089 10891314 (USA/NORTH CAROLINA/57/F)	Placebo	Dose 2/56	30NOV2020	11DEC2020	Neg/Neg/Neg	New or increased cough Sore throat Diarrhea	Pos/, 30NOV2020, B.1.2
C4591001 1090 10901022 (USA/NORTH CAROLINA/52/F)	BNT162b2 (30 µg)	Dose 2/114	19DEC2020	07JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 31DEC2020, B.1.1.222
C4591001 1090 10901075 (USA/NORTH CAROLINA/73/M)	Placebo	Dose 2/96	01DEC2020	18DEC2020	Neg/Neg/Neg	Diarrhea	Pos/, 21DEC2020, B.1.2
C4591001 1090 10901086 (USA/NORTH CAROLINA/55/M)	Placebo	Dose 2/165	08FEB2021		Neg/Neg/Neg	New or increased muscle pain	Pos/, 10FEB2021, B.1.429
C4591001 1090 10901121 (USA/NORTH CAROLINA/58/F)	Placebo	Dose 2/49	18OCT2020	22OCT2020	Neg/Neg/Neg	Fever New loss of taste or smell	Pos/, 20OCT2020, B.1.369
C4591001 1090 10901278 (USA/NORTH CAROLINA/46/M)	Placebo	Dose 2/81	10DEC2020	22DEC2020	Neg/Neg/Neg	Fever	Pos/, 14DEC2020, B.1.239

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1090 10901349 (USA/NORTH CAROLINA/53/M)	Placebo	Dose 2/105	11JAN2021	16JAN2021	Neg/Neg/Neg	New or increased muscle pain Diarrhea	Pos/, 12JAN2021, B.1.1.244
C4591001 1090 10901353 (USA/NORTH CAROLINA/63/M)	Placebo	Dose 2/40	08NOV2020	29NOV2020	Neg/Neg/Neg	Fever	Pos/, 09NOV2020, B.1.349
C4591001 1090 10901528 (USA/NORTH CAROLINA/53/F)	Placebo	Dose 2/43	24DEC2020	24JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 28DEC2020, B.1.2
C4591001 1091 10911003 (USA/OHIO/59/M)	Placebo	Dose 2/135	01JAN2021	10JAN2021	Neg/Neg/Neg	New or increased muscle pain	Pos/, 14JAN2021, B.1
C4591001 1091 10911071 (USA/OHIO/66/F)	Placebo	Dose 2/164	10FEB2021	27FEB2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 18FEB2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1091 10911119 (USA/OHIO/44/F)	Placebo	Dose 2/121	31DEC2020	21JAN2021	Neg/Neg/Neg	Sore throat	Pos/Pos, 05JAN2021, B.1.2
C4591001 1091 10911183 (USA/OHIO/26/M)	Placebo	Dose 2/62	17NOV2020	26NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 18NOV2020, B.1.1.253
C4591001 1091 10911198 (USA/OHIO/34/M)	Placebo	Dose 2/93	17DEC2020	30DEC2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 18DEC2020, B.1.400

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1091 10911203 (USA/43/M)	Placebo	Dose 2/44	05NOV2020		Neg/Neg/Neg	New loss of taste or smell New or increased cough	Unk/Pos, 05NOV2020, NS
C4591001 1091 10911327 (USA/OHIO/40/F)	Placebo	Dose 2/38	18NOV2020	25NOV2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 20NOV2020, B.1.2
C4591001 1091 10911365 (USA/OHIO/73/F)	Placebo	Dose 2/50	24DEC2020	07JAN2021	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell Fever New or increased cough Sore throat Diarrhea	Pos/, 26DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1091 10911371 (USA/OHIO/31/M)	Placebo	Dose 2/14	24NOV2020	09DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 26NOV2020, B.1.2
C4591001 1091 10911404 (USA/OHIO/13/F)	Placebo	Dose 2/27	23JAN2021		Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 25JAN2021, B.1.361
C4591001 1092 10921021 (USA/OHIO/60/F)	Placebo	Dose 2/48	27OCT2020	17NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 29OCT2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1092 10921055 (USA/OHIO/19/F)	Placebo	Dose 2/88	10DEC2020	20DEC2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 14DEC2020, B.1.2
C4591001 1092 10921079 (USA/OHIO/67/M)	Placebo	Dose 2/122	15JAN2021	04FEB2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 03FEB2021, NS
C4591001 1092 10921089 (USA/OHIO/63/F)	BNT162b2 (30 µg)	Dose 2/101	25DEC2020	01JAN2021	Neg/Neg/Neg	Chills	Pos/, 27DEC2020, B.1.2
C4591001 1092 10921092 (USA/OHIO/66/M)	Placebo	Dose 2/66	21NOV2020	11DEC2020	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills	Pos/, 25NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1092 10921130 (USA/OHIO/53/M)	Placebo	Dose 2/18	09OCT2020		Neg/Neg/Neg	New or increased muscle pain Sore throat Vomiting Fever	Pos/, 12OCT2020, B.1.2
C4591001 1092 10921176 (USA/OHIO/68/M)	Placebo	Dose 2/86	24DEC2020	17JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New loss of taste or smell Sore throat Diarrhea Fever	Pos/, 28DEC2020, B.1.2
						New or increased cough	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1092 10921242 (USA/OHIO/69/M)	Placebo	Dose 2/9	12NOV2020	10JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/ (R1 Pos), 17NOV2020 (01DEC2020), B.1.2 (B.1)
C4591001 1092 10921258 (USA/OHIO/60/F)	Placebo	Dose 2/52	01JAN2021	14JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 06JAN2021, B.1.2
C4591001 1093 10931019 (USA/IOWA/28/M)	Placebo	Dose 2/87	03DEC2020	12DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat New or increased cough	Pos/, 04DEC2020, B.1.234

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1093 10931028 (USA/IOWA/38/M)	Placebo	Dose 2/69	17NOV2020	23NOV2020	Neg/Neg/Neg	New or increased shortness of breath Chills New loss of taste or smell Sore throat Diarrhea Vomiting	Pos/, 18NOV2020, B.1.240
C4591001 1093 10931081 (USA/IOWA/67/F)	Placebo	Dose 2/19	05OCT2020	19OCT2020	Neg/Neg/Neg	Sore throat	Pos/, 06OCT2020, B.1.2
C4591001 1093 10931121 (USA/IOWA/37/F)	Placebo	Dose 2/50	23NOV2020	01DEC2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell	Pos/, 30NOV2020, B.1.234

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1093 10931177 (USA/IOWA/55/F)	Placebo	Dose 2/15	23NOV2020	27NOV2020	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain	Pos/, 30NOV2020, B.1.234
C4591001 1093 10931189 (USA/IOWA/74/M)	Placebo	Dose 2/26	04DEC2020	15DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/, 07DEC2020, B.1.240
C4591001 1093 10931216 (USA/IOWA/35/M)	Placebo	Dose 2/11	30NOV2020	02DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 02DEC2020, B.1
C4591001 1094 10941056 (USA/TEXAS/58/F)	Placebo	Dose 2/68	21NOV2020	22DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 25NOV2020, NS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1094 10941163 (USA/TEXAS/53/F)	Placebo	Dose 2/61	19DEC2020	19JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 22DEC2020, B.1.2
C4591001 1094 10941171 (USA/TEXAS/71/M)	Placebo	Dose 2/60	25DEC2020	12JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 28DEC2020, B.1.2
C4591001 1095 10951002 (USA/TEXAS/20/F)	Placebo	Dose 2/140	07JAN2021	08JAN2021	Neg/Neg/Neg	Fever Chills	Pos/, 11JAN2021, B.1.2
C4591001 1095 10951060 (USA/TEXAS/36/M)	Placebo	Dose 2/104	08DEC2020	07JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Diarrhea Vomiting	Pos/, 09DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1095 10951098 (USA/TEXAS/59/F)	Placebo	Dose 2/71	06NOV2020	17DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 10NOV2020, B.1.2
C4591001 1095 10951117 (USA/TEXAS/70/M)	Placebo	Dose 2/96	15DEC2020	02JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 19DEC2020, B.1
C4591001 1095 10951196 (USA/TEXAS/50/M)	Placebo	Dose 2/88	18DEC2020	21DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 21DEC2020, NS
C4591001 1095 10951223 (USA/TEXAS/42/M)	Placebo	Dose 2/95	27DEC2020	01JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 30DEC2020, B.1.243

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1095 10951238 (USA/TEXAS/63/F)	Placebo	Dose 2/19	02NOV2020	20DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 09NOV2020, B.1.2
C4591001 1095 10951260 (USA/TEXAS/25/M)	Placebo	Dose 2/9	05NOV2020	05NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 09NOV2020, B.1
C4591001 1096 10961021 (USA/TEXAS/67/F)	Placebo	Dose 2/98	08DEC2020	09JAN2021	Neg/Neg/Neg	Chills	Pos/, 18DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1096 10961072 (USA/TEXAS/49/M)	Placebo	Dose 2/98	22DEC2020	08JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat Diarrhea	Pos/, 28DEC2020, INDETERMINATE
C4591001 1096 10961164 (USA/TEXAS/62/F)	BNT162b2 (30 µg)	Dose 2/104	29DEC2020	25JAN2021	Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/, 05JAN2021, B.1.2
C4591001 1096 10961172 (USA/TEXAS/51/M)	Placebo	Dose 2/49	06NOV2020	08NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 10NOV2020, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1096 10961258 (USA/TEXAS/55/F)	Placebo	Dose 2/25	22OCT2020	26OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/Pos, 26OCT2020, B.1.2
C4591001 1097 10971038 (USA/SOUTH CAROLINA/64/M)	Placebo	Dose 2/79	04DEC2020	15DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 08DEC2020, B.1.110.3
C4591001 1098 10981028 (USA/TEXAS/58/M)	Placebo	Dose 2/102	21DEC2020	02JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 22DEC2020, B.1.2
C4591001 1098 10981046 (USA/TEXAS/66/F)	BNT162b2 (30 µg)	Dose 2/70	23NOV2020	23NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 25NOV2020, B.1.1.29
C4591001 1098 10981058 (USA/TEXAS/69/F)	Placebo	Dose 2/130	23JAN2021	06FEB2021	Neg/Neg/Neg	Fever	Pos/, 04FEB2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1098 10981062 (USA/TEXAS/63/F)	Placebo	Dose 2/32	17OCT2020	20OCT2020	Neg/Neg/Neg	New or increased muscle pain New or increased muscle pain	Pos/, 19OCT2020, B.1.2
C4591001 1098 10981187 (USA/TEXAS/23/M)	Placebo	Dose 2/124	07FEB2021	18FEB2021	Neg/Neg/Neg	Fever	Pos/, 10FEB2021, B.1.429
C4591001 1098 10981216 (USA/TEXAS/52/M)	Placebo	Dose 2/42	23NOV2020	29NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat	Pos/, 25NOV2020, B.1.2
C4591001 1101 11011041 (USA/NEBRASKA/54/F)	Placebo	Dose 2/107	15JAN2021	21JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 19JAN2021, B.1.2
C4591001 1101 11011095 (USA/NEBRASKA/60/M)	Placebo	Dose 2/20	02NOV2020	06NOV2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 04NOV2020, B.1.2
C4591001 1101 11011105 (USA/NEBRASKA/22/F)	Placebo	Dose 2/18	19NOV2020	27NOV2020	Neg/Neg/Neg	Fever	Pos/, 24NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1107 11071037 (USA/ALABAMA/59/M)	Placebo	Dose 2/124	26DEC2020	29JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 03JAN2021, B.1.2
C4591001 1107 11071121 (USA/ALABAMA/77/M)	Placebo	Dose 2/98	14DEC2020	30DEC2020	Neg/Neg/Neg	New or increased muscle pain Chills	Pos/, 27DEC2020, B.1.2
C4591001 1107 11071170 (USA/ALABAMA/61/F)	Placebo	Dose 2/101	23DEC2020	02JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 27DEC2020, B.1.349

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1107 11071171 (USA/ALABAMA/39/M)	Placebo	Dose 2/58	10NOV2020	20NOV2020	Neg/Neg/Neg	Fever	Pos/, 11NOV2020, B.1
C4591001 1107 11071190 (USA/ALABAMA/42/F)	Placebo	Dose 2/82	13DEC2020	28DEC2020	Neg/Neg/Neg	Chills New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 14DEC2020, B.1.234
C4591001 1109 11091067 (USA/FLORIDA/42/M)	Placebo	Dose 2/84	11NOV2020	28NOV2020	Neg/Neg/Neg	New or increased shortness of breath Sore throat	Pos/, 11NOV2020, B.1.311
C4591001 1109 11091092 (USA/FLORIDA/18/M)	Placebo	Dose 2/70	31OCT2020	24NOV2020	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 10NOV2020, B.1.240
C4591001 1109 11091147 (USA/FLORIDA/46/F)	Placebo	Dose 2/151	20JAN2021	26JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 22JAN2021, B.1.306

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1109 11091229 (USA/FLORIDA/69/F)	Placebo	Dose 2/82	26NOV2020	12JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 28NOV2020, B.1.2
C4591001 1109 11091233 (USA/FLORIDA/59/F)	BNT162b2 (30 µg)	Dose 2/115	26DEC2020	28DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 29DEC2020, B.1.311
C4591001 1109 11091309 (USA/FLORIDA/24/F)	Placebo	Dose 2/124	11JAN2021	21JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New loss of taste or smell	Pos/, 15JAN2021, B.1
C4591001 1109 11091316 (USA/FLORIDA/47/M)	Placebo	Dose 2/115	05JAN2021		Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/, 08JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1109 11091323 (USA/FLORIDA/64/M)	Placebo	Dose 2/47	31OCT2020	02NOV2020	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 03NOV2020, B.1.2
C4591001 1109 11091346 (USA/FLORIDA/64/M)	Placebo	Dose 2/99	24DEC2020		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 04JAN2021, INDETERMINATE
C4591001 1109 11091415 (USA/FLORIDA/48/F)	Placebo	Dose 2/93	27DEC2020	18JAN2021	Neg/Neg/Neg	New loss of taste or smell Fever New or increased cough New or increased	Pos/, 29DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1109 11091416 (USA/FLORIDA/46/F)	Placebo	Dose 2/41	03NOV2020	17NOV2020	Neg/Neg/Neg	shortness of breath Chills Sore throat Fever	Pos/, 11NOV2020, B.1.2
C4591001 1109 11091448 (USA/FLORIDA/46/F)	Placebo	Dose 2/9	06OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/ (R1 Pos), 09OCT2020 (23OCT2020), B.1.2 (B.1.2)
						New or increased cough New or increased shortness of breath New or increased muscle pain	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1109 11091482 (USA/FLORIDA/63/M)	Placebo	Dose 2/28	29OCT2020	13NOV2020	Neg/Neg/Neg	Sore throat New or increased cough	Pos/, 03NOV2020, B.1.369
C4591001 1110 11101050 (USA/FLORIDA/47/M)	BNT162b2 (30 µg)	Dose 2/76	10NOV2020	12JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough Chills	Pos/, 12NOV2020, B.1.2
C4591001 1110 11101079 (USA/FLORIDA/71/F)	Placebo	Dose 2/88	28NOV2020	13DEC2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain	Pos/, 04DEC2020, B.1.2
C4591001 1110 11101108 (USA/FLORIDA/58/M)	Placebo	Dose 2/95	11DEC2020	15JAN2021	Neg/Neg/Neg	New loss of taste or smell Fever Chills	Pos/, 15DEC2020, B.1.1.143

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1110 11101111 (USA/FLORIDA/45/M)	Placebo	Dose 2/108	25DEC2020	06JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/, 02JAN2021, B.1.2
C4591001 1110 11101136 (USA/FLORIDA/62/M)	Placebo	Dose 2/52	04NOV2020	15JAN2021	Neg/Neg/Neg	Diarrhea New or increased cough Chills Diarrhea	Pos/, 06NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1110 11101162 (USA/FLORIDA/51/M)	BNT162b2 (30 µg)	Dose 2/34	24OCT2020	04NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 26OCT2020, B.1.2
C4591001 1110 11101232 (USA/FLORIDA/62/M)	BNT162b2 (30 µg)	Dose 2/113	21JAN2021	15FEB2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 22JAN2021, B.1.2
C4591001 1110 11101325 (USA/FLORIDA/42/F)	Placebo	Dose 2/75	04JAN2021	26JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 07JAN2021, B.1.2
C4591001 1111 11111010 (USA/FLORIDA/75/M)	Placebo	Dose 2/45	04OCT2020	05OCT2020	Neg/Neg/Neg	Fever Chills	Pos/, 06OCT2020, B.1.2
C4591001 1111 11111128 (USA/FLORIDA/60/F)	Placebo	Dose 2/127	12JAN2021	19JAN2021	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 15JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1111 11111150 (USA/FLORIDA/57/M)	Placebo	Dose 2/43	02NOV2020	17NOV2020	Neg/Neg/Neg	Sore throat Chills	Pos/, 17NOV2020, B.1.311
C4591001 1111 11111186 (USA/FLORIDA/88/M)	Placebo	Dose 2/79	29DEC2020	05JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 05JAN2021, B.1.2
C4591001 1112 11121003 (USA/GEORGIA/64/F)	Placebo	Dose 2/116	12DEC2020	28DEC2020	Neg/Neg/Neg	Diarrhea Fever	Pos/, 15DEC2020, B.1.1.222
C4591001 1112 11121064 (USA/GEORGIA/42/M)	Placebo	Dose 2/131	02JAN2021	18JAN2021	Neg/Neg/Neg	New or increased cough Sore throat Diarrhea	Pos/, 06JAN2021, B.1.2
C4591001 1112 11121210 (USA/GEORGIA/69/F)	Placebo	Dose 2/88	21DEC2020	06JAN2021	Neg/Neg/Neg	Diarrhea New loss of taste or smell	Pos/, 21DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1112 11121224 (USA/GEORGIA/45/F)	Placebo	Dose 2/76	07DEC2020	28DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 15DEC2020, B.1.2
C4591001 1112 11121245 (USA/GEORGIA/41/F)	Placebo	Dose 2/91	30DEC2020	02JAN2021	Neg/Neg/Neg	New or increased cough Chills	Pos/, 04JAN2021, B.1.2
C4591001 1112 11121301 (USA/GEORGIA/47/M)	Placebo	Dose 2/27	28NOV2020	19DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 29NOV2020, B.1.280
C4591001 1114 11141008 (USA/KANSAS/22/M)	Placebo	Dose 2/80	19NOV2020	23NOV2020	Neg/Neg/Neg	Fever	Pos/, 20NOV2020, B.1.2
C4591001 1114 11141014 (USA/KANSAS/20/F)	BNT162b2 (30 µg)	Dose 2/123	01JAN2021	21JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 06JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1114 11141024 (USA/KANSAS/18/F)	Placebo	Dose 2/126	07JAN2021	31JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 11JAN2021, B.1.2
C4591001 1114 11141075 (USA/KANSAS/40/F)	Placebo	Dose 2/110	28DEC2020	16FEB2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/, 04JAN2021, QNS
C4591001 1116 11161072 (USA/MISSISSIPPI/52/F)	Placebo	Dose 2/81	10DEC2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 14DEC2020, B.1.2
C4591001 1116 11161075 (USA/MISSISSIPPI/73/M)	Placebo	Dose 2/43	03NOV2020	19JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 05NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1116 11161104 (USA/MISSISSIPPI/38/F)	Placebo	Dose 2/140	07FEB2021	01MAR2021	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased cough	Pos/, 09FEB2021, B.1.2
C4591001 1116 11161111 (USA/MISSISSIPPI/71/F)	Placebo	Dose 2/111	12JAN2021	04FEB2021	Neg/Neg/Neg	New or increased cough	Pos/, 21JAN2021, INDETERMINATE
C4591001 1116 11161160 (USA/MISSISSIPPI/47/M)	Placebo	Dose 2/103	08JAN2021	18JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 13JAN2021, B.1.2
C4591001 1116 11161184 (USA/MISSISSIPPI/77/M)	Placebo	Dose 2/72	09DEC2020	24DEC2020	Neg/Neg/Neg	New or increased cough Chills	Pos/, 15DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1116 11161207 (USA/MISSISSIPPI/58/F)	Placebo	Dose 2/64	02DEC2020	25DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 03DEC2020, B.1.243
C4591001 1116 11161224 (USA/MISSISSIPPI/52/F)	Placebo	Dose 2/46	14NOV2020	20NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/, 16NOV2020, B.1.2
						New or increased cough Chills New or increased muscle pain Sore throat	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1116 11161250 (USA/MISSISSIPPI/62/F)	Placebo	Dose 2/55	01DEC2020	11DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 03DEC2020, B.1.234
C4591001 1116 11161275 (USA/MISSISSIPPI/58/F)	Placebo	Dose 2/80	01JAN2021	09JAN2021	Neg/Neg/Neg	Fever Chills Diarrhea	Pos/, 03JAN2021, B.1.234
C4591001 1116 11161283 (USA/MISSISSIPPI/72/F)	Placebo	Dose 2/39	20NOV2020	02DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 02DEC2020, B.1.361
C4591001 1117 11171010 (USA/MISSOURI/72/F)	Placebo	Dose 2/34	11OCT2020	19OCT2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 11OCT2020, B.1.2
C4591001 1117 11171028 (USA/MISSOURI/67/M)	Placebo	Dose 2/62	10NOV2020	01DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 13NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1117 11171031 (USA/MISSOURI/74/F)	Placebo	Dose 2/82	29NOV2020	07DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 05DEC2020, B.1.2
C4591001 1117 11171120 (USA/MISSOURI/60/M)	Placebo	Dose 2/67	11DEC2020	16DEC2020	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell	Pos/, 15DEC2020, B.1.2
C4591001 1117 11171121 (USA/MISSOURI/34/F)	Placebo	Dose 2/42	16NOV2020	11JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 22NOV2020, B.1.2
C4591001 1117 11171141 (USA/MISSOURI/73/F)	Placebo	Dose 2/53	04DEC2020	25DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 06DEC2020, INDETERMINATE

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1117 11171173 (USA/MISSOURI/61/M)	Placebo	Dose 2/38	22NOV2020	09DEC2020	Neg/Neg/Neg	New or increased shortness of breath New or increased muscle pain Diarrhea	Pos/, 30NOV2020, B.1.2
C4591001 1118 11181014 (USA/NEW YORK/38/F)	Placebo	Dose 2/119	28DEC2020	13JAN2021	Neg/Neg/Neg	Sore throat New or increased cough Chills New loss of taste or smell	Pos/, 30DEC2020, B.1.243
C4591001 1118 11181076 (USA/NEW YORK/33/F)	Placebo	Dose 2/110	27DEC2020	08JAN2021	Neg/Neg/Neg	Sore throat Fever New or increased cough	Pos/, 28DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1118 11181088 (USA/NEW YORK/73/M)	Placebo	Dose 2/36	20OCT2020	10NOV2020	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 29OCT2020, INDETERMINATE
C4591001 1120 11201091 (USA/GEORGIA/67/F)	Placebo	Dose 2/135	15JAN2021	19JAN2021	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 20JAN2021, B.1.243
C4591001 1120 11201101 (USA/GEORGIA/48/F)	Placebo	Dose 2/133	04JAN2021	07FEB2021	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 06JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1120 11201115 (USA/GEORGIA/19/F)	Placebo	Dose 2/73	06NOV2020	12NOV2020	Neg/Neg/Neg	New or increased muscle pain Diarrhea Vomiting Fever	Pos/, 09NOV2020, B.1
C4591001 1120 11201154 (USA/GEORGIA/35/F)	Placebo	Dose 2/168	17FEB2021		Neg/Neg/Neg	New or increased muscle pain Sore throat Diarrhea Fever	Pos/, 19FEB2021, B.1.2
C4591001 1120 11201191 (USA/GEORGIA/23/M)	Placebo	Dose 2/86	26NOV2020	28NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills Sore throat	Pos/, 27NOV2020, B.1.1.222

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1120 11201353 (USA/GEORGIA/59/F)	Placebo	Dose 2/98	18FEB2021	10MAR2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat Diarrhea	Pos/, 04MAR2021, B.1
C4591001 1120 11201374 (USA/GEORGIA/71/F)	Placebo	Dose 2/49	28DEC2020	04JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 30DEC2020, B.1.2
C4591001 1121 11211069 (USA/ILLINOIS/45/M)	Placebo	Dose 2/71	01DEC2020	20DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 04DEC2020, QNS
C4591001 1121 11211070 (USA/ILLINOIS/43/F)	Placebo	Dose 2/56	16NOV2020	20DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 27NOV2020, B.1.369
C4591001 1121 11211094 (USA/ILLINOIS/28/M)	Placebo	Dose 2/86	23DEC2020		Neg/Neg/Neg	New or increased shortness of breath	Pos/, 23DEC2020, B.1.139

090177e1972f8110\Final\Final On: 02-Jun-2021 12:50 (GMT)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1121 11211105 (USA/ILLINOIS/52/M)	Placebo	Dose 2/39	05NOV2020	10DEC2020	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/, 06NOV2020, B.1.2
C4591001 1122 11221025 (USA/OHIO/40/M)	Placebo	Dose 2/32	01NOV2020	16NOV2020	Neg/Neg/Neg	New or increased cough Sore throat Fever	Pos/, 03NOV2020, B.1.2
C4591001 1123 11231025 (USA/NEBRASKA/60/F)	Placebo	Dose 2/77	08NOV2020	13DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell New or increased cough New loss of taste or smell	Pos/, 11NOV2020, B.1.234

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1123 11231073 (USA/NEBRASKA/25/F)	Placebo	Dose 2/10	10SEP2020	25SEP2020	Neg/Neg/Neg	Sore throat New or increased cough Chills New or increased muscle pain	Pos/Pos, 11SEP2020, B.1.369
C4591001 1123 11231086 (USA/NEBRASKA/35/F)	Placebo	Dose 2/57	27OCT2020	18NOV2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain	Pos/, 28OCT2020, B.1.2
C4591001 1123 11231102 (USA/NEBRASKA/52/F)	Placebo	Dose 2/88	28NOV2020	11DEC2020	Neg/Neg/Neg	Diarrhea	Pos/, 01DEC2020, B.1.509
C4591001 1123 11231103 (USA/NEBRASKA/63/M)	BNT162b2 (30 µg)	Dose 2/105	15DEC2020	26DEC2020	Neg/Neg/Neg	Fever New or increased cough Diarrhea	Pos/, 23DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1123 11231117 (USA/NEBRASKA/55/F)	Placebo	Dose 2/64	10NOV2020	22NOV2020	Neg/Neg/Neg	Chills	Pos/, 11NOV2020, B.1.234
C4591001 1123 11231123 (USA/NEBRASKA/47/F)	Placebo	Dose 2/84	01DEC2020	11DEC2020	Neg/Neg/Neg	Fever New or increased muscle pain New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Diarrhea Vomiting	Pos/, 07DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1123 11231132 (USA/NEBRASKA/32/F)	Placebo	Dose 2/99	15DEC2020	26DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 16DEC2020, QNS
C4591001 1123 11231156 (USA/NEBRASKA/33/F)	Placebo	Dose 2/55	07NOV2020	30NOV2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/, 12NOV2020, B.1.2
C4591001 1123 11231182 (USA/NEBRASKA/65/M)	Placebo	Dose 2/108	30DEC2020	08JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 30DEC2020, B.1.324

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1123 11231214 (USA/NEBRASKA/60/F)	Placebo	Dose 2/34	26OCT2020	01DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New loss of taste or smell Sore throat	Pos/, 05NOV2020, B.1.2
C4591001 1123 11231232 (USA/NEBRASKA/39/F)	BNT162b2 (30 µg)	Dose 2/83	21DEC2020	08JAN2021	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell	Pos/, 23DEC2020, B.1.2
C4591001 1123 11231234 (USA/NEBRASKA/29/M)	Placebo	Dose 2/32	02NOV2020	12NOV2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 03NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1123 11231255 (USA/NEBRASKA/76/M)	Placebo	Dose 2/20	24OCT2020	01NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 02NOV2020, B.1.349
C4591001 1123 11231256 (USA/NEBRASKA/72/F)	Placebo	Dose 2/20	24OCT2020	25NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 02NOV2020, B.1.349
C4591001 1123 11231284 (USA/NEBRASKA/67/M)	Placebo	Dose 2/12	24OCT2020	24NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 26OCT2020, B.1.2
C4591001 1123 11231339 (USA/NEBRASKA/35/F)	Placebo	Dose 2/38	02DEC2020	15JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased	Pos/, 09DEC2020, B.1.369

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1123 11231357 (USA/NEBRASKA/51/F)	Placebo	Dose 2/44	11DEC2020	18FEB2021	Neg/Neg/Neg	shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 15DEC2020, B.1
C4591001 1124 11241007 (USA/RHODE ISLAND/60/F)	Placebo	Dose 2/85	23NOV2020	03DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Fever	Pos/, 24NOV2020, B.1.517

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1124 11241052 (USA/RHODE ISLAND/39/F)	Placebo	Dose 2/101	18DEC2020	31DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 21DEC2020, B.1
C4591001 1124 11241117 (USA/RHODE ISLAND/57/F)	Placebo	Dose 2/60	14NOV2020	19NOV2020	Neg/Neg/Neg	New or increased shortness of breath	Pos/, 15NOV2020, B.1.2
C4591001 1124 11241128 (USA/RHODE ISLAND/67/M)	Placebo	Dose 2/88	17DEC2020		Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath	Pos/, 18JAN2021, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1124 11241176 (USA/RHODE ISLAND/49/M)	Placebo	Dose 2/72	03DEC2020	20DEC2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/, 04DEC2020, B.1.517
C4591001 1125 11251006 (USA/NEBRASKA/35/M)	Placebo	Dose 2/42	11OCT2020	12OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Fever	Pos/, 11OCT2020, B.1.139
						New or increased cough Chills	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1125 11251014 (USA/NEBRASKA/45/F)	Placebo	Dose 2/59	30OCT2020	17NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills New or increased muscle pain Diarrhea	Pos/, 10NOV2020, B.1.413
C4591001 1125 11251023 (USA/NEBRASKA/49/M)	Placebo	Dose 2/56	27OCT2020	18NOV2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/, 06NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1125 11251028 (USA/NEBRASKA/39/F)	Placebo	Dose 2/27	29SEP2020	02OCT2020	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 01OCT2020, B.1
C4591001 1125 11251038 (USA/NEBRASKA/28/M)	Placebo	Dose 2/74	16NOV2020		Neg/Neg/Neg	Chills New or increased muscle pain Sore throat	Pos/, 23NOV2020, B.1.240
C4591001 1125 11251049 (USA/NEBRASKA/52/M)	Placebo	Dose 2/50	27OCT2020	24DEC2020	Neg/Neg/Neg	Diarrhea New loss of taste or smell	Pos/, 02NOV2020, B.1.2
C4591001 1125 11251088 (USA/NEBRASKA/67/M)	Placebo	Dose 2/92	14DEC2020	10JAN2021	Neg/Neg/Neg	Sore throat New or increased cough New or increased shortness of breath	Pos/, 23DEC2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1125 11251098 (USA/NEBRASKA/33/F)	Placebo	Dose 2/78	02DEC2020		Neg/Neg/Neg	New or increased cough	Pos/, 03DEC2020, B.1.2
C4591001 1125 11251106 (USA/NEBRASKA/44/F)	Placebo	Dose 2/68	20NOV2020	04DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 20NOV2020, B.1.2
C4591001 1125 11251109 (USA/NEBRASKA/46/F)	Placebo	Dose 2/51	04NOV2020	18NOV2020	Neg/Neg/Neg	Fever New or increased shortness of breath New or increased muscle pain Diarrhea	Pos/, 05NOV2020, B.1.2
C4591001 1125 11251114 (USA/NEBRASKA/59/M)	Placebo	Dose 2/38	22OCT2020	26OCT2020	Neg/Neg/Neg	Fever	Pos/Pos, 28OCT2020, B.1.2
C4591001 1125 11251124 (USA/NEBRASKA/39/M)	Placebo	Dose 2/53	08NOV2020	10NOV2020	Neg/Neg/Neg	Fever Chills	Pos/, 10NOV2020, B.1.139

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1125 11251177 (USA/NEBRASKA/50/F)	BNT162b2 (30 µg)	Dose 2/68	29NOV2020	13DEC2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 03DEC2020, B.1.2
C4591001 1125 11251208 (USA/NEBRASKA/51/F)	Placebo	Dose 2/43	13NOV2020	18NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/Pos, 19NOV2020, B.1.139
C4591001 1125 11251215 (USA/NEBRASKA/43/M)	Placebo	Dose 2/25	06NOV2020	13NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 11NOV2020, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1125 11251218 (USA/NEBRASKA/41/F)	Placebo	Dose 2/37	20NOV2020	04DEC2020	Neg/Neg/Neg	Chills New loss of taste or smell	Pos/, 23NOV2020, B.1.2
C4591001 1126 11261017 (USA/CALIFORNIA/34/F)	Placebo	Dose 2/50	20OCT2020	20NOV2020	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 21OCT2020, B.1.2
C4591001 1126 11261179 (USA/CALIFORNIA/60/M)	Placebo	Dose 2/85	30DEC2020	28JAN2021	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/, 04JAN2021, B.1.311
C4591001 1128 11281156 (USA/TEXAS/53/M)	Placebo	Dose 2/115	31DEC2020	15JAN2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 06JAN2021, B.1.2

090177e1972f8110\Final\Final On: 02-Jun-2021 12:50 (GMT)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1128 11281165 (USA/TEXAS/26/F)	Placebo	Dose 2/46	29OCT2020	03NOV2020	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain Diarrhea	Pos/, 02NOV2020, B.1.2
C4591001 1128 11281194 (USA/TEXAS/82/M)	Placebo	Dose 2/112	05JAN2021	19JAN2021	Neg/Neg/Neg	Sore throat New or increased cough Vomiting	Pos/, 21JAN2021, A.2
C4591001 1128 11281224 (USA/TEXAS/46/M)	Placebo	Dose 2/88	14DEC2020	29DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath	Pos/, 17DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1128 11281281 (USA/TEXAS/36/F)	Placebo	Dose 2/51	12NOV2020	13NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Fever	Pos/, 13NOV2020, B.1.2
C4591001 1128 11281312 (USA/TEXAS/40/M)	Placebo	Dose 2/66	04DEC2020	15JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat New or increased cough	Pos/, 08DEC2020, B.1.2
C4591001 1128 11281375 (USA/TEXAS/57/F)	Placebo	Dose 2/81	27DEC2020	29DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 28DEC2020, B.1.2
C4591001 1129 11291044 (USA/FLORIDA/62/F)	Placebo	Dose 2/92	24NOV2020	09DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 24NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1131 11311036 (USA/OHIO/62/F)	Placebo	Dose 2/112	29DEC2020	13JAN2021	Neg/Neg/Neg	Diarrhea Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 30DEC2020, B.1.2
C4591001 1131 11311039 (USA/OHIO/69/F)	Placebo	Dose 2/107	23DEC2020	26DEC2020	Neg/Neg/Neg	New or increased cough Diarrhea	Pos/, 28DEC2020, B.1.2
C4591001 1131 11311045 (USA/OHIO/40/M)	Placebo	Dose 2/143	31JAN2021	07FEB2021	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 01FEB2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1131 11311100 (USA/OHIO/64/M)	Placebo	Dose 2/58	12NOV2020	30NOV2020	Neg/Neg/Neg	Diarrhea Vomiting Fever	Pos/, 13NOV2020, B.1.2
C4591001 1131 11311113 (USA/OHIO/40/F)	Placebo	Dose 2/59	21NOV2020	23NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell New or increased cough	Pos/, 23NOV2020, B.1.2
C4591001 1131 11311138 (USA/OHIO/45/F)	Placebo	Dose 2/45	07NOV2020	01DEC2020	Neg/Neg/Neg	New or increased shortness of breath New or increased cough New or increased shortness of breath	Pos/, 10NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1131 11311160 (USA/OHIO/27/F)	Placebo	Dose 2/52	18NOV2020	02DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/, 23NOV2020, B.1.2
C4591001 1131 11311170 (USA/OHIO/60/F)	BNT162b2 (30 µg)	Dose 2/58	27NOV2020	22FEB2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 29NOV2020, B.1.2
C4591001 1131 11311241 (USA/OHIO/50/M)	Placebo	Dose 2/63	03JAN2021	10JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 11JAN2021, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1131 11311269 (USA/OHIO/16/M)	Placebo	Dose 2/45	28JAN2021	04FEB2021	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain New or increased cough	Pos/, 28JAN2021, B.1.429
C4591001 1133 11331097 (USA/FLORIDA/46/F)	Placebo	Dose 2/143	18JAN2021	08FEB2021	Neg/Neg/Neg	New or increased shortness of breath Chills Fever New or increased cough New or increased	Pos/, 02FEB2021, QNS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1133 11331209 (USA/FLORIDA/30/M)	Placebo	Dose 2/32	10OCT2020	15OCT2020	Neg/Neg/Neg	shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 13OCT2020, B.1
C4591001 1133 11331333 (USA/FLORIDA/46/F)	Placebo	Dose 2/108	08JAN2021	09FEB2021	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain	Pos/, 18JAN2021, B.1.1.29
C4591001 1133 11331335 (USA/FLORIDA/51/M)	Placebo	Dose 2/108	08JAN2021	27JAN2021	Neg/Neg/Neg	Fever	Pos/, 18JAN2021, B.1.1.29

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1133 11331445 (USA/FLORIDA/61/F)	Placebo	Dose 2/73	18DEC2020	15JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Fever	Pos/, 11JAN2021, QNS
C4591001 1133 11331511 (USA/FLORIDA/30/M)	BNT162b2 (30 µg)	Dose 2/50	02DEC2020	10DEC2020	Neg/Neg/Neg	Chills New or increased muscle pain Diarrhea New or increased shortness of breath	Pos/, 07DEC2020, B.1.1
C4591001 1133 11331525 (USA/FLORIDA/45/M)	Placebo	Dose 2/16	26NOV2020	27NOV2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 01DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1133 11331526 (USA/FLORIDA/55/M)	Placebo	Dose 2/20	30NOV2020	16DEC2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 01DEC2020, B.1.2
C4591001 1133 11331604 (USA/FLORIDA/54/M)	Placebo	Dose 2/19	07DEC2020	15DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 14DEC2020, B.1.2
C4591001 1134 11341022 (USA/NORTH CAROLINA/66/M)	Placebo	Dose 2/29	29SEP2020	03OCT2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 30SEP2020, B.1.369
C4591001 1134 11341031 (USA/NORTH CAROLINA/31/M)	Placebo	Dose 2/92	30NOV2020	05DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 01DEC2020, B.1.2
C4591001 1134 11341035 (USA/NORTH CAROLINA/59/F)	Placebo	Dose 2/114	23DEC2020	06JAN2021	Neg/Neg/Neg	Fever	Pos/, 24DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1134 11341086 (USA/NORTH CAROLINA/41/F)	Placebo	Dose 2/134	19JAN2021	15FEB2021	Neg/Neg/Neg	New or increased cough Diarrhea	Pos/, 20JAN2021, B.1.2
C4591001 1134 11341190 (USA/NORTH CAROLINA/52/F)	Placebo	Dose 2/94	19DEC2020	31DEC2020	Neg/Neg/Neg	New or increased cough Fever	Pos/, 20DEC2020, INDETERMINATE
C4591001 1134 11341254 (USA/NORTH CAROLINA/29/F)	Placebo	Dose 2/106	07JAN2021	03FEB2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Chills New or increased shortness of breath Sore throat	Neg/ (R1 Pos), (19JAN2021), (B.1.2)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1134 11341406 (USA/NORTH CAROLINA/48/M)	Placebo	Dose 2/43	14DEC2020	07JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Chills	Pos/, 28DEC2020, B.1.2
C4591001 1134 11341411 (USA/NORTH CAROLINA/69/M)	Placebo	Dose 2/18	20NOV2020	21NOV2020	Neg/Neg/Neg	Fever	Pos/, 21NOV2020, B.1.2
C4591001 1135 11351001 (USA/CALIFORNIA/18/M)	Placebo	Dose 2/83	15NOV2020	07DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 17NOV2020, B.1
C4591001 1135 11351023 (USA/CALIFORNIA/37/F)	Placebo	Dose 2/128	30DEC2020	06JAN2021	Neg/Neg/Neg	New or increased cough New or increased	Pos/, 02JAN2021, B.1.429

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1135 11351029 (USA/CALIFORNIA/27/M)	Placebo	Dose 2/84	18NOV2020	24NOV2020	Neg/Neg/Neg	shortness of breath New or increased cough	Pos/, 20NOV2020, B.1.2
C4591001 1135 11351038 (USA/CALIFORNIA/48/M)	Placebo	Dose 2/97	07DEC2020	15DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 08DEC2020, B.1.438
C4591001 1135 11351041 (USA/CALIFORNIA/29/F)	Placebo	Dose 2/122	27DEC2020	22JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Diarrhea	Pos/, 29DEC2020, B.1.404
C4591001 1135 11351045 (USA/CALIFORNIA/57/F)	Placebo	Dose 2/106	08DEC2020	22FEB2021	Neg/Neg/Neg	New or increased cough	Pos/, 10DEC2020, B.1.400

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1135 11351082 (USA/CALIFORNIA/39/F)	Placebo	Dose 2/116	21DEC2020	08JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough New or increased shortness of breath New or increased muscle pain Diarrhea Vomiting	Pos/, 24DEC2020, B.1.177
C4591001 1135 11351111 (USA/CALIFORNIA/53/F)	Placebo	Dose 2/128	05JAN2021	12JAN2021	Neg/Neg/Neg	New or increased muscle pain	Pos/, 06JAN2021, B.1.429
C4591001 1135 11351177 (USA/CALIFORNIA/46/F)	Placebo	Dose 2/70	18NOV2020	28NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 19NOV2020, B.1.311

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1135 11351207 (USA/CALIFORNIA/33/F)	Placebo	Dose 2/30	13OCT2020	28OCT2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Vomiting	Pos/, 19OCT2020, B.1.1.63
C4591001 1135 11351230 (USA/CALIFORNIA/38/M)	Placebo	Dose 2/48	15NOV2020	18NOV2020	Neg/Neg/Neg	Diarrhea Fever	Pos/, 17NOV2020, B.1.239
C4591001 1135 11351237 (USA/CALIFORNIA/75/F)	Placebo	Dose 2/99	28DEC2020	31DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New or increased cough	Pos/, 29DEC2020, B.1.427

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1135 11351294 (USA/CALIFORNIA/42/M)	Placebo	Dose 2/95	26DEC2020	29DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 29DEC2020, B.1.429
C4591001 1135 11351361 (USA/CALIFORNIA/24/F)	Placebo	Dose 2/106	20JAN2021	28JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 25JAN2021, B.1.2
C4591001 1135 11351388 (USA/CALIFORNIA/63/F)	Placebo	Dose 2/65	12DEC2020	30DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 15DEC2020, B.1.2
C4591001 1135 11351390 (USA/CALIFORNIA/60/M)	Placebo	Dose 2/56	03DEC2020	15DEC2020	Neg/Neg/Neg	Fever	Pos/, 04DEC2020, B.1.189

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1135 11351400 (USA/CALIFORNIA/37/M)	Placebo	Dose 2/57	08DEC2020	01JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 11DEC2020, B.1.429
C4591001 1135 11351426 (USA/CALIFORNIA/57/M)	Placebo	Dose 2/69	23DEC2020	02JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Vomiting New or increased cough Chills	Pos/, 02JAN2021, B.1.429

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1135 11351451 (USA/CALIFORNIA/50/F)	Placebo	Dose 2/30	08DEC2020	21DEC2020	Neg/Neg/Neg	New loss of taste or smell New or increased cough Chills New or increased muscle pain	Pos/, 09DEC2020, B.1.1.29
C4591001 1135 11351527 (USA/CALIFORNIA/43/M)	Placebo	Dose 2/81	01FEB2021		Neg/Neg/Neg	New or increased cough	Pos/, 04FEB2021, B.1.427
C4591001 1135 11351534 (USA/CALIFORNIA/37/F)	Placebo	Dose 2/30	15DEC2020	11JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 21DEC2020, B.1.2
C4591001 1136 11361011 (USA/NEVADA/72/M)	Placebo	Dose 2/62	18NOV2020	02DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 25NOV2020, B.47
C4591001 1136 11361012 (USA/NEVADA/39/M)	Placebo	Dose 2/82	28NOV2020	21DEC2020	Neg/Neg/Neg	New or increased cough Chills	Pos/, 30NOV2020, B.1.403

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1140 11401028 (USA/NEW YORK/53/F)	Placebo	Dose 2/91	09DEC2020	18DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Diarrhea	Pos/, 10DEC2020, B.1.243
C4591001 1140 11401039 (USA/NEW YORK/53/F)	Placebo	Dose 2/121	22DEC2020	03JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 25DEC2020, B.1.240
C4591001 1140 11401063 (USA/NEW YORK/49/M)	BNT162b2 (30 µg)	Dose 2/108	11DEC2020	23DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 13DEC2020, B.1.234
C4591001 1140 11401135 (USA/NEW YORK/54/M)	Placebo	Dose 2/110	26DEC2020	29DEC2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/, 29DEC2020, B.1.243

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1140 11401263 (USA/NEW YORK/66/F)	Placebo	Dose 2/67	31DEC2020		Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/, 02JAN2021, B.1.2
C4591001 1140 11401281 (USA/NEW YORK/23/M)	Placebo	Dose 2/65	05JAN2021	31JAN2021	Neg/Neg/Neg	Sore throat Fever	Pos/, 06JAN2021, B.1.2
C4591001 1141 11411006 (USA/IOWA/25/M)	BNT162b2 (30 µg)	Dose 2/119	17DEC2020	19DEC2020	Pos/Neg/Neg	New or increased cough Chills Sore throat New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/, 20DEC2020, QNS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1141 11411032 (USA/IOWA/22/F)	Placebo	Dose 2/72	20NOV2020	29NOV2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 24NOV2020, B.1.2
C4591001 1141 11411045 (USA/IOWA/46/F)	Placebo	Dose 2/81	16NOV2020	05JAN2021	Neg/Neg/Neg	Fever New or increased cough Chills New loss of taste or smell Sore throat	Neg/ (R1 Pos), (20DEC2020), (B.1.2)
C4591001 1141 11411088 (USA/IOWA/52/M)	Placebo	Dose 2/29	07OCT2020	10OCT2020	Neg/Neg/Neg	Fever Chills Sore throat	Pos/, 08OCT2020, B.1.2
C4591001 1141 11411161 (USA/IOWA/25/F)	Placebo	Dose 2/47	08NOV2020	15NOV2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 10NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1141 11411162 (USA/IOWA/20/M)	Placebo	Dose 2/44	05NOV2020	09NOV2020	Neg/Neg/Neg	New or increased muscle pain Diarrhea Vomiting New or increased cough	Pos/, 08NOV2020, B.1.139
C4591001 1141 11411175 (USA/IOWA/28/F)	Placebo	Dose 2/51	14NOV2020	30NOV2020	Neg/Neg/Neg	Sore throat New or increased cough Chills	Pos/, 17NOV2020, B
C4591001 1141 11411195 (USA/IOWA/36/F)	Placebo	Dose 2/94	15JAN2021		Neg/Neg/Neg	New or increased muscle pain Fever New or increased cough	Pos/ (R1 Pos), 26JAN2021 (03FEB2021), B.1.2 (B.1)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1141 11411204 (USA/IOWA/21/F)	Placebo	Dose 2/61	30NOV2020	13DEC2020	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/, 07DEC2020, B.1.2
						New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1141 11411221 (USA/IOWA/46/F)	Placebo	Dose 2/76	21DEC2020	02JAN2021	Neg/Neg/Neg	Fever	Pos/, 22DEC2020, B.1.311
C4591001 1141 11411242 (USA/IOWA/22/F)	Placebo	Dose 2/25	08NOV2020	30NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain	Pos/, 20NOV2020, B.1.139
C4591001 1142 11421120 (USA/TEXAS/68/M)	Placebo	Dose 2/96	12DEC2020	31DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 15DEC2020, B.1.2
C4591001 1142 11421148 (USA/TEXAS/59/M)	Placebo	Dose 2/59	11NOV2020	20NOV2020	Neg/Neg/Neg	New or increased muscle pain Fever Chills	Pos/, 16NOV2020, B.1.405

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1142 11421197 (USA/TEXAS/48/F)	Placebo	Dose 2/70	08DEC2020	14DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 09DEC2020, B.1.2
C4591001 1142 11421255 (USA/TEXAS/48/M)	Placebo	Dose 2/68	20DEC2020	10JAN2021	Neg/Neg/Neg	New or increased shortness of breath Chills New or increased shortness of breath	Pos/, 23DEC2020, B.1.2
C4591001 1142 11421388 (USA/TEXAS/15/M)	Placebo	Dose 2/25	19FEB2021		Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 19FEB2021, B.1.2
C4591001 1145 11451056 (USA/MARYLAND/67/F)	Placebo	Dose 2/59	14NOV2020	20NOV2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 16NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1146 11461004 (USA/NEW JERSEY/40/F)	Placebo	Dose 2/84	24NOV2020	28DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 27NOV2020, B.1.1.207
C4591001 1146 11461070 (USA/NEW JERSEY/54/F)	Placebo	Dose 2/116	03JAN2021	08JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell Diarrhea	Pos/, 07JAN2021, B.1.243
C4591001 1146 11461071 (USA/NEW JERSEY/54/M)	BNT162b2 (30 µg)	Dose 2/116	03JAN2021	08JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 11JAN2021, QNS
C4591001 1146 11461156 (USA/NEW JERSEY/60/M)	Placebo	Dose 2/54	09NOV2020	23NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 16NOV2020, B.1.240

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1146 11461235 (USA/65/M)	Placebo	Dose 2/60	03DEC2020	08DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Unk/Pos, 03DEC2020, NS
C4591001 1146 11461268 (USA/NEW JERSEY/42/M)	Placebo	Dose 2/73	20JAN2021	27JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 21JAN2021, B.1.1.220
C4591001 1146 11461309 (USA/NEW JERSEY/52/F)	Placebo	Dose 2/17	28NOV2020	02DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 28NOV2020, B.1.234
C4591001 1146 11461379 (USA/NEW JERSEY/45/M)	Placebo	Dose 2/17	03DEC2020		Neg/Neg/Neg	Sore throat Diarrhea	Pos/, 05DEC2020, B.1
C4591001 1147 11471021 (USA/LOUISIANA/35/F)	Placebo	Dose 2/108	13DEC2020	20DEC2020	Neg/Neg/Neg	New loss of taste or smell	Pos/Pos, 24DEC2020, B.1.234
C4591001 1147 11471025 (USA/LOUISIANA/35/M)	Placebo	Dose 2/101	04DEC2020	18DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 05DEC2020, B.1.240

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1147 11471176 (USA/LOUISIANA/20/M)	Placebo	Dose 2/106	23DEC2020	28DEC2020	Neg/Neg/Neg	Chills New or increased muscle pain Fever	Pos/, 26DEC2020, B.1.234
C4591001 1147 11471205 (USA/LOUISIANA/57/M)	Placebo	Dose 2/79	08DEC2020	11DEC2020	Neg/Neg/Neg	New or increased cough Chills	Pos/, 09DEC2020, B.1.243
C4591001 1147 11471228 (USA/LOUISIANA/59/F)	BNT162b2 (30 µg)	Dose 2/74	11DEC2020	18DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 13DEC2020, B.1.243
C4591001 1149 11491113 (USA/CALIFORNIA/69/M)	BNT162b2 (30 µg)	Dose 2/44	23OCT2020	24OCT2020	Neg/Neg/Neg	Fever	Pos/, 26OCT2020, B.1
C4591001 1149 11491135 (USA/CALIFORNIA/71/M)	Placebo	Dose 2/76	28NOV2020	23JAN2021	Neg/Neg/Neg	Chills Vomiting Fever	Pos/, 01DEC2020, B.1
						New or increased cough	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1149 11491160 (USA/CALIFORNIA/34/F)	Placebo	Dose 2/112	06JAN2021	22JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 08JAN2021, B.1.215
C4591001 1149 11491260 (USA/CALIFORNIA/60/M)	Placebo	Dose 2/77	24DEC2020	01JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain Sore throat New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell	Pos/, 04JAN2021, B.1.429

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1149 11491263 (USA/CALIFORNIA/24/F)	BNT162b2 (30 µg)	Dose 2/96	12JAN2021	26JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat Diarrhea	Pos/, 14JAN2021, B.1.2
C4591001 1149 11491265 (USA/CALIFORNIA/59/M)	Placebo	Dose 2/107	26JAN2021	13FEB2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/, 03FEB2021, B.1.2
C4591001 1149 11491340 (USA/CALIFORNIA/47/F)	Placebo	Dose 2/30	18DEC2020	20DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 19DEC2020, B.1.429

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1150 11501009 (USA/OHIO/29/M)	Placebo	Dose 2/123	09JAN2021	17JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 11JAN2021, B.1.2
C4591001 1150 11501055 (USA/OHIO/42/F)	Placebo	Dose 2/107	30DEC2020	08JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 30DEC2020, B.1.429
C4591001 1150 11501093 (USA/OHIO/45/F)	Placebo	Dose 2/84	16DEC2020	09JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 28DEC2020, B.1.2
C4591001 1150 11501204 (USA/OHIO/14/M)	Placebo	Dose 2/32	04FEB2021		Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 05FEB2021, B.1.2
C4591001 1152 11521010 (USA/CALIFORNIA/34/F)	Placebo	Dose 2/87	27NOV2020	27DEC2020	Neg/Neg/Neg	Fever New or increased shortness of breath New loss of taste or smell	Pos/, 07DEC2020, INDETERMINATE

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1152 11521032 (USA/CALIFORNIA/22/F)	Placebo	Dose 2/113	22DEC2020	16JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 28DEC2020, B.1.1.222
C4591001 1152 11521039 (USA/CALIFORNIA/39/F)	Placebo	Dose 2/93	03DEC2020	20DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New loss of taste or smell	Pos/, 15DEC2020, B.1.1.222
C4591001 1152 11521063 (USA/CALIFORNIA/35/F)	Placebo	Dose 2/117	26DEC2020	10JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 06JAN2021, B.1.427

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1152 11521082 (USA/CALIFORNIA/62/F)	Placebo	Dose 2/115	25DEC2020	20JAN2021	Neg/Neg/Neg	New or increased cough Diarrhea	Unk/Pos, 07JAN2021, B.1.2
C4591001 1152 11521226 (USA/CALIFORNIA/47/M)	Placebo	Dose 2/68	21NOV2020	10DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 24NOV2020, B.1.1.222
C4591001 1152 11521265 (USA/CALIFORNIA/77/M)	BNT162b2 (30 µg)	Dose 2/53	12NOV2020	30NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 24NOV2020, B.1.2
C4591001 1152 11521309 (USA/CALIFORNIA/31/F)	Placebo	Dose 2/69	29NOV2020	15DEC2020	Neg/Neg/Neg	New or increased shortness of breath Chills Sore throat Diarrhea	Pos/, 30NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1152 11521322 (USA/CALIFORNIA/20/M)	Placebo	Dose 2/109	08JAN2021	22JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 12JAN2021, B.1.429
C4591001 1152 11521339 (USA/CALIFORNIA/35/M)	Placebo	Dose 2/64	26NOV2020	12DEC2020	Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 30NOV2020, B.1.2
C4591001 1152 11521342 (USA/CALIFORNIA/57/F)	Placebo	Dose 2/98	28DEC2020		Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 06JAN2021, B.1.404
C4591001 1152 11521363 (USA/CALIFORNIA/19/M)	Placebo	Dose 2/9	06OCT2020	10OCT2020	Neg/Neg/Neg	New or increased cough	Pos/, 07OCT2020, B.1.232
C4591001 1152 11521372 (USA/CALIFORNIA/28/F)	Placebo	Dose 2/32	29OCT2020	07NOV2020	Neg/Neg/Neg	New or increased cough Chills	Pos/, 31OCT2020, B.1.243

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1152 11521413 (USA/CALIFORNIA/27/F)	Placebo	Dose 2/105	11JAN2021		Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/, 14JAN2021, B.1.429
C4591001 1152 11521455 (USA/CALIFORNIA/53/F)	Placebo	Dose 2/83	28DEC2020	13JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 14JAN2021, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1152 11521473 (USA/CALIFORNIA/60/M)	Placebo	Dose 2/76	28DEC2020	19FEB2021	Neg/Neg/Neg	New loss of taste or smell Chills	Pos/, 13JAN2021, B.1.404
C4591001 1152 11521501 (USA/CALIFORNIA/27/F)	Placebo	Dose 2/13	10NOV2020	12NOV2020	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/, 16NOV2020, B.1.1.152
C4591001 1152 11521573 (USA/CALIFORNIA/59/F)	Placebo	Dose 2/48	03JAN2021		Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Diarrhea	Pos/, 06JAN2021, B.1.404
C4591001 1152 11521666 (USA/CALIFORNIA/15/F)	Placebo	Dose 2/17	15JAN2021	23JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 21JAN2021, B.1.427

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1156 11561067 (USA/FLORIDA/63/F)	Placebo	Dose 2/98	27DEC2020	14JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough Sore throat	Pos/, 29DEC2020, B.1.2
C4591001 1156 11561178 (USA/FLORIDA/50/F)	Placebo	Dose 2/73	27DEC2020	31DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 28DEC2020, B.1.2
C4591001 1156 11561260 (USA/FLORIDA/15/F)	Placebo	Dose 2/82	01FEB2021	05FEB2021	Neg/Neg/Neg	New or increased muscle pain	Pos/, 01FEB2021, B.1.2
C4591001 1156 11561263 (USA/FLORIDA/15/M)	Placebo	Dose 2/41	20DEC2020	25DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 22DEC2020, B.1.369
C4591001 1157 11571098 (USA/CALIFORNIA/65/F)	Placebo	Dose 2/70	23NOV2020	27NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 25NOV2020, B.1.311
C4591001 1157 11571147 (USA/CALIFORNIA/67/F)	Placebo	Dose 2/14	12NOV2020	03DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 13NOV2020, B.1.119

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1157 11571148 (USA/CALIFORNIA/61/F)	Placebo	Dose 2/22	20NOV2020	03DEC2020	Neg/Neg/Unk	New or increased muscle pain New loss of taste or smell Sore throat Vomiting	Pos/, 27NOV2020, B.1.2
C4591001 1157 11571166 (USA/CALIFORNIA/26/M)	Placebo	Dose 2/50	30DEC2020	06JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 31DEC2020, B.1.404
C4591001 1162 11621011 (USA/GEORGIA/56/M)	Placebo	Dose 2/150	21JAN2021		Neg/Neg/Neg	Chills	Pos/, 22JAN2021, B.1.2
C4591001 1162 11621075 (USA/GEORGIA/40/F)	Placebo	Dose 2/67	06NOV2020	08NOV2020	Neg/Neg/Neg	Diarrhea New or increased muscle pain	Pos/, 09NOV2020, B.1.2
C4591001 1162 11621103 (USA/GEORGIA/39/F)	Placebo	Dose 2/97	09DEC2020		Neg/Neg/Neg	New or increased shortness of breath Chills	Pos/, 11DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1162 11621124 (USA/GEORGIA/36/M)	Placebo	Dose 2/112	29DEC2020	04JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 04JAN2021, B.1.2
C4591001 1162 11621241 (USA/GEORGIA/68/M)	Placebo	Dose 2/102	02JAN2021	09JAN2021	Neg/Neg/Neg	New or increased cough Sore throat Vomiting	Pos/, 08JAN2021, B.1.139
C4591001 1162 11621281 (USA/GEORGIA/56/M)	Placebo	Dose 2/97	29DEC2020	01JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 04JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1162 11621554 (USA/GEORGIA/49/F)	Placebo	Dose 2/44	24DEC2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 08JAN2021, B.1.2
C4591001 1163 11631009 (USA/LOUISIANA/72/F)	BNT162b2 (30 µg)	Dose 2/93	24NOV2020	04DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New or increased muscle pain	Pos/, 01DEC2020, B.1.2
C4591001 1163 11631014 (USA/LOUISIANA/66/M)	BNT162b2 (30 µg)	Dose 2/80	13NOV2020	18NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 16NOV2020, B.1.234
C4591001 1163 11631037 (USA/LOUISIANA/37/M)	Placebo	Dose 2/118	19DEC2020	28DEC2020	Neg/Neg/Neg	New or increased cough Chills Diarrhea	Pos/, 21DEC2020, INDETERMINATE
C4591001 1163 11631113 (USA/LOUISIANA/25/M)	Placebo	Dose 2/43	14OCT2020	22OCT2020	Neg/Neg/Neg	Fever	Pos/, 19OCT2020, B.1.265

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1163 11631135 (USA/LOUISIANA/42/M)	Placebo	Dose 2/21	30SEP2020	02OCT2020	Neg/Neg/Neg	New or increased cough Chills Sore throat Fever	Pos/, 30SEP2020, B.1.243
C4591001 1166 11661005 (USA/OHIO/40/M)	Placebo	Dose 2/79	26NOV2020	02DEC2020	Neg/Neg/Neg	New or increased muscle pain Diarrhea New or increased cough Chills New or increased muscle pain Diarrhea	Pos/, 30NOV2020, B.1.265
C4591001 1166 11661025 (USA/OHIO/31/M)	BNT162b2 (30 µg)	Dose 2/69	17NOV2020	09DEC2020	Neg/Neg/Neg	Fever New or increased	Pos/, 01DEC2020, QNS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1166 11661035 (USA/OHIO/38/M)	Placebo	Dose 2/66	12NOV2020	31DEC2020	Neg/Neg/Neg	shortness of breath Chills New or increased muscle pain Fever	Pos/, 17NOV2020, B.1.2
C4591001 1166 11661094 (USA/OHIO/54/M)	Placebo	Dose 2/51	03DEC2020	11DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/, 08DEC2020, B.1
C4591001 1167 11671031 (USA/TENNESSEE/72/M)	Placebo	Dose 2/90	08DEC2020	12DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 08DEC2020, B.1.2
C4591001 1167 11671046 (USA/TENNESSEE/54/M)	Placebo	Dose 2/113	01JAN2021	11JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 04JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1167 11671152 (USA/TENNESSEE/41/F)	Placebo	Dose 2/26	20OCT2020	10NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/Pos, 26OCT2020, B.1.1.29
C4591001 1167 11671157 (USA/TENNESSEE/58/M)	Placebo	Dose 2/16	14OCT2020	26OCT2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/, 15OCT2020, B.1.2
C4591001 1167 11671171 (USA/TENNESSEE/59/F)	Placebo	Dose 2/55	22NOV2020	04JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 07DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1167 11671186 (USA/TENNESSEE/66/M)	Placebo	Dose 2/72	18DEC2020	20DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/, 23DEC2020, B.1.2
C4591001 1167 11671211 (USA/TENNESSEE/54/M)	BNT162b2 (30 µg)	Dose 2/65	15DEC2020	30JAN2021	Neg/Neg/Neg	New loss of	Pos/, 17DEC2020, INDETERMINATE
C4591001 1168 11681004 (USA/OKLAHOMA/54/M)	Placebo	Dose 2/67	07NOV2020	19NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 11NOV2020, B.1.243
C4591001 1168 11681007 (USA/OKLAHOMA/33/F)	Placebo	Dose 2/36	06OCT2020	28FEB2021	Neg/Neg/Neg	New or increased cough New or increased	Pos/, 08OCT2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1168 11681008 (USA/OKLAHOMA/37/M)	Placebo	Dose 2/35	05OCT2020	20NOV2020	Neg/Neg/Neg	shortness of breath New or increased muscle pain New loss of taste or smell Sore throat New or increased cough	Pos/, 06OCT2020, B.1
C4591001 1168 11681078 (USA/OKLAHOMA/20/M)	Placebo	Dose 2/77	29NOV2020	15DEC2020	Neg/Neg/Neg	New loss of taste or smell Fever New or increased cough New or increased shortness of breath Chills	Pos/, 06DEC2020, B.1.234

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1168 11681079 (USA/OKLAHOMA/41/M)	BNT162b2 (30 µg)	Dose 2/114	06JAN2021		Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Chills	Pos/, 07JAN2021, B.1.1.222
C4591001 1168 11681080 (USA/OKLAHOMA/37/F)	Placebo	Dose 2/108	31DEC2020	12FEB2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough Chills	Pos/, 07JAN2021, B.1.1.222
C4591001 1168 11681090 (USA/OKLAHOMA/18/F)	Placebo	Dose 2/107	01JAN2021	15JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea New or increased cough New or increased	Pos/, 07JAN2021, B.1.1.29

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1168 11681114 (USA/OKLAHOMA/46/F)	Placebo	Dose 2/23	13OCT2020		Neg/Neg/Neg	shortness of breath New loss of taste or smell Fever	Pos/, 13OCT2020, B.1.311
C4591001 1168 11681117 (USA/OKLAHOMA/37/M)	Placebo	Dose 2/45	04NOV2020	08NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Fever	Pos/, 05NOV2020, B.1.2
C4591001 1168 11681147 (USA/OKLAHOMA/66/M)	Placebo	Dose 2/96	02JAN2021		Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 03JAN2021, B.1.240

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1168 11681187 (USA/OKLAHOMA/34/F)	Placebo	Dose 2/40	17NOV2020	25DEC2020	Neg/Neg/Neg	Sore throat Fever	Pos/, 19NOV2020, NS
C4591001 1168 11681202 (USA/OKLAHOMA/24/M)	Placebo	Dose 2/88	08JAN2021	22JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 11JAN2021, B.1.1
						New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1168 11681230 (USA/OKLAHOMA/61/M)	BNT162b2 (30 µg)	Dose 2/57	04JAN2021	10JAN2021	Neg/Neg/Neg	Vomiting New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 06JAN2021, B.1.2
C4591001 1168 11681232 (USA/OKLAHOMA/67/F)	BNT162b2 (30 µg)	Dose 2/60	07JAN2021	14JAN2021	Neg/Neg/Neg	Fever	Pos/, 08JAN2021, B.1.2
C4591001 1169 11691007 (USA/PENNSYLVANIA/28/F)	Placebo	Dose 2/19	11OCT2020	11NOV2020	Neg/Neg/Neg	New loss of taste or smell New or increased shortness of breath New loss of taste or smell	Pos/, 13OCT2020, B.1.234
C4591001 1170 11701060 (USA/TEXAS/30/F)	Placebo	Dose 2/84	01DEC2020	15DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 07DEC2020, B.1.234
C4591001 1170 11701089 (USA/TEXAS/25/F)	Placebo	Dose 2/16	01OCT2020	05OCT2020	Neg/Neg/Neg	Fever	Pos/, 03OCT2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1170 11701149 (USA/TEXAS/27/F)	Placebo	Dose 2/74	04DEC2020	12DEC2020	Neg/Neg/Neg	Sore throat Fever	Pos/, 07DEC2020, B.1.2
C4591001 1170 11701195 (USA/TEXAS/54/F)	Placebo	Dose 2/68	30NOV2020	14DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Fever	Pos/, 04DEC2020, B.1.2
C4591001 1170 11701221 (USA/TEXAS/48/M)	Placebo	Dose 2/43	10NOV2020	30NOV2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased shortness of breath Chills	Pos/, 16NOV2020, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1170 11701312 (USA/TEXAS/41/F)	Placebo	Dose 2/77	20DEC2020	15JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 26DEC2020, B.1.2
C4591001 1170 11701479 (USA/TEXAS/28/M)	Placebo	Dose 2/45	31DEC2020		Neg/Neg/Neg	Fever	Pos/, 31DEC2020, B.1.2
C4591001 1171 11711056 (USA/TEXAS/24/F)	Placebo	Dose 2/56	08NOV2020	09NOV2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 13NOV2020, B.1.2
C4591001 1171 11711081 (USA/TEXAS/36/F)	Placebo	Dose 2/71	18NOV2020	30NOV2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain	Pos/, 20NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1171 11711117 (USA/TEXAS/60/M)	Placebo	Dose 2/109	01JAN2021	04JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 04JAN2021, B.1.2
C4591001 1171 11711161 (USA/TEXAS/42/M)	Placebo	Dose 2/107	05JAN2021	08JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 08JAN2021, INDETERMINATE
C4591001 1171 11711199 (USA/TEXAS/58/M)	Placebo	Dose 2/77	15DEC2020	30DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 22DEC2020, B.1.1
C4591001 1171 11711212 (USA/TEXAS/33/M)	Placebo	Dose 2/50	04DEC2020	30DEC2020	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/, 07DEC2020, B.1.2
C4591001 1177 11771026 (USA/HAWAII/29/F)	Placebo	Dose 2/114	01JAN2021	09FEB2021	Neg/Neg/Neg	Chills Sore throat New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 18JAN2021, B.1.235

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1177 11771170 (USA/HAWAII/19/M)	BNT162b2 (30 µg)	Dose 2/113	07JAN2021	10JAN2021	Neg/Neg/Neg	New or increased muscle pain	Pos/, 07JAN2021, B.1.2
C4591001 1178 11781058 (USA/TENNESSEE/36/M)	Placebo	Dose 2/86	16DEC2020	30DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath New loss of taste or smell	Pos/, 17DEC2020, B.1.324
C4591001 1178 11781065 (USA/TENNESSEE/48/M)	Placebo	Dose 2/23	13OCT2020	25OCT2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 14OCT2020, B.1.361

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1178 11781085 (USA/TENNESSEE/60/F)	Placebo	Dose 2/72	03DEC2020	18DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 14DEC2020, B.1.2
C4591001 1178 11781124 (USA/TENNESSEE/59/M)	Placebo	Dose 2/70	07DEC2020	21DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 08DEC2020, B.1.234
C4591001 1178 11781238 (USA/TENNESSEE/60/F)	Placebo	Dose 2/16	29OCT2020	03NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 30OCT2020, B.1.2
C4591001 1178 11781251 (USA/TENNESSEE/28/F)	Placebo	Dose 2/89	11JAN2021	19JAN2021	Neg/Neg/Neg	New or increased cough Chills	Pos/, 13JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1178 11781280 (USA/TENNESSEE/58/M)	Placebo	Dose 2/9	03NOV2020	24NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/, 04NOV2020, B.1.2
C4591001 1178 11781282 (USA/TENNESSEE/65/F)	Placebo	Dose 2/32	26NOV2020	12DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 27NOV2020, B.1.2
C4591001 1179 11791054 (USA/MICHIGAN/51/F)	Placebo	Dose 2/69	01DEC2020		Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 07DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1179 11791073 (USA/MICHIGAN/62/M)	Placebo	Dose 2/61	01DEC2020		Neg/Neg/Neg	New or increased muscle pain	Pos/, 02DEC2020, B.1.2
C4591001 1179 11791079 (USA/MICHIGAN/26/F)	Placebo	Dose 2/42	10NOV2020	20NOV2020	Neg/Neg/Neg	Chills New loss of taste or smell Sore throat	Pos/, 12NOV2020, B.1.2
C4591001 1179 11791080 (USA/MICHIGAN/68/F)	Placebo	Dose 2/104	11JAN2021	21JAN2021	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell Sore throat Diarrhea	Pos/, 12JAN2021, B.1.2
C4591001 1179 11791085 (USA/MICHIGAN/34/M)	Placebo	Dose 2/34	09NOV2020		Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain	Pos/, 10NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1179 11791107 (USA/MICHIGAN/29/M)	Placebo	Dose 2/37	26NOV2020		Neg/Neg/Neg	New loss of taste or smell	Pos/, 30NOV2020, B.1.2
C4591001 1179 11791118 (USA/MICHIGAN/30/F)	Placebo	Dose 2/16	14NOV2020		Neg/Neg/Neg	Sore throat	Pos/, 16NOV2020, B.1.2
C4591001 1194 11941017 (DEU/69/M)	Placebo	Dose 2/64	06JAN2021	27JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills Diarrhea	Pos/Pos, 13JAN2021, B.1.177
C4591001 1205 12051070 (TUR/68/M)	Placebo	Dose 2/28	28DEC2020	28DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 30DEC2020, B.1
C4591001 1207 12071025 (TUR/55/M)	Placebo	Dose 2/20	07DEC2020	21DEC2020	Neg/Neg/Neg	Fever	Pos/, 08DEC2020, B.1.1.54
C4591001 1207 12071042 (TUR/44/F)	Placebo	Dose 2/26	19DEC2020	27DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 21DEC2020, B.1.1.105
C4591001 1212 12121004 (TUR/38/M)	Placebo	Dose 2/30	11DEC2020	12DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 11DEC2020, B.1.177

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1212 12121019 (TUR/43/M)	Placebo	Dose 2/9	28NOV2020	31DEC2020	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 01DEC2020, B.1.1.29
C4591001 1217 12171003 (TUR/34/M)	Placebo	Dose 2/16	27NOV2020	04JAN2021	Neg/Neg/Unk	Fever	Pos/, 01DEC2020, B.1.1.120
C4591001 1223 12231005 (USA/CONNECTICUT/20/F)	Placebo	Dose 2/51	06NOV2020	16NOV2020	Neg/Neg/Neg	New or increased cough Chills Sore throat	Pos/, 07NOV2020, B.1.1.220
C4591001 1223 12231008 (USA/CONNECTICUT/24/F)	Placebo	Dose 2/61	16NOV2020	25NOV2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 19NOV2020, NS
C4591001 1223 12231096 (USA/CONNECTICUT/77/F)	Placebo	Dose 2/48	11NOV2020	30DEC2020	Neg/Neg/Neg	New or increased cough Chills	Pos/ (R1 Pos), 11NOV2020 (14NOV2020), B.1.265 (B.1.1.220)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1223 12231224 (USA/CONNECTICUT/41/M)	Placebo	Dose 2/109	12FEB2021		Neg/Neg/Neg	Fever Chills New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 15FEB2021, B.1.526
C4591001 1223 12231252 (USA/CONNECTICUT/48/M)	Placebo	Dose 2/68	10JAN2021	25JAN2021	Neg/Neg/Neg	Fever	Pos/, 11JAN2021, B.1.409
C4591001 1224 12241004 (USA/COLORADO/63/M)	Placebo	Dose 2/74	12NOV2020	25NOV2020	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 16NOV2020, B.1.2
C4591001 1224 12241105 (USA/COLORADO/36/F)	Placebo	Dose 2/65	25NOV2020	21DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 29NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1224 12241142 (USA/COLORADO/63/F)	Placebo	Dose 2/57	18NOV2020	19NOV2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 18NOV2020, B.1.234
C4591001 1226 12261005 (BRA/45/M)	Placebo	Dose 2/121	22DEC2020	06JAN2021	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 23DEC2020, P.2
C4591001 1226 12261064 (BRA/74/F)	Placebo	Dose 2/135	12JAN2021	25JAN2021	Neg/Neg/Neg	New or increased shortness of breath Chills	Pos/, 13JAN2021, B.1.1.33
C4591001 1226 12261137 (BRA/52/M)	Placebo	Dose 2/126	06JAN2021	08JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 11JAN2021, B.1.1.34

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261218 (BRA/38/M)	BNT162b2 (30 µg)	Dose 2/87	03DEC2020	15DEC2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 08DEC2020, B.1.1.33
C4591001 1226 12261219 (BRA/68/M)	Placebo	Dose 2/83	29NOV2020	20DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 01DEC2020, P.2
C4591001 1226 12261226 (BRA/30/M)	Placebo	Dose 2/120	05JAN2021	20JAN2021	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell Sore throat	Pos/, 14JAN2021, B.1.1.28
C4591001 1226 12261309 (BRA/61/M)	Placebo	Dose 2/40	20OCT2020	26OCT2020	Neg/Neg/Neg	New or increased cough	Pos/, 27OCT2020, B.1.1.28

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261322 (BRA/49/M)	Placebo	Dose 2/131	19JAN2021	21JAN2021	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 20JAN2021, B.1.1.28
C4591001 1226 12261354 (BRA/46/M)	Placebo	Dose 2/72	21NOV2020	30NOV2020	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell Diarrhea	Pos/, 23NOV2020, B.1.1.28
C4591001 1226 12261363 (BRA/48/F)	Placebo	Dose 2/23	03OCT2020	15DEC2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat Vomiting	Pos/, 06OCT2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261383 (BRA/39/F)	Placebo	Dose 2/78	30NOV2020	08DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 01DEC2020, B.1.1.28
C4591001 1226 12261384 (BRA/36/M)	Placebo	Dose 2/111	02JAN2021	15FEB2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 11JAN2021, B.1.1.28
C4591001 1226 12261400 (BRA/45/M)	Placebo	Dose 2/75	28NOV2020	04DEC2020	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 30NOV2020, P.2
C4591001 1226 12261497 (BRA/26/M)	Placebo	Dose 2/70	27NOV2020	06DEC2020	Neg/Neg/Neg	Fever	Pos/, 02DEC2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261521 (BRA/32/M)	Placebo	Dose 2/111	12JAN2021	10FEB2021	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/, 19JAN2021, P.2
C4591001 1226 12261548 (BRA/37/F)	Placebo	Dose 2/63	25NOV2020	02DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Chills	Pos/, 30NOV2020, B.1.1.28
C4591001 1226 12261549 (BRA/41/M)	Placebo	Dose 2/65	27NOV2020	20DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Chills	Pos/, 30NOV2020, B.1.1.28

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261559 (BRA/49/M)	BNT162b2 (30 µg)	Dose 2/108	10JAN2021	12JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough New or increased muscle pain	Pos/, 12JAN2021, B.1.1.28
C4591001 1226 12261575 (BRA/41/M)	Placebo	Dose 2/95	31DEC2020	22JAN2021	Neg/Neg/Neg	New or increased shortness of breath	Pos/, 05JAN2021, QNS
C4591001 1226 12261586 (BRA/37/M)	Placebo	Dose 2/47	13NOV2020	22NOV2020	Neg/Neg/Neg	New or increased muscle pain Diarrhea	Pos/, 16NOV2020, QNS
C4591001 1226 12261587 (BRA/42/M)	Placebo	Dose 2/49	15NOV2020	26NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 17NOV2020, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261599 (BRA/41/F)	BNT162b2 (30 µg)	Dose 2/36	06NOV2020	13NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough New loss of taste or smell	Pos/, 07NOV2020, B.1.1.94
C4591001 1226 12261624 (BRA/52/M)	Placebo	Dose 2/34	02NOV2020	14NOV2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat	Pos/, 05NOV2020, B.1.1.143

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261660 (BRA/27/F)	Placebo	Dose 2/37	05NOV2020	10NOV2020	Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 06NOV2020, B.1.1.33
C4591001 1226 12261682 (BRA/32/F)	Placebo	Dose 2/102	11JAN2021	26JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat Diarrhea	Pos/, 13JAN2021, B.1.182
C4591001 1226 12261732 (BRA/31/M)	Placebo	Dose 2/64	08DEC2020	15DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 10DEC2020, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261743 (BRA/36/F)	Placebo	Dose 2/103	16JAN2021	22JAN2021	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 20JAN2021, B.1.1.143
C4591001 1226 12261778 (BRA/41/F)	BNT162b2 (30 µg)	Dose 2/100	14JAN2021	20JAN2021	Pos/Pos/Pos	Sore throat New or increased muscle pain Diarrhea Vomiting	Pos/, 18JAN2021, QNS
C4591001 1226 12261780 (BRA/43/M)	Placebo	Dose 2/35	10NOV2020	18NOV2020	Neg/Neg/Neg	Fever	Pos/, 13NOV2020, P.2
C4591001 1226 12261790 (BRA/43/F)	BNT162b2 (30 µg)	Dose 2/106	20JAN2021	22JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 21JAN2021, P.2
C4591001 1226 12261800 (BRA/34/M)	BNT162b2 (30 µg)	Dose 2/89	03JAN2021	11JAN2021	Neg/Neg/Neg	New or increased cough Sore throat Diarrhea	Pos/, 07JAN2021, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261803 (BRA/33/M)	Placebo	Dose 2/93	06JAN2021	13JAN2021	Neg/Neg/Neg	Fever	Pos/, 07JAN2021, P.2
						Chills New or increased muscle pain	
C4591001 1226 12261885 (BRA/30/F)	Placebo	Dose 2/32	17NOV2020	05DEC2020	Neg/Neg/Neg	Chills	Pos/, 19NOV2020, P.2
						New or increased muscle pain New loss of taste or smell Sore throat	
C4591001 1226 12261888 (BRA/49/M)	BNT162b2 (30 µg)	Dose 2/96	18JAN2021	21JAN2021	Neg/Neg/Neg	Fever	Pos/, 20JAN2021, P.2
						New or increased cough	
C4591001 1226 12261920 (BRA/28/M)	Placebo	Dose 2/36	24NOV2020	29NOV2020	Pos/Neg/Neg	New or increased muscle pain	Pos/, 27NOV2020, QNS
C4591001 1226 12261927 (BRA/38/M)	Placebo	Dose 2/12	16NOV2020		Neg/Neg/Neg	Fever	Pos/, 18NOV2020, INDETERMINATE

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12261964 (BRA/27/F)	Placebo	Dose 2/9	29OCT2020	13NOV2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 04NOV2020, N.1
C4591001 1226 12261995 (BRA/55/M)	BNT162b2 (30 µg)	Dose 2/70	30DEC2020	15JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 05JAN2021, B.1.1.33
C4591001 1226 12262020 (BRA/60/M)	BNT162b2 (30 µg)	Dose 2/28	18NOV2020	23NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 25NOV2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12262028 (BRA/42/F)	Placebo	Dose 2/50	10DEC2020	20DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 11DEC2020, B.1.1.143
C4591001 1226 12262111 (BRA/51/M)	Placebo	Dose 2/12	10NOV2020	09DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 12NOV2020, P.2
C4591001 1226 12262183 (BRA/29/M)	Placebo	Dose 2/61	03JAN2021	10JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 06JAN2021, B.1.1.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12262187 (BRA/43/M)	BNT162b2 (30 µg)	Dose 2/47	20DEC2020	30DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 23DEC2020, B.1.1.143
C4591001 1226 12262196 (BRA/51/M)	Placebo	Dose 2/59	01JAN2021	17JAN2021	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 06JAN2021, P.2
C4591001 1226 12262204 (BRA/38/M)	Placebo	Dose 2/64	06JAN2021	05FEB2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 11JAN2021, P.2
C4591001 1226 12262211 (BRA/39/F)	Placebo	Dose 2/23	28NOV2020	15DEC2020	Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell	Pos/, 30NOV2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12262226 (BRA/39/F)	Placebo	Dose 2/63	08JAN2021	13JAN2021	Neg/Neg/Neg	Sore throat Sore throat	Pos/, 11JAN2021, B.1.1.34
C4591001 1226 12262287 (BRA/46/M)	Placebo	Dose 2/8	16NOV2020	28NOV2020	Neg/Neg/Neg	Diarrhea Fever	Pos/, 18NOV2020, P.2
C4591001 1226 12262298 (BRA/42/F)	Placebo	Dose 2/58	03JAN2021	13JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain Diarrhea	Pos/, 07JAN2021, P.2
C4591001 1226 12262314 (BRA/31/F)	Placebo	Dose 2/47	27DEC2020	29DEC2020	Neg/Neg/Neg	Chills New or increased muscle pain Fever	Pos/, 29DEC2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1226 12262318 (BRA/26/F)	Placebo	Dose 2/34	10DEC2020	27DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 18DEC2020, B.1.1.44
C4591001 1229 12291102 (ZAF/63/F)†	Placebo	Dose 2/66	30DEC2020	17JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 08JAN2021, NS
C4591001 1231 12311014 (ARG/62/F)	Placebo	Dose 2/134	06JAN2021	14JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 08JAN2021, B.1.1.33
C4591001 1231 12311043 (ARG/46/M)	Placebo	Dose 2/40	10OCT2020	11OCT2020	Neg/Neg/Neg	New or increased cough Chills	Pos/, 11OCT2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12311069 (ARG/41/M)	Placebo	Dose 2/117	27DEC2020	12JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 27DEC2020, B.1.1.33
C4591001 1231 12311083 (ARG/51/F)	BNT162b2 (30 µg)	Dose 2/160	08FEB2021	15FEB2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 11FEB2021, B.1.1.70
C4591001 1231 12311205 (ARG/29/F)	Placebo	Dose 2/87	28NOV2020	14DEC2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 01DEC2020, B.1.1.33
C4591001 1231 12311224 (ARG/35/M)	Placebo	Dose 2/117	28DEC2020	29DEC2020	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 02JAN2021, B.1.1.33
C4591001 1231 12311267 (ARG/67/M)	Placebo	Dose 2/24	26SEP2020	07OCT2020	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 02OCT2020, B.1.1.33
C4591001 1231 12311285 (ARG/26/F)	Placebo	Dose 2/151	01FEB2021	19FEB2021	Neg/Neg/Neg	New or increased cough	Pos/, 03FEB2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12311297 (ARG/49/M)	Placebo	Dose 2/98	13DEC2020	25DEC2020	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 15DEC2020, B.1.1.33
C4591001 1231 12311407 (ARG/63/M)	Placebo	Dose 2/24	27SEP2020	06OCT2020	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/, 01OCT2020, B.1.499
C4591001 1231 12311480 (ARG/40/M)	BNT162b2 (30 µg)	Dose 2/147	27JAN2021	06FEB2021	Neg/Neg/Neg	Chills New or increased muscle pain Diarrhea	Pos/, 29JAN2021, B.1.1.33
C4591001 1231 12311520 (ARG/29/M)	BNT162b2 (30 µg)	Dose 2/130	14JAN2021	21JAN2021	Neg/Neg/Neg	Sore throat New loss of taste or smell	Pos/, 18JAN2021, B.1.499
C4591001 1231 12311531 (ARG/35/M)	Placebo	Dose 2/9	16SEP2020	27SEP2020	Neg/Neg/Neg	Fever New or increased	Pos/, 19SEP2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12311556 (ARG/24/M)	Placebo	Dose 2/45	21OCT2020	09NOV2020	Neg/Neg/Neg	shortness of breath New or increased muscle pain	Pos/, 22OCT2020, B.1.499
C4591001 1231 12311560 (ARG/44/M)	Placebo	Dose 2/70	12NOV2020	19NOV2020	Neg/Neg/Neg	Fever	Pos/, 12NOV2020, B.1.1.33
C4591001 1231 12311599 (ARG/34/M)	Placebo	Dose 2/139	23JAN2021	18FEB2021	Neg/Neg/Neg	New or increased cough Fever	Pos/, 23JAN2021, B.1.1.33
C4591001 1231 12311609 (ARG/25/M)	BNT162b2 (30 µg)	Dose 2/113	28DEC2020	08JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 30DEC2020, B.1.428
						New loss of taste or smell	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12311648 (ARG/50/F)	Placebo	Dose 2/140	25JAN2021	01FEB2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 28JAN2021, B.1.1.33
C4591001 1231 12311651 (ARG/52/F)	Placebo	Dose 2/8	14SEP2020	01OCT2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Vomiting	Pos/, 20SEP2020, N.3
C4591001 1231 12311664 (ARG/34/F)	Placebo	Dose 2/9	15SEP2020	03OCT2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 17SEP2020, B.1
C4591001 1231 12311728 (ARG/59/F)	Placebo	Dose 2/101	18DEC2020	14JAN2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 22DEC2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12311754 (ARG/54/M)	Placebo	Dose 2/38	14OCT2020	25OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Diarrhea Fever	Pos/, 16OCT2020, B.1.1.33
C4591001 1231 12311764 (ARG/34/M)	Placebo	Dose 2/63	09NOV2020	09NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 10NOV2020, B.1
C4591001 1231 12311793 (ARG/43/M)	Placebo	Dose 2/131	15JAN2021	01FEB2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough Sore throat	Pos/, 19JAN2021, B.1.1.33
C4591001 1231 12311809 (ARG/28/M)	Placebo	Dose 2/161	14FEB2021	20FEB2021	Neg/Neg/Neg	New or increased cough	Pos/, 15FEB2021, B.1.1.33
C4591001 1231 12311841 (ARG/24/M)	BNT162b2 (30 µg)	Dose 2/77	22NOV2020	06DEC2020	Neg/Neg/Neg	Sore throat	Pos/, 27NOV2020, B.1.1.35
C4591001 1231 12311866 (ARG/21/F)	Placebo	Dose 2/137	21JAN2021	03FEB2021	Neg/Neg/Neg	Fever	Pos/, 22JAN2021, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12311982 (ARG/41/F)	Placebo	Dose 2/37	14OCT2020	24OCT2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough	Pos/, 20OCT2020, B.1.1.33
C4591001 1231 12312119 (ARG/32/M)	Placebo	Dose 2/139	23JAN2021	03FEB2021	Neg/Neg/Neg	New or increased muscle pain Sore throat Fever New or increased cough New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 24JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12312133 (ARG/38/M)	Placebo	Dose 2/119	04JAN2021	28JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 05JAN2021, B.1.1.33
C4591001 1231 12312188 (ARG/36/M)	Placebo	Dose 2/147	02FEB2021	13FEB2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 03FEB2021, B.1.1.28
C4591001 1231 12312223 (ARG/61/F)	Placebo	Dose 2/133	18JAN2021	30JAN2021	Neg/Neg/Neg	New or increased muscle pain	Pos/, 23JAN2021, B.1.1.33
C4591001 1231 12312275 (ARG/21/F)	Placebo	Dose 2/148	02FEB2021	05FEB2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 04FEB2021, B.1.1.33
C4591001 1231 12312282 (ARG/19/F)	BNT162b2 (30 µg)	Dose 2/133	18JAN2021	24JAN2021	Neg/Neg/Neg	Fever	Pos/, 19JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12312349 (ARG/24/F)	Placebo	Dose 2/116	01JAN2021	10JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 04JAN2021, B.1.1.33
C4591001 1231 12312479 (ARG/43/M)	Placebo	Dose 2/30	09OCT2020	07NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell	Pos/, 11OCT2020, B.1.1.33
C4591001 1231 12312492 (ARG/70/M)	Placebo	Dose 2/153	07FEB2021	12FEB2021	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 10FEB2021, B.1.499
C4591001 1231 12312507 (ARG/47/F)	Placebo	Dose 2/10	17SEP2020	28SEP2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 19SEP2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12312572 (ARG/46/M)	Placebo	Dose 2/111	27DEC2020	25JAN2021	Neg/Neg/Neg	Sore throat Fever	Pos/, 29DEC2020, B.1.1.200
C4591001 1231 12312617 (ARG/27/M)	BNT162b2 (30 µg)	Dose 2/122	09JAN2021	26JAN2021	Neg/Neg/Neg	New or increased cough New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 12JAN2021, P.2
C4591001 1231 12312630 (ARG/39/F)	Placebo	Dose 2/44	23OCT2020	14NOV2020	Neg/Neg/Neg	Sore throat Fever New or increased cough New or increased shortness of breath	Pos/, 26OCT2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12312635 (ARG/71/M)	Placebo	Dose 2/27	04OCT2020	26OCT2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Fever	Pos/, 06OCT2020, B.1.1.33
C4591001 1231 12312663 (ARG/34/F)	Placebo	Dose 2/110	26DEC2020	15FEB2021	Neg/Neg/Neg	New or increased cough Chills Sore throat	Pos/, 27DEC2020, B.1
C4591001 1231 12312675 (ARG/41/M)	BNT162b2 (30 µg)	Dose 2/161	15FEB2021	25FEB2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 20FEB2021, B.1.1.33
C4591001 1231 12312680 (ARG/31/M)	BNT162b2 (30 µg)	Dose 2/171	25FEB2021	02MAR2021	Neg/Neg/Neg	Sore throat	Pos/, 28FEB2021, B.1.1.1
C4591001 1231 12312702 (ARG/30/F)	Placebo	Dose 2/114	02JAN2021	13FEB2021	Neg/Neg/Neg	New or increased cough	Pos/, 07JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12312704 (ARG/49/M)	Placebo	Dose 2/110	28DEC2020	06FEB2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Fever	Pos/, 09JAN2021, QNS
C4591001 1231 12312769 (ARG/47/M)	Placebo	Dose 2/63	12NOV2020	14NOV2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 13NOV2020, B.1.1.33
C4591001 1231 12312867 (ARG/40/F)	Placebo	Dose 2/35	14OCT2020	01NOV2020	Neg/Neg/Neg	Fever New loss of taste or smell	Pos/, 16OCT2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12312901 (ARG/28/M)	Placebo	Dose 2/140	27JAN2021	19FEB2021	Neg/Neg/Neg	Diarrhea Fever	Pos/, 31JAN2021, P.2
C4591001 1231 12312914 (ARG/50/M)	Placebo	Dose 2/43	26OCT2020	17NOV2020	Neg/Neg/Neg	Diarrhea Fever New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 29OCT2020, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12313040 (ARG/51/M)	Placebo	Dose 2/137	28JAN2021	11FEB2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 30JAN2021, B.1.1.33
C4591001 1231 12313085 (ARG/23/F)	Placebo	Dose 2/148	07FEB2021	14FEB2021	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 10FEB2021, B.1.1.33
C4591001 1231 12313182 (ARG/33/M)	Placebo	Dose 2/10	20SEP2020	19OCT2020	Neg/Neg/Neg	New or increased shortness of breath New loss of taste or smell	Pos/, 25SEP2020, B.1.1.33
C4591001 1231 12313244 (ARG/21/F)	Placebo	Dose 2/121	12JAN2021	27JAN2021	Neg/Neg/Neg	Fever New loss of taste or smell Diarrhea	Pos/, 17JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12313259 (ARG/41/M)	Placebo	Dose 2/153	09FEB2021	15FEB2021	Neg/Neg/Neg	Sore throat	Pos/, 14FEB2021, B.1.1.1
C4591001 1231 12313296 (ARG/49/F)	Placebo	Dose 2/25	04OCT2020	20OCT2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 06OCT2020, B.1.1.289
C4591001 1231 12313372 (ARG/24/F)	Placebo	Dose 2/119	07JAN2021	02FEB2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat Diarrhea	Pos/, 11JAN2021, B.1.1.33
C4591001 1231 12313400 (ARG/46/M)	Placebo	Dose 2/37	19OCT2020	28OCT2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/, 21OCT2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12313422 (ARG/34/M)	Placebo	Dose 2/44	28OCT2020	27DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Fever	Pos/, 29OCT2020, B.1.2
C4591001 1231 12313437 (ARG/36/F)	Placebo	Dose 2/172	03MAR2021	14MAR2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Diarrhea Fever	Pos/, 04MAR2021, B.1.1.33
						New or increased cough Sore throat	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12313470 (ARG/54/F)	Placebo	Dose 2/159	27FEB2021	11MAR2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 01MAR2021, B.1.1.1
C4591001 1231 12313504 (ARG/36/M)	Placebo	Dose 2/94	15DEC2020	24DEC2020	Neg/Neg/Neg	New loss of taste or smell Diarrhea	Pos/, 16DEC2020, B.1.1.33
C4591001 1231 12313520 (ARG/28/F)	Placebo	Dose 2/8	22SEP2020	09OCT2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 25SEP2020, B.1.499
C4591001 1231 12313596 (ARG/41/M)	Placebo	Dose 2/106	27DEC2020	07JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 30DEC2020, B.1.1.33
C4591001 1231 12313668 (ARG/33/M)	Placebo	Dose 2/12	24SEP2020	02OCT2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 25SEP2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12313697 (ARG/55/M)	Placebo	Dose 2/119	11JAN2021		Neg/Neg/Neg	Fever	Pos/, 14JAN2021, P.2
C4591001 1231 12313787 (ARG/58/M)	Placebo	Dose 2/48	02NOV2020	05NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 04NOV2020, B.1.1.33
C4591001 1231 12313801 (ARG/55/F)	Placebo	Dose 2/127	19JAN2021	30JAN2021	Neg/Neg/Neg	Sore throat New or increased muscle pain	Pos/, 28JAN2021, QNS
C4591001 1231 12313881 (ARG/36/M)	Placebo	Dose 2/149	10FEB2021	19FEB2021	Neg/Neg/Neg	Fever	Pos/, 11FEB2021, B.1.1.33
C4591001 1231 12313895 (ARG/50/F)	Placebo	Dose 2/21	03OCT2020	17OCT2020	Neg/Neg/Neg	Sore throat New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 07OCT2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12313996 (ARG/50/F)	Placebo	Dose 2/68	20NOV2020	03DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 21NOV2020, B.1.1.33
C4591001 1231 12314112 (ARG/52/M)	Placebo	Dose 2/42	28OCT2020	02NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 29OCT2020, B.1
C4591001 1231 12314123 (ARG/37/F)	Placebo	Dose 2/147	09FEB2021	21FEB2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 11FEB2021, B.1.1.33
C4591001 1231 12314193 (ARG/36/M)	Placebo	Dose 2/104	29DEC2020	31DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 30DEC2020, B.1.499
C4591001 1231 12314209 (ARG/68/M)	Placebo	Dose 2/66	18NOV2020	04DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 21NOV2020, INDETERMINATE
C4591001 1231 12314213 (ARG/66/M)	Placebo	Dose 2/133	25JAN2021	20FEB2021	Neg/Neg/Neg	Fever	Pos/, 27JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12314308 (ARG/31/F)	Placebo	Dose 2/15	30SEP2020	11OCT2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased cough	Pos/, 01OCT2020, B.1.1.33
C4591001 1231 12314329 (ARG/52/M)	Placebo	Dose 2/97	19DEC2020	29DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat Vomiting New or increased cough	Pos/, 21DEC2020, B.1.1.33
C4591001 1231 12314477 (ARG/36/M)	Placebo	Dose 2/16	03OCT2020	15OCT2020	Pos/Neg/Neg	New or increased muscle pain New loss of taste or smell New or increased cough	Pos/, 06OCT2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12314499 (ARG/52/F)	Placebo	Dose 2/141	03FEB2021	17FEB2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 05FEB2021, B.1
C4591001 1231 12314534 (ARG/18/F)	Placebo	Dose 2/21	05OCT2020	09OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain Sore throat	Pos/, 08OCT2020, B.1.499
C4591001 1231 12314551 (ARG/76/M)	Placebo	Dose 2/137	29JAN2021	12FEB2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 01FEB2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12314565 (ARG/41/F)	BNT162b2 (30 µg)	Dose 2/104	29DEC2020	19JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/, 30DEC2020, B.1.1.33
C4591001 1231 12314583 (ARG/20/F)	Placebo	Dose 2/134	26JAN2021	03FEB2021	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/, 27JAN2021, B.1.1.33
C4591001 1231 12314622 (ARG/32/F)	Placebo	Dose 2/15	01OCT2020	07OCT2020	Neg/Neg/Neg	New loss of taste or smell Fever New or increased cough New or increased shortness of breath Chills	Pos/, 03OCT2020, B.1.499

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12314681 (ARG/66/F)	Placebo	Dose 2/104	28DEC2020	28DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 29DEC2020, B.1.1.33
C4591001 1231 12314746 (ARG/21/M)	Placebo	Dose 2/107	01JAN2021	10FEB2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Sore throat	Pos/, 12JAN2021, B.1.1.33
C4591001 1231 12314912 (ARG/31/F)	BNT162b2 (30 µg)	Dose 2/123	18JAN2021	02FEB2021	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/, 20JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12314941 (ARG/60/F)	Placebo	Dose 2/109	02JAN2021	13JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat Diarrhea	Pos/, 04JAN2021, B.1.499
C4591001 1231 12315003 (ARG/76/M)	Placebo	Dose 2/90	14DEC2020	18DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 19DEC2020, B.1.499
C4591001 1231 12315038 (ARG/56/F)	Placebo	Dose 2/147	09FEB2021	19FEB2021	Neg/Neg/Neg	Fever	Pos/, 10FEB2021, B.1
C4591001 1231 12315062 (ARG/25/M)	Placebo	Dose 2/107	01JAN2021	06JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Fever	Pos/, 04JAN2021, B.1.499
						New or increased cough	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12315074 (ARG/36/M)	Placebo	Dose 2/169	04MAR2021	16MAR2021	Neg/Neg/Neg	New or increased muscle pain Diarrhea Fever	Pos/, 05MAR2021, B.1.1.33
C4591001 1231 12315136 (ARG/23/M)	Placebo	Dose 2/123	18JAN2021	14FEB2021	Neg/Neg/Neg	New or increased muscle pain Fever	Pos/, 21JAN2021, B.1.1.33
C4591001 1231 12315216 (ARG/52/M)	Placebo	Dose 2/94	19DEC2020	08JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Fever	Pos/, 27DEC2020, B.1.1.33
						New or increased cough New or increased muscle pain	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12315247 (ARG/34/F)	Placebo	Dose 2/174	10MAR2021	20MAR2021	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/, 11MAR2021, B.1.1.33
C4591001 1231 12315287 (ARG/46/F)	Placebo	Dose 2/127	21JAN2021	01FEB2021	Neg/Neg/Neg	New or increased muscle pain New or increased cough	Pos/, 27JAN2021, B.1.1.33
C4591001 1231 12315299 (ARG/20/F)	BNT162b2 (30 µg)	Dose 2/101	26DEC2020	14JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/, 29DEC2020, B.1.1.33
C4591001 1231 12315324 (ARG/58/F)	Placebo	Dose 2/99	25DEC2020	31JAN2021	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/, 26DEC2020, B.1.1.291

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12315349 (ARG/39/F)	Placebo	Dose 2/110	04JAN2021	23JAN2021	Neg/Neg/Neg	New or increased cough Chills Fever	Pos/, 08JAN2021, B.1
C4591001 1231 12315392 (ARG/64/F)	Placebo	Dose 2/75	02DEC2020	15DEC2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Fever	Pos/, 04DEC2020, B.1.1.33
C4591001 1231 12315497 (ARG/34/F)	Placebo	Dose 2/139	03FEB2021	28FEB2021	Neg/Neg/Neg	New or increased cough Diarrhea Vomiting New or increased muscle pain	Pos/, 06FEB2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12315500 (ARG/57/F)	Placebo	Dose 2/88	14DEC2020	30JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough	Pos/, 17DEC2020, B.1.1.33
C4591001 1231 12315553 (ARG/42/F)	Placebo	Dose 2/83	10DEC2020	21DEC2020	Neg/Neg/Neg	New loss of taste or smell Diarrhea New or increased cough	Pos/, 11DEC2020, B.1.1.33
C4591001 1231 12315624 (ARG/44/M)	Placebo	Dose 2/87	17DEC2020	21DEC2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 19DEC2020, B.1
C4591001 1231 12315628 (ARG/55/M)	Placebo	Dose 2/115	11JAN2021	16JAN2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 14JAN2021, B.1.1.33
C4591001 1231 12315636 (ARG/53/F)	Placebo	Dose 2/35	23OCT2020	21NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 26OCT2020, B.1.302

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1231 12315637 (ARG/40/F)	Placebo	Dose 2/11	29SEP2020	08OCT2020	Neg/Neg/Neg	Sore throat Fever	Pos/, 01OCT2020, B.1.1.33
C4591001 1232 12321046 (USA/GEORGIA/39/M)	Placebo	Dose 2/109	26DEC2020	04JAN2021	Neg/Neg/Neg	Chills New or increased muscle pain New loss of taste or smell	Pos/, 30DEC2020, B.1.2
C4591001 1232 12321301 (USA/GEORGIA/44/M)	Placebo	Dose 2/65	29DEC2020	10FEB2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 04JAN2021, B.1.2
C4591001 1232 12321426 (USA/GEORGIA/37/F)	Placebo	Dose 2/29	22DEC2020	06JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 23DEC2020, B.1.2
C4591001 1235 12351024 (USA/LOUISIANA/27/M)	Placebo	Dose 2/48	11NOV2020	12NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain	Pos/, 16NOV2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1235 12351064 (USA/LOUISIANA/25/F)	Placebo	Dose 2/47	17NOV2020	25NOV2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/, 18NOV2020, B.1.2
C4591001 1235 12351093 (USA/LOUISIANA/30/F)	BNT162b2 (30 µg)	Dose 2/32	08NOV2020	14NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 11NOV2020, B.1.2
C4591001 1235 12351112 (USA/LOUISIANA/24/F)	Placebo	Dose 2/86	02JAN2021	13JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell	Pos/, 08JAN2021, B.1
C4591001 1235 12351140 (USA/LOUISIANA/72/M)	Placebo	Dose 2/55	09DEC2020	13DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 11DEC2020, B.1.1.222

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1235 12351243 (USA/LOUISIANA/15/M)	Placebo	Dose 2/42	09FEB2021	11FEB2021	Neg/Neg/Neg	New or increased cough Sore throat Diarrhea	Pos/, 11FEB2021, B.1.2
C4591001 1241 12411043 (BRA/33/F)	Placebo	Dose 2/116	25DEC2020	29DEC2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/Pos, 27DEC2020, B.1.1.28
C4591001 1241 12411252 (BRA/57/F)	Placebo	Dose 2/123	09JAN2021	18JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/Pos, 13JAN2021, P.2
C4591001 1241 12411277 (BRA/42/F)	Placebo	Dose 2/121	07JAN2021	20JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/, 11JAN2021, B.1.1.28

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411319 (BRA/52/F)	Placebo	Dose 2/69	18NOV2020	30NOV2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat Diarrhea Vomiting	Pos/Pos, 24NOV2020, B.1.1.33
C4591001 1241 12411347 (BRA/23/F)	Placebo	Dose 2/86	04DEC2020	17DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/Pos, 06DEC2020, B.1.1.33
C4591001 1241 12411404 (BRA/58/F)	Placebo	Dose 2/61	10NOV2020	20NOV2020	Neg/Neg/Neg	New loss of taste or smell	Pos/, 14NOV2020, B.1.1.33
C4591001 1241 12411410 (BRA/45/F)	Placebo	Dose 2/117	08JAN2021	18JAN2021	Neg/Neg/Neg	Sore throat	Pos/Pos, 13JAN2021, INDETERMINATE
C4591001 1241 12411421 (BRA/37/F)	Placebo	Dose 2/58	10NOV2020	17NOV2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/Pos, 13NOV2020, B.1.1.28

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411433 (BRA/29/M)	Placebo	Dose 2/126	17JAN2021	19JAN2021	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain Sore throat	Pos/Pos, 19JAN2021, B.1.1.143
C4591001 1241 12411478 (BRA/39/F)	Placebo	Dose 2/91	14DEC2020	26DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 15DEC2020, P.2
C4591001 1241 12411481 (BRA/27/F)	Placebo	Dose 2/74	28NOV2020	12JAN2021	Neg/Neg/Neg	Fever New or increased cough Diarrhea	Pos/Pos, 04DEC2020, B.1
C4591001 1241 12411566 (BRA/18/F)	Placebo	Dose 2/116	15JAN2021	20JAN2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 17JAN2021, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411581 (BRA/52/M)	Placebo	Dose 2/125	24JAN2021	05FEB2021	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough Chills	Pos/, 26JAN2021, P.2
C4591001 1241 12411617 (BRA/47/M)	Placebo	Dose 2/84	15DEC2020	05JAN2021	Neg/Neg/Neg	New or increased cough Chills	Pos/, 17DEC2020, B.1.1.34
C4591001 1241 12411625 (BRA/34/M)	Placebo	Dose 2/102	02JAN2021	08JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea	Pos/Pos, 04JAN2021, P.2
C4591001 1241 12411658 (BRA/35/F)	BNT162b2 (30 µg)	Dose 2/105	11JAN2021	15FEB2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/Pos, 13JAN2021, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411659 (BRA/32/M)	Placebo	Dose 2/95	01JAN2021	16JAN2021	Neg/Neg/Neg	Sore throat New or increased cough Chills New or increased muscle pain	Pos/Pos, 09JAN2021, P.2
C4591001 1241 12411661 (BRA/34/M)	Placebo	Dose 2/84	21DEC2020	24DEC2020	Neg/Neg/Neg	Sore throat Fever New or increased cough Chills	Pos/Pos, 22DEC2020, P.2
C4591001 1241 12411746 (BRA/58/M)	Placebo	Dose 2/54	28NOV2020	10DEC2020	Neg/Neg/Neg	Diarrhea Fever Chills New or increased muscle pain	Pos/Pos, 01DEC2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411747 (BRA/31/M)	Placebo	Dose 2/106	19JAN2021	23JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat Fever	Pos/, 21JAN2021, P.2
C4591001 1241 12411768 (BRA/42/F)	Placebo	Dose 2/94	07JAN2021	21JAN2021	Neg/Neg/Neg	New or increased cough Chills New loss of taste or smell	Pos/Pos, 10JAN2021, P.2
C4591001 1241 12411770 (BRA/69/F)	Placebo	Dose 2/94	07JAN2021	14JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/Pos, 10JAN2021, P.2
C4591001 1241 12411787 (BRA/54/M)	Placebo	Dose 2/103	19JAN2021	27JAN2021	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/Pos, 22JAN2021, P.2
C4591001 1241 12411788 (BRA/62/M)	Placebo	Dose 2/68	14DEC2020	04JAN2021	Neg/Neg/Neg	Fever New or increased cough	Pos/, 17DEC2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411837 (BRA/53/M)	BNT162b2 (30 µg)	Dose 2/110	25JAN2021	01FEB2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/Pos, 27JAN2021, P.1
C4591001 1241 12411845 (BRA/43/F)	Placebo	Dose 2/111	26JAN2021	10FEB2021	Neg/Neg/Neg	Fever	Pos/Pos, 29JAN2021, P.1
C4591001 1241 12411858 (BRA/18/M)	Placebo	Dose 2/90	03JAN2021	10JAN2021	Neg/Neg/Neg	New or increased cough New loss of taste or smell New or increased muscle pain Sore throat	Pos/Pos, 07JAN2021, B.1.1.28
C4591001 1241 12411885 (BRA/23/M)	BNT162b2 (30 µg)	Dose 2/14	22OCT2020	24OCT2020	Pos/Neg/Neg	Diarrhea Sore throat	Pos/Neg, 23OCT2020, QNS
C4591001 1241 12411896 (BRA/62/F)	Placebo	Dose 2/39	16NOV2020	24NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/Neg, 18NOV2020, QNS

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12411950 (BRA/34/M)	BNT162b2 (30 µg)	Dose 2/95	09JAN2021	21JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 11JAN2021, B.1.1.143
C4591001 1241 12411991 (BRA/29/F)	Placebo	Dose 2/67	18DEC2020	26DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills	Pos/, 20DEC2020, B.1.1.28
C4591001 1241 12411998 (BRA/53/F)	Placebo	Dose 2/39	20NOV2020	05DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/, 24NOV2020, B.1
C4591001 1241 12412017 (BRA/59/M)	Placebo	Dose 2/9	29OCT2020	02NOV2020	Neg/Neg/Neg	Fever New or increased muscle pain	Pos/Pos, 30OCT2020, B.1.1.28
C4591001 1241 12412018 (BRA/55/F)	Placebo	Dose 2/8	28OCT2020	15NOV2020	Neg/Neg/Neg	Fever New loss of taste or smell Sore throat	Pos/Pos, 30OCT2020, B.1.1.28
C4591001 1241 12412087 (BRA/37/M)	Placebo	Dose 2/31	21NOV2020	02DEC2020	Neg/Neg/Neg	New or increased muscle pain	Pos/Pos, 25NOV2020, B.1.1.28

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12412111 (BRA/44/F)	Placebo	Dose 2/82	10JAN2021	20JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough Chills New or increased muscle pain Sore throat	Pos/Pos, 13JAN2021, P.2
C4591001 1241 12412114 (BRA/24/F)	Placebo	Dose 2/98	27JAN2021	08FEB2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain New loss of taste or smell Sore throat	Pos/Pos, 31JAN2021, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12412140 (BRA/16/F)	Placebo	Dose 2/76	09JAN2021	18JAN2021	Neg/Neg/Neg	Diarrhea Sore throat	Pos/, 12JAN2021, P.2
C4591001 1241 12412170 (BRA/27/F)	Placebo	Dose 2/60	01JAN2021	11JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 06JAN2021, P.2
C4591001 1241 12412235 (BRA/38/M)	Placebo	Dose 2/42	16DEC2020	20DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills Sore throat	Pos/Pos, 19DEC2020, B.1.1.34
C4591001 1241 12412259 (BRA/35/M)	Placebo	Dose 2/41	15DEC2020	28DEC2020	Neg/Neg/Neg	New or increased cough New or increased	Pos/Pos, 18DEC2020, B.1.1.28

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12412334 (BRA/41/M)	Placebo	Dose 2/26	04DEC2020	14DEC2020	Neg/Neg/Neg	shortness of breath New or increased muscle pain Sore throat Diarrhea Fever	Pos/, 07DEC2020, B.1.1.33
C4591001 1241 12412397 (BRA/24/F)	Placebo	Dose 2/10	19NOV2020	29NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain New or increased cough New loss of taste or smell	Pos/Pos, 20NOV2020, P.2
C4591001 1241 12412458 (BRA/28/F)	Placebo	Dose 2/8	18NOV2020	20NOV2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 20NOV2020, P.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1241 12412512 (BRA/47/F)	Placebo	Dose 2/37	18DEC2020	30DEC2020	Neg/Neg/Neg	Fever New or increased cough New loss of taste or smell Sore throat Diarrhea	Pos/Pos, 20DEC2020, B.1
C4591001 1246 12461072 (ZAF/39/F)	Placebo	Dose 2/82	12JAN2021	16FEB2021	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain Sore throat Diarrhea Vomiting	Pos/, 26JAN2021, B.1.351
C4591001 1246 12461110 (ZAF/19/M)	Placebo	Dose 2/68	03JAN2021	27JAN2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 06JAN2021, B.1.351

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1246 12461126 (ZAF/22/M)	Placebo	Dose 2/63	31DEC2020	17JAN2021	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 11JAN2021, B.1.351
C4591001 1247 12471016 (ZAF/30/F)	Placebo	Dose 2/80	01JAN2021	12JAN2021	Neg/Neg/Neg	Fever Chills New or increased muscle pain New loss of taste or smell Sore throat Diarrhea	Pos/, 05JAN2021, B.1.351
C4591001 1247 12471053 (ZAF/30/M)	Placebo	Dose 2/78	31DEC2020	09JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 02JAN2021, B.1.351
C4591001 1247 12471070 (ZAF/58/M)	Placebo	Dose 2/107	02FEB2021	08FEB2021	Neg/Neg/Neg	Fever Chills	Pos/, 02FEB2021, B.1.351

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1247 12471085 (ZAF/54/F)	Placebo	Dose 2/12	30OCT2020	03NOV2020	Neg/Neg/Neg	New or increased muscle pain Sore throat New or increased cough Chills Diarrhea	Pos/, 02NOV2020, QNS
C4591001 1247 12471091 (ZAF/39/F)	Placebo	Dose 2/69	27DEC2020	03JAN2021	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 29DEC2020, B.1.351
C4591001 1247 12471092 (ZAF/37/M)	Placebo	Dose 2/49	16DEC2020	06JAN2021	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills	Pos/, 23DEC2020, B.1.351

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1247 12471141 (ZAF/27/F)	Placebo	Dose 2/53	13DEC2020	06JAN2021	Pos/Neg/Neg	New or increased muscle pain New loss of taste or smell Sore throat New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell	Pos/, 17DEC2020, P.2
C4591001 1251 12511032 (USA/FLORIDA/25/F)	Placebo	Dose 2/142	30JAN2021	17FEB2021	Neg/Neg/Neg	New loss of taste or smell	Pos/, 01FEB2021, B.1.2
C4591001 1251 12511065 (USA/FLORIDA/50/F)	Placebo	Dose 2/48	04NOV2020	28NOV2020	Neg/Neg/Neg	New or increased cough	Pos/, 12NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1251 12511084 (USA/FLORIDA/48/F)	Placebo	Dose 2/55	14NOV2020	17NOV2020	Neg/Neg/Neg	New or increased shortness of breath Fever	Pos/, 16NOV2020, B.1.2
C4591001 1251 12511121 (USA/FLORIDA/49/M)	Placebo	Dose 2/81	12DEC2020	30DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat	Pos/, 15DEC2020, B.1.2
C4591001 1251 12511159 (USA/FLORIDA/37/F)	Placebo	Dose 2/26	26OCT2020	29OCT2020	Neg/Neg/Neg	New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 28OCT2020, B.1
C4591001 1251 12511160 (USA/FLORIDA/59/F)	Placebo	Dose 2/102	10JAN2021	28JAN2021	Neg/Neg/Neg	Fever Chills New or increased muscle pain	Pos/, 12JAN2021, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1251 12511201 (USA/FLORIDA/44/F)	Placebo	Dose 2/24	04NOV2020	23NOV2020	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain New loss of taste or smell Diarrhea Vomiting	Pos/, 20NOV2020, QNS
C4591001 1252 12521018 (USA/SOUTH CAROLINA/74/F)	Placebo	Dose 2/126	13JAN2021	18JAN2021	Neg/Neg/Neg	New or increased cough	Pos/, 15JAN2021, B.1.1.207
C4591001 1252 12521026 (USA/SOUTH CAROLINA/72/F)	Placebo	Dose 2/125	13JAN2021	18JAN2021	Neg/Neg/Neg	Diarrhea	Pos/, 15JAN2021, INDETERMINATE
C4591001 1254 12541017 (USA/CALIFORNIA/73/M)	Placebo	Dose 2/96	22DEC2020	27DEC2020	Neg/Neg/Neg	New or increased cough	Pos/, 29DEC2020, B.1
C4591001 1254 12541058 (USA/CALIFORNIA/54/M)	Placebo	Dose 2/88	17DEC2020	20DEC2020	Neg/Neg/Neg	Fever New or increased cough	Pos/, 22DEC2020, B.1.1.285

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1254 12541134 (USA/CALIFORNIA/53/M)	Placebo	Dose 2/91	31DEC2020	23JAN2021	Neg/Neg/Neg	Fever New or increased cough New or increased shortness of breath Sore throat Diarrhea	Pos/, 05JAN2021, B.1
C4591001 1254 12541157 (USA/CALIFORNIA/41/M)	Placebo	Dose 2/82	27DEC2020	26JAN2021	Neg/Neg/Neg	Sore throat	Pos/, 29DEC2020, B.1.429
C4591001 1260 12601031 (USA/MASSACHUSETTS/67/F)	Placebo	Dose 2/95	02JAN2021	07JAN2021	Neg/Neg/Neg	New or increased cough New or increased muscle pain	Pos/, 02JAN2021, B.1.2
C4591001 1264 12641045 (USA/CALIFORNIA/72/F)	Placebo	Dose 2/94	16DEC2020		Neg/Neg/Neg	New or increased cough New loss of taste or smell	Pos/, 21DEC2020, B.1.2

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1264 12641048 (USA/CALIFORNIA/34/M)	Placebo	Dose 2/81	03DEC2020	06DEC2020	Neg/Neg/Neg	Fever	Pos/Pos, 06DEC2020, B.1.234
C4591001 1264 12641056 (USA/CALIFORNIA/47/M)	Placebo	Dose 2/54	09NOV2020	20NOV2020	Neg/Neg/Neg	Chills New or increased muscle pain	Pos/, 12NOV2020, B.1.2
C4591001 1264 12641090 (USA/CALIFORNIA/34/M)	Placebo	Dose 2/108	06JAN2021	19JAN2021	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 06JAN2021, B.1.2
C4591001 1264 12641111 (USA/CALIFORNIA/57/M)	Placebo	Dose 2/51	12NOV2020	10DEC2020	Neg/Neg/Neg	Fever New or increased cough Chills New loss of taste or smell Sore throat	Pos/, 13NOV2020, B.1
						New or increased muscle pain Sore throat	

090177e1972f8110\Final\Final On: 02-Jun-2021 12:50 (GMT)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1264 12641182 (USA/CALIFORNIA/70/M)	Placebo	Dose 2/64	14DEC2020	28DEC2020	Neg/Neg/Neg	Fever Chills New or increased muscle pain Sore throat	Pos/, 15DEC2020, B.1.2
C4591001 1264 12641183 (USA/CALIFORNIA/47/F)	Placebo	Dose 2/31	13NOV2020	16NOV2020	Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell	Pos/, 15NOV2020, B.1.404
C4591001 1264 12641184 (USA/CALIFORNIA/24/F)	Placebo	Dose 2/33	15NOV2020	18NOV2020	Neg/Neg/Neg	Fever New or increased cough Chills New or increased muscle pain	Pos/, 16NOV2020, B.1.404

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1265 12651039 (USA/CALIFORNIA/72/M)	Placebo	Dose 2/105	03JAN2021	03JAN2021	Neg/Neg/Neg	New loss of taste or smell Fever	Pos/, 04JAN2021, B.1.2
C4591001 1265 12651152 (USA/CALIFORNIA/70/F)	Placebo	Dose 2/57	07DEC2020	10DEC2020	Neg/Neg/Neg	New or increased cough New or increased shortness of breath Chills New or increased muscle pain Sore throat Diarrhea Vomiting Fever	Pos/, 09DEC2020, B.1.429
						New or increased cough	

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1269 12691061 (USA/CALIFORNIA/60/M)	Placebo	Dose 2/74	28NOV2020	16DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat Diarrhea	Pos/, 01DEC2020, B.1.400
C4591001 1270 12701010 (USA/CALIFORNIA/46/F)	Placebo	Dose 2/86	10DEC2020	28DEC2020	Neg/Neg/Neg	New or increased muscle pain Sore throat New loss of taste or smell	Pos/, 14DEC2020, B.1.2
C4591001 1270 12701033 (USA/CALIFORNIA/41/M)	Placebo	Dose 2/98	28DEC2020	01JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain	Pos/, 29DEC2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 1270 12701048 (USA/CALIFORNIA/22/F)	Placebo	Dose 2/68	01DEC2020	15DEC2020	Neg/Neg/Neg	New loss of taste or smell Sore throat New or increased cough Chills	Pos/, 03DEC2020, B.1.400
C4591001 1270 12701146 (USA/CALIFORNIA/16/F)	Placebo	Dose 2/39	31DEC2020	11JAN2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough New or increased shortness of breath	Pos/, 03JAN2021, B.1.2
C4591001 4444 44441004 (ARG/23/F)	Placebo	Dose 2/86	06JAN2021	17JAN2021	Neg/Neg/Neg	New or increased muscle pain Sore throat	Pos/, 07JAN2021, B.1.1.35
C4591001 4444 44441046 (ARG/57/F)	Placebo	Dose 2/99	19JAN2021	29JAN2021	Neg/Neg/Neg	Fever Chills	Pos/, 24JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 4444 44441092 (ARG/64/M)	Placebo	Dose 2/23	03NOV2020	16NOV2020	Neg/Neg/Neg	New or increased muscle pain New or increased cough New or increased shortness of breath New or increased muscle pain New loss of taste or smell Sore throat	Pos/, 08NOV2020, B.1.1.33
C4591001 4444 44441144 (ARG/38/M)	Placebo	Dose 2/26	07NOV2020	18NOV2020	Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell Diarrhea	Pos/, 10NOV2020, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 4444 44441204 (ARG/59/F)	BNT162b2 (30 µg)	Dose 2/21	02NOV2020	14DEC2020	Neg/Neg/Neg	New or increased muscle pain New loss of taste or smell	Pos/, 03NOV2020, B.1.1.33
C4591001 4444 44441211 (ARG/42/M)	Placebo	Dose 2/116	05FEB2021	15FEB2021	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain New loss of taste or smell	Pos/, 07FEB2021, B.1.1.33
C4591001 4444 44441222 (ARG/59/M)	BNT162b2 (30 µg)	Dose 2/61	12DEC2020	17DEC2020	Neg/Neg/Neg	New or increased cough Sore throat	Pos/, 15DEC2020, B.1.1.33
C4591001 4444 44441224 (ARG/52/M)	Placebo	Dose 2/13	25OCT2020	10NOV2020	Neg/Neg/Neg	Fever New or increased	Pos/, 26OCT2020, B.1.1.33

090177e1972f8110\Final\Final On: 02-Jun-2021 12:50 (GMT)

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 4444 44441563 (ARG/38/M)	Placebo	Dose 2/8	21OCT2020	29OCT2020	Neg/Neg/Neg	shortness of breath New or increased muscle pain	Pos/, 22OCT2020, B.1.1.1
C4591001 4444 44441586 (ARG/45/F)	Placebo	Dose 2/141	03MAR2021	16MAR2021	Neg/Neg/Neg	Diarrhea New or increased cough	Pos/, 05MAR2021, B.1.1.7
C4591001 4444 44441632 (ARG/55/F)	Placebo	Dose 2/112	01FEB2021	18FEB2021	Neg/Neg/Neg	New loss of taste or smell New or increased cough	Pos/, 11FEB2021, B.1.1.33
C4591001 4444 44441636 (ARG/48/M)	Placebo	Dose 2/106	26JAN2021	07FEB2021	Neg/Neg/Neg	New loss of taste or smell Diarrhea Fever New or increased cough	Pos/, 29JAN2021, B.1.1.33

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 4444 44441735 (ARG/52/M)	Placebo	Dose 2/106	27JAN2021	08FEB2021	Neg/Neg/Neg	New or increased muscle pain New or increased cough New or increased muscle pain	Pos/, 29JAN2021, P.2
C4591001 4444 44441786 (ARG/52/F)	Placebo	Dose 2/85	04JAN2021	26JAN2021	Neg/Neg/Neg	Fever New or increased muscle pain New loss of taste or smell	Pos/, 04JAN2021, B.1.1.33
C4591001 4444 44441985 (ARG/44/F)	Placebo	Dose 2/71	25DEC2020	12JAN2021	Neg/Neg/Neg	Fever New or increased cough Sore throat	Pos/, 28DEC2020, B.1.499
C4591001 4444 44441996 (ARG/32/F)	BNT162b2 (30 µg)	Dose 2/32	14NOV2020	28NOV2020	Neg/Neg/Neg	Diarrhea	Pos/, 19NOV2020, B.1

16.2.8.6 Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2 and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Evaluable Efficacy (7 Days) Population

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage
C4591001 4444 44442167 (ARG/35/F)	BNT162b2 (30 µg)	Dose 2/84	07JAN2021	17JAN2021	Neg/Unk/Neg	New or increased muscle pain Sore throat	Pos/, 09JAN2021, B.1.511

Abbreviations: ARG = Argentina; BRA = Brazil; DEU = Germany; NAAT = nucleic acid amplification test; NS = not sequenced; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; QNS = not quantifiable samples; R1 = repeat central swab 1; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; TUR = Turkey; Unk = unknown; ZAF = South Africa.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

Note: † = HIV-positive subject.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 01JUN2021 (17:11) Source Data: adsympt Table Generation: 01JUN2021 (22:07)

(Cutoff Date: 13MAR2021, Snapshot Date: 28MAY2021) Output File: ./nda2_unblinded/C4591001_BLA_Sequence/adxb_l001_seq_d2_cov_eval

**16.2.8.7 Listing of Subjects and SARS-CoV-2 Variants With Multiple COVID-19 Occurrence After Dose 1
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
C4591001 1116 11161224 (USA/MISSISSIPPI/52/F)	Placebo	Dose 2/46	14NOV2020	20NOV2020	Neg/Neg/Neg	Fever	Pos/, 16NOV2020, B.1.2
		Dose 2/82	20DEC2020	15JAN2021	Neg/Neg/Neg	New or increased cough Chills New or increased muscle pain Sore throat	Pos/, 23DEC2020, B
C4591001 1221 12211002 (USA/MARYLAND/43/M)	Placebo	Dose 1/20	01NOV2020	20NOV2020	Neg/Neg/Unk	Chills	Pos/Pos, 02NOV2020, B.1
		Dose 4/5*	26FEB2021	02MAR2021	Neg/Neg/Unk	Vomiting New or increased cough Chills New loss of taste or smell	Pos/Pos, 27FEB2021, QNS

**16.2.8.7 Listing of Subjects and SARS-CoV-2 Variants With Multiple COVID-19 Occurrence After Dose 1
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
C4591001 1231 12312660 (ARG/35/M)	Placebo	Dose 1/23	11SEP2020	23SEP2020	Neg/Neg/Neg	New or increased cough New loss of taste or smell Sore throat	Pos/, 11SEP2020, B.1
		Dose 1/99	26NOV2020	27NOV2020	Neg/Neg/Neg	Vomiting	Pos/, 26NOV2020, QNS
C4591001 1231 12312679 (ARG/32/M)	Placebo	Dose 2/4	14SEP2020	12NOV2020	Neg/Neg/Neg	Fever New or increased cough New or increased muscle pain Diarrhea	Pos/, 19SEP2020, B.1.499
		Dose 2/151	08FEB2021	17FEB2021	Neg/Neg/Neg	Fever Sore throat Diarrhea	Pos/, 12FEB2021, B.1.142
C4591001 1231 12313510 (ARG/29/F)	Placebo	Dose 1/13	04SEP2020	07SEP2020	Neg/Neg/Pos	Fever New or increased cough	Pos/, 05SEP2020, B.1.499

**16.2.8.7 Listing of Subjects and SARS-CoV-2 Variants With Multiple COVID-19 Occurrence After Dose 1
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date of First Symptom	Stop Date of Last Symptom	Visit 1 N-Binding Assay/ Visit 1 NAAT/ Visit 2 NAAT	Signs and Symptoms	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS-CoV-2 Lineage
C4591001 1270 12701237 (USA/CALIFORNIA/13/F)	Placebo	Dose 1/69	30OCT2020	12NOV2020	Neg/Neg/Pos	Diarrhea	Pos/, 14NOV2020, QNS
		Dose 1/13	19JAN2021	20JAN2021	Neg/Pos/Pos	New or increased shortness of breath	Pos/, 21JAN2021, B.1.1.38
		Dose 1/20	26JAN2021	26JAN2021	Neg/Pos/Pos	Diarrhea	Pos/, 29JAN2021, B.1.1.1

Abbreviations: ARG = Argentina; NAAT = nucleic acid amplification test; NS = not sequenced; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = negative; Pos = positive; QNS = not quantifiable samples; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; Unk = unknown.
Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.
Note: * = COVID-19 occurrence after subject was unblinded.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.
b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 01JUN2021 (17:11) Source Data: adsympt Table Generation: 01JUN2021 (22:07)
(Cutoff Date: 13MAR2021, Snapshot Date: 28MAY2021) Output File: ./nda2_unblinded/C4591001_BLA_Sequence/adxb_l001_seq_d1_mul_cov_aai

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1003 10031167 (USA/NEW YORK/57/F)*	Placebo	Dose 2/87	22NOV2020	23DEC2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/Pos, 19DEC2020, B.1.404	CDC- defined
		Dose 2/117	22DEC2020	23DEC2020		Hospitalized due to COVID-19 illness		
C4591001 1007 10071306 (USA/OHIO/58/F)*	Placebo	Dose 2/71	11JAN2021		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 01JAN2021, B.1.2	Both
		Dose 2/71	11JAN2021	12JAN2021		Hospitalized due to COVID-19 illness		
C4591001 1008 10081285 (USA/MISSOURI/60/F)*	Placebo	Dose 2/71	11DEC2020	14DEC2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 27NOV2020, B.1.2	CDC- defined
C4591001 1009 10091128 (USA/UTAH/51/M)*	Placebo	Dose 2/67	21NOV2020		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 20OCT2020, B.1.2	Protocol- defined

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1013 10131296 (USA/FLORIDA/44/M)*	Placebo	Dose 2/83	06DEC2020	08DEC2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 30NOV2020, B.1.1.122	CDC- defined
C4591001 1038 10381051 (USA/TENNESSEE/69/M)*	Placebo	Dose 2/61	17NOV2020	22NOV2020	Neg/Neg/Neg	Admission to an ICU	Pos/, 09NOV2020, B.1.361	Both
C4591001 1047 10471252 (USA/ALABAMA/63/M)	Placebo	Dose 1/26	16OCT2020		Neg/Neg/Pos	SpO ₂ ≤93% on room air at sea level	Pos/, 14OCT2020, B.1.2	Both
		Dose 1/26	16OCT2020			High-flow oxygen therapy		
		Dose 1/26	16OCT2020	20OCT2020		Hospitalized due to COVID-19 illness		
C4591001 1054 10541202 (USA/CALIFORNIA/57/M)*	Placebo	Dose 2/71	22JAN2021	27JAN2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 12JAN2021, INDETERMINATE	CDC- defined
C4591001 1072 10721037 (USA/ALABAMA/71/F)	Placebo	Dose 2/82	27DEC2020		Neg/Neg/Neg	High-flow oxygen therapy	Pos/Pos, 21DEC2020, B.1.2	Both
		Dose 2/82	27DEC2020	02JAN2021		Hospitalized due to		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1093 10931050 (USA/IOWA/62/M)	Placebo	Dose 1/33	25SEP2020	27SEP2020	Neg/Neg/Unk	Hospitalized due to COVID-19 illness	Pos/, 21SEP2020, B.1.448	CDC- defined
C4591001 1093 10931122 (USA/IOWA/58/F)*	Placebo	Dose 2/17	16OCT2020	20OCT2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 09OCT2020, B.1	CDC- defined
C4591001 1109 11091415 (USA/FLORIDA/48/F)*	Placebo	Dose 2/95	29DEC2020		Neg/Neg/Neg	DBP <60 mm Hg	Pos/, 29DEC2020, B.1.2	Both
		Dose 2/95	29DEC2020	31DEC2020		Hospitalized due to COVID-19 illness		
C4591001 1112 11121301 (USA/GEORGIA/47/M)*	Placebo	Dose 2/37	08DEC2020	09DEC2020	Neg/Neg/Neg	High-flow oxygen therapy	Pos/, 29NOV2020, B.1.280	Both
		Dose 2/37	08DEC2020	09DEC2020		Hospitalized due to COVID-19 illness		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1114 11141075 (USA/KANSAS/40/F)*	Placebo	Dose 2/118	05JAN2021		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 04JAN2021, QNS	Both
		Dose 2/118	05JAN2021	11JAN2021		High-flow oxygen therapy		
		Dose 2/118	05JAN2021	13JAN2021		Hospitalized due to COVID-19 illness		
C4591001 1116 11161160 (USA/MISSISSIPPI/47/M)*	Placebo	Dose 2/108	13JAN2021		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 13JAN2021, B.1.2	Protocol- defined
C4591001 1116 11161224 (USA/MISSISSIPPI/52/F)*	Placebo	Dose 2/85	23DEC2020	25DEC2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 23DEC2020, B	CDC- defined
C4591001 1116 11161253 (USA/MISSISSIPPI/61/M)	Placebo	Dose 1/11	28SEP2020		Neg/Neg/Pos	HR ≥125 beats/minute	Pos/, 28SEP2020, B.1.234	Protocol- defined
C4591001 1120 11201101 (USA/GEORGIA/48/F)*	Placebo	Dose 2/148	19JAN2021	23JAN2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 06JAN2021, B.1.2	CDC- defined

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1124 11241128 (USA/RHODE ISLAND/67/M)*	Placebo	Dose 2/95	24DEC2020		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 18JAN2021, B.1.361	Both
		Dose 2/95	24DEC2020	30DEC2020		Hospitalized due to COVID-19 illness		
C4591001 1125 11251014 (USA/NEBRASKA/45/F)*	Placebo	Dose 2/68	08NOV2020		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 10NOV2020, B.1.413	Protocol- defined
C4591001 1131 11311100 (USA/OHIO/64/M)*	Placebo	Dose 2/67	21NOV2020	30NOV2020	Neg/Neg/Neg	High-flow oxygen therapy	Pos/, 13NOV2020, B.1.2	Both
		Dose 2/67	21NOV2020	24NOV2020		Hospitalized due to COVID-19 illness		
		Dose 2/70	24NOV2020			DBP <60 mm Hg		
C4591001 1134 11341035 (USA/NORTH CAROLINA/59/F)*	Placebo	Dose 2/122	31DEC2020	05JAN2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 24DEC2020, B.1.2	CDC- defined
C4591001 1146 11461235 (USA/65/M)*	Placebo	Dose 2/60	03DEC2020	07DEC2020	Neg/Neg/Neg	Non-invasive positive	Unk/Pos, 03DEC2020, NS	Both

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
		Dose 2/60	03DEC2020	07DEC2020		pressure ventilation Hospitalized due to COVID-19 illness		
C4591001 1156 11561006 (USA/FLORIDA/45/M)	BNT162b2 (30 µg)	Dose 1/12	31AUG2020	02SEP2020	Neg/Pos/Neg	Hospitalized due to COVID-19 illness	Pos/Pos, 02SEP2020, B.1.306	CDC- defined
C4591001 1156 11561044 (USA/FLORIDA/63/M)	Placebo	Dose 1/8	03SEP2020		Neg/Neg/Neg	Significant acute renal dysfunction	Pos/, 03SEP2020, B.1.2	Both
		Dose 1/8	03SEP2020	09SEP2020		Significant acute hepatic dysfunction		
		Dose 1/10	05SEP2020			SpO ₂ ≤93% on room air at sea level		
		Dose 1/10	05SEP2020	09SEP2020		High-flow oxygen therapy		
		Dose 1/10	05SEP2020	19SEP2020		Admission to an ICU		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1171 11711212 (USA/TEXAS/33/M)*	Placebo	Dose 1/10	05SEP2020	19SEP2020		Hospitalized due to COVID-19 illness		
		Dose 1/19	14SEP2020			SpO ₂ ≤93% on room air at sea level		
		Dose 1/34	29SEP2020			SpO ₂ ≤93% on room air at sea level		
		Dose 1/36	01OCT2020			SpO ₂ ≤93% on room air at sea level		
C4591001 1205 12051070 (TUR/68/M)*	Placebo	Dose 2/58	12DEC2020	18DEC2020	Neg/Neg/Neg	Admission to an ICU	Pos/, 07DEC2020, B.1.2	Both
		Dose 2/58	12DEC2020	18DEC2020		Hospitalized due to COVID-19 illness		
C4591001 1205 12051078 (TUR/52/M)	Placebo	Dose 1/10	19NOV2020	20NOV2020	Neg/Pos/Pos	Hospitalized due to	Pos/Pos, 19NOV2020, A	CDC- defined

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1217 12171044 (TUR/34/M)	Placebo	Dose 1/8	11NOV2020	16NOV2020	Neg/Neg/Pos	COVID-19 illness	Pos/, 12NOV2020, B.1.1.162	Both
		Dose 1/17	20NOV2020			Hospitalized due to COVID-19 illness		
		Dose 1/17	20NOV2020	21NOV2020		PaO ₂ /FiO ₂ <300 mm Hg		
		Dose 1/17	20NOV2020	29NOV2020		Non-invasive positive pressure ventilation		
		Dose 1/19	22NOV2020	28NOV2020		Hospitalized due to COVID-19 illness		
C4591001 1221 12211002 (USA/MARYLAND/43/M)	Placebo	Dose 2/2	03NOV2020		Neg/Neg/Unk	High-flow oxygen therapy	Pos/Pos, 02NOV2020, B.1	Both
		Dose 2/2	03NOV2020	06NOV2020		RR ≥30 breaths/minute		
		Dose 2/2	03NOV2020	06NOV2020		Hospitalized due to		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1223 12231252 (USA/CONNECTICUT/48/M) *	Placebo	Dose 2/77	19JAN2021		Neg/Neg/Neg	COVID-19 illness PaO ₂ /FiO ₂ <300 mm Hg	Pos/, 11JAN2021, B.1.409	Both
		Dose 2/77	19JAN2021	21JAN2021		Needs mechanical ventilation		
		Dose 2/77	19JAN2021	26JAN2021		Admission to an ICU		
C4591001 1226 12261599 (BRA/41/F)*	BNT162b2 (30 µg)	Dose 2/37	07NOV2020		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 07NOV2020, B.1.1.94	Protocol- defined
C4591001 1226 12261624 (BRA/52/M)*	Placebo	Dose 2/37	05NOV2020		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 05NOV2020, B.1.1.143	Protocol- defined
C4591001 1231 12311014 (ARG/62/F)*	Placebo	Dose 2/136	08JAN2021		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 08JAN2021, B.1.1.33	Both
		Dose 2/136	08JAN2021	14JAN2021		Hospitalized due to COVID-19 illness		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
					Visit 2 NAAT			
C4591001 1231 12311087 (ARG/44/M)	Placebo	Dose 1/18	29AUG2020	07SEP2020	Neg/Neg/Pos	Hospitalized due to COVID-19 illness	Pos/, 27AUG2020, N.3	CDC- defined
C4591001 1231 12311531 (ARG/35/M)*	Placebo	Dose 2/19	26SEP2020	29SEP2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 19SEP2020, B.1	CDC- defined
C4591001 1231 12312119 (ARG/32/M)*	Placebo	Dose 2/144	28JAN2021	05FEB2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 24JAN2021, B.1.1.33	CDC- defined
C4591001 1231 12312130 (ARG/64/F)	Placebo	Dose 1/3	20AUG2020	27AUG2020	Neg/Pos/Neg	Hospitalized due to COVID-19 illness	Pos/, 26AUG2020, B.1.452	CDC- defined
C4591001 1231 12312572 (ARG/46/M)*	Placebo	Dose 2/120	05JAN2021	11JAN2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 29DEC2020, B.1.1.200	CDC- defined
C4591001 1231 12312635 (ARG/71/M)*	Placebo	Dose 2/40	17OCT2020	20OCT2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 06OCT2020, B.1.1.33	CDC- defined

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1231 12312914 (ARG/50/M)*	Placebo	Dose 2/54	06NOV2020		Neg/Neg/Neg	SpO ₂ ≤93% on room air at sea level	Pos/, 29OCT2020, B.1.1.33	Both
		Dose 2/54	06NOV2020	14NOV2020		Hospitalized due to COVID-19 illness		
C4591001 1231 12313090 (ARG/57/M)	Placebo	Dose 1/21	11SEP2020	14SEP2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 25SEP2020, B.1.241	CDC-defined
C4591001 1231 12313125 (ARG/48/M)	Placebo	Dose 1/77	06NOV2020	09NOV2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 11NOV2020, B.1.1.33	CDC-defined
C4591001 1231 12313422 (ARG/34/M)*	Placebo	Dose 2/48	01NOV2020	23NOV2020	Neg/Neg/Neg	Admission to an ICU	Pos/, 29OCT2020, B.1.2	Both
		Dose 2/48	01NOV2020	23NOV2020		Hospitalized due to COVID-19 illness		
		Dose 2/53	06NOV2020	16NOV2020		Needs mechanical ventilation		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
		Dose 2/53	06NOV2020	19NOV2020		Admission to an ICU		
		Dose 2/54	07NOV2020			PaO ₂ /FiO ₂ <300 mm Hg		
C4591001 1231 12313697 (ARG/55/M)*	Placebo	Dose 2/123	15JAN2021	22JAN2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 14JAN2021, P.2	CDC-defined
C4591001 1231 12313895 (ARG/50/F)*	Placebo	Dose 2/21	03OCT2020	06OCT2020	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 07OCT2020, B.1	CDC-defined
C4591001 1231 12314681 (ARG/66/F)*	Placebo	Dose 2/110	03JAN2021	12JAN2021	Neg/Neg/Neg	High-flow oxygen therapy	Pos/, 29DEC2020, B.1.1.33	Both
		Dose 2/110	03JAN2021	13JAN2021		Hospitalized due to COVID-19 illness		
C4591001 1231 12315324 (ARG/58/F)*	Placebo	Dose 2/110	05JAN2021		Neg/Neg/Neg	Admission to an ICU	Pos/, 26DEC2020, B.1.1.291	Both
		Dose 2/110	05JAN2021			Hospitalized due to COVID-19 illness		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1235 12351071 (USA/LOUISIANA/50/M)	Placebo	Dose 2/119	14JAN2021	31JAN2021		Significant acute renal dysfunction		
		Dose 2/119	14JAN2021	31JAN2021		Admission to an ICU		
		Dose 2/121	16JAN2021			Needs mechanical ventilation		
		Dose 1/9	22SEP2020	26SEP2020	Neg/Neg/Unk	Admission to an ICU	Pos/, 22SEP2020, B.1.2	Both
		Dose 1/11	24SEP2020			SpO ₂ ≤93% on room air at sea level		
C4591001 1246 12461110 (ZAF/19/M)*	Placebo	Dose 2/71	06JAN2021		Neg/Neg/Neg	DBP <60 mm Hg	Pos/, 06JAN2021, B.1.351	Protocol- defined
C4591001 1247 12471066 (ZAF/58/F)	Placebo	Dose 1/25	23OCT2020	24OCT2020	Neg/Neg/Unk	High-flow oxygen therapy	Pos/, 16OCT2020, B.1.237	Both
		Dose 1/25	23OCT2020	26OCT2020		Hospitalized due to COVID-19 illness		

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT / Visit 2 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
C4591001 1247 12471092 (ZAF/37/M)*	Placebo	Dose 2/65	01JAN2021		Neg/Neg/Neg	RR \geq 30 breaths/minute ^e	Pos/, 23DEC2020, B.1.351	Both
		Dose 2/65	01JAN2021	03JAN2021		High-flow oxygen therapy		
		Dose 2/66	02JAN2021			Admission to an ICU		
		Dose 2/66	02JAN2021			Hospitalized due to COVID-19 illness		
C4591001 4444 44441985 (ARG/44/F)*	Placebo	Dose 2/82	05JAN2021	12JAN2021	Neg/Neg/Neg	Hospitalized due to COVID-19 illness	Pos/, 28DEC2020, B.1.499	CDC- defined
C4591001 4444 44442304 (ARG/49/M)	Placebo	Dose 2/13	27OCT2020		Neg/Neg/Neg	HR \geq 125 beats/minute	Pos/, 27OCT2020, B.1.1.33	Protocol- defined

Abbreviations: ARG = Argentina; BRA = Brazil; CDC = Centers for Disease Control and Prevention; HR = heart rate; ICU = intensive care unit; FDA = Food and Drug Administration; FiO₂ = fraction of inspired oxygen; NAAT = nucleic acid amplification test; NS = not sequenced; N-binding = SARS-CoV-2 nucleoprotein-binding; Neg = Negative; PaO₂ = partial pressure of oxygen, arterial; Pos = Positive; QNS = not quantifiable samples; RR = respiratory rate; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SpO₂ = oxygen saturation as measured by pulse oximetry; TUR = Turkey; Unk = Unknown; ZAF = South Africa.

Note: * indicates subject in the evaluable efficacy (7 days) population with first severe COVID-19 occurrence from 7 days after Dose 2 and with or without

**16.2.8.8 Listing of Subjects and SARS-CoV-2 Variants With First Severe COVID-19 Occurrence Based on CDC-Defined or FDA-Defined Symptoms After Dose 1 – Blinded Placebo-Controlled Follow-up Period
– Dose 1 All-Available Efficacy Population**

Subject (Country/Region/Age in Years/Sex)	Vaccine Group (as Randomized)	Dose/Rel Day ^a	Start Date	Stop Date	Visit 1 N-Binding Assay/ Visit 1 NAAT	Signs, Symptoms, and Events	SARS-CoV-2 NAAT Result (Central Lab/Local Lab ^b), Swab Date, SARS- CoV-2 Lineage	FDA- Defined/ CDC- Defined Symptom s
					/		Visit 2 NAAT	

evidence of infection prior to 7 days after Dose 2.

Note: HIV-positive subjects are included in this listing but not included in the analyses of the overall study objectives.

a. Relative Day (Rel Day) = date of first symptom - date of last dose before first symptom + 1.

b. SARS-CoV-2 NAAT results from the local lab are based on the Cepheid Xpert[®] Xpress SARS-CoV-2 test, Roche cobas[®] SARS-CoV-2 real-time RT-PCR test (EUA200009/A001), or Abbott RealTime SARS-CoV-2 assay (EUA200023/A001) only.

PFIZER CONFIDENTIAL SDTM Creation: 01JUN2021 (17:11) Source Data: adsympt Table Generation: 01JUN2021 (22:07)

(Cutoff Date: 13MAR2021, Snapshot Date: 28MAY2021) Output File: ./nda2_unblinded/C4591001_BLA_Sequence/adxb_l001_seq_d2_cov_cdc_aai